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The epithelial layer of the respiratory system has a critical and fundamental role in 
the defence against microbes via the secretion of a number of proteins that function in 
the process of host innate defence. One such protein, bactericidal/permeability-
increasing fold-containing family member-A1 (Bpifa1) is secreted by the epithelium of 
the respiratory tract, and has previously been implicated in the inhibition of binding and 
entry of influenza A virus (IAV). However, its precise biological functions remain unclear.  
In order to investigate the role of Bpifa1 during IAV infection, in vivo expression of 
recombinant mouse Bpifa1 and human BPIFA1 using a mammalian expression vector 
was attempted. Unfortunately, though Bpifa1 was successfully expressed in vitro, no in 
vivo expression could be elicited. Instead, the role of Bpifa1 in the transmission of IAV 
and the associated immune response were explored using a mouse model. For this 
purpose, control wild-type C57BL/6J and Bpifa1-/- mice were infected with IAV using 
different virus doses at high or low and subjected to a transmission study. It was found 
that Bpifa1-/- mice were more susceptible to transmission and showed deficient IgA 
production, especially at low dose infection. The histological changes were similar in all 
groups, though more severe in Bpifa1-/- mice and at high dose. IAV infection of the nasal 
cavity and the associated loss of epithelial cells was more pronounced in Bpifa1-/- mice, 
in addition to mononuclear mucosal infiltration and nasal-associated lymphoid tissue 
(NALT) formation. Importantly, this study highlights that IAV transmitted more 
frequently and efficiently to Bpifa1-/- mice, indicating a role for Bpifa1 in protection from 
IAV infection and the efficient generation of virus-specific IgA in the respiratory tract. 
The work presented in this thesis indicates for the first time that Bpifa1 has an 
important role not only in innate immune defence but also in the adaptive immune 
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 BPIFA1 structure, expression and role 
The respiratory system epithelium has a critical role in the initial defence 
mechanism against microbes and secretes a number of host-defence molecules and 
proteins that function in innate immune defence (Whitsett and Alenghat, 2015). Palate 
lung and nasal epithelial clone (PLUNC) proteins are a family of molecules, which have 
a similar structure to that of bacterial/permeability increasing protein (BPI), and are 
mainly expressed at sites where innate defence mechanisms are essential 
requirements, particularly, in the mucous epithelial cells of the major salivary glands 
and the minor mucosal glands of the oral cavity as well as in the nasal, tracheal, and 
bronchial passages (Bingle and Bingle, 2011). Expression of these genes has also been 
observed in the mouse thymus (LeClair et al., 2001) and gastrointestinal tract (LeClair 
et al., 2001; Hou et al., 2004). PLUNC family members are classified into two groups 
based on their size. The first group, which is called “short” proteins, a group comprising 
Short palate, lung, and nasal epithelium clone 1 (SPLUNC1 denotes human protein and 
Splunc1 denotes mouse protein), which is also known as bactericidal/permeability-
increasing fold-containing family member A-1 (BPIFA1 denotes human protein and 
Bpifa1 denotes mouse protein) (256 amino acids), SPLUNC2/ BPIFA2 (249 amino acids) 
and SPLUNC3/ BPIFA3 (253 amino acids). The second group, called “long” proteins, 
comprising Long palate, lung, and nasal epithelium clone 1 (LPLUNC1); also known as 
bactericidal/permeability-increasing fold-containing family member B-1 (BPIFB1) (484 
amino acids), LPLUNC2/ BPIFB2 (458 amino acids), LPLUNC3/ BPIFB3 (463 amino acids), 
LPLUNC4/ BPIFB4 (> 469 amino acids) (Bingle and Craven, 2002; Canny and Levy, 2008; 
Bingle and Bingle, 2011). The N-terminal domains of both short and long PLUNC 
proteins are structurally similar to the N-terminal domain of BPI. However, the C-
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terminal domain of short and long PLUNC proteins is more variable (Bingle and Craven, 
2002).  
Several studies have investigated and characterised the expression of PLUNC 
proteins; however, their biological roles are poorly understood (Zhang et al., 2019). 
BPIFA1 is a 25-kilodaltons (kDa) glycoprotein which is one of the most abundant and 
highly expressed proteins in the epithelial cells and submucosal glands of the upper 
airways in humans and mice (LeClair et al., 2001; LeClair et al., 2004). Bpifa1 was 
described for the first time in the nasal epithelium of the mouse embryo and the upper 
respiratory tract (trachea/bronchi) of adult mice (Weston et al., 1999).  
Bpifa1 expression was reported in coronal sections of head and lung samples from 
adult mice using immunohistology (IH) technique and anti-mouse Bpifa1 antibodies. It 
was found that Bpifa1 is expressed in regions of the head and upper respiratory tract 
(URT), especially in the patches of respiratory epithelium (squamous epithelium) within 
the anterior part of the nasal cavity, in some Bowman’s glands and Bowman’s gland 
ducts, and in non-ciliated cells. It was found that Bpifa1 is associated with the cell 
surface and in the mucous of the nasal passages in this region. In the larynx, Bpifa1 is 
present in the ducts and submucosal glands associated with this region, particularly 
cells of the ducts and within the luminal contents (Figure 1-1A, B) and in some serous 
and mucous cells of the glands (Figure 1-1C). In the trachea, Bpifa1 is present in the 
mucous cells of the submucosal glands (Figure1-1D), while it is expressed in the non-
ciliated cells of the bronchial passages (Figure 1-1E, F) (Musa et al., 2012; Akram et al., 




Figure 1-1. Expression sites of Bpifa1 in the adult mouse.  
Bpifa1 is expressed in the upper part of the respiratory tract. A-C. Expression of Bpifa1 in the 
larynx. A. and B. In cells of the ducts and within the luminal contents, scale bar= 200 and 50 µm, 
respectively. C. Serous and mucous cells of the submucosal glands, scale bar= 50 µm. D. 
Trachea. E. Bronchi. F. Bronchioles. Arrows show expression of Bpifa1 using IH technique, scale 
bar= 50 µm, 10 µm and 20 µm, respectively. Figure adapted from Musa et al., 2012 and Akram 
et al., 2018.   
 
On the other hand, it was shown in human that BPIFA1 is expressed in serous cells 
of submucosal glands in nasal mucosa using IH, and also was detected in nasal 
secretions of healthy volunteers using western immunoblotting (Kim et al., 2006). Also, 
BPIFA1 was detected in cells of the mucous acini and within ducts of submandibular 
salivary glands using IH (Vargas et al., 2008), along with non-ciliated epithelial cells, 
mucous cells of the minor glands of tongue, nose, sinuses and surrounding the tonsils, 
also in the mucous cells of submucosal glands in the trachea and upper airways using 
IH. These locations are known to express proteins associated with host protection of 
the URT (Bingle et al., 2005).  
The expression of Bpifa1 is controlled by several factors such as environmental 
pathogen-associated molecular patterns (PAMPs) and inflammatory mediators. Under 
basal state and very early during infection, Bpifa1 is highly expressed in the respiratory 
tract, while this expression is markedly inhibited during acute infection and 
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inflammation. This raises the possibility of that fluctuation of Bpifa1 may play a role in 
regulation of inflammation and mucociliary clearance, therefore triggering a rapid 
activation of innate immune response and initiation of inflammatory responses, as a 
result Bpifa1 serves as an integrator of both innate an adaptive immunity (Britto et al., 
2013). On the other hand, Leeming et al., 2015 showed that the expression and storage 
of Bpifa1 during murine herpesvirus-68 (MHV-68) infection of wood mice (Apodemus 
sylvaticus) was seen in granules within club cells and this expression decreased and was 
associated with release of the stored protein at day 7 post-infection (pi). In contrast, at 
day 14 pi, an increase in the protein expression was noted and associated with mucus 
production in club cells.   
In addition, De Smet et al., 2018 found that mRNA expression of BPIFA1 in lung 
tissue using quantitative real time polymerase chain reaction (qRT-PCR) and protein 
expression in the airway epithelium by IH increased in patients with chronic obstructive 
pulmonary disease (COPD) in comparison to those without COPD. COPD is a lung disease 
characterised by an abnormal inflammatory response as a result of noxious particles 
and gases inhalation. This inflammation leads to small airway obstruction and 
emphysema (Vogelmeier et al., 2017), and the main risk factor for COPD is cigarette 
smoking (Rostron et al., 2014). From these findings, the authors hypothesised that the 
increase in production and storage of BPIFA1 occurs as a result to the need for more 
BPIFA1 in response of the airway epithelium to this need. Its known that neutrophil 
elastase reduces BPIFA1 (Jiang et al., 2013), and COPD patients often have bacterial 
infections and high amounts of neutrophils elastase, which accounts for increased 
BPIFA1 secretion.  
It has been found contribution of interleukin-13 (IL-13), a cytokine secreted mainly 
by T helper 2 (Th2) cells to allergic conditions of airways which leads to suppression of 
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BPIFA1 expression in nasal epithelial cells (Yeh et al., 2010).  Research has shown that 
IL-13 and lipopolysaccharide (LPS) affect BPIFA1 expression and secretion. Tsou et al., 
2015 showed that IL-13 inhibits BPIFA1 mRNA expression in in vitro using cultures of 
human nasal septum squamous carcinoma RPMI-2650 cells using qRT-PCR and BPIFA1 
protein using western immunoblotting, after treatment of these cells with different 
concentrations (0–20 μg/ml) of LPS from Escherichia coli (E. coli) for 2 and 24 hours (h), 
respectively. Also, sinonasal tissues obtained from 12 patients with chronic 
rhinosinusitis with nasal polyps (CRSwNP) with eosinophilic predominant type were 
collected and examined using IH for evaluation of IL-13 and BPIFA1 expression. CRSwNP 
is an inflammatory condition characterised by TH2 cells inflammation and tissue 
eosinophilia caused by microbial infections (Hsu and Peters, 2011). 
Results showed a significant increase in BPIFA1 mRNA and BPIFA1 protein after 
treatment with LPS. This LPS-induced expression was inhibited by IL-13 using western 
immunoblotting. On the other hand, IH results showed that some patients who were 
not infected with bacteria, no expression for both BPIFA1 and IL-13 was seen in the 
sinonasal tissue, while there was a marked reduction in BPIFA1 expression in tissues 
with bacterial infection and expressing a high level of IL-13 in comparison with tissues 
without IL-13 expression. This finding suggested that IL-13 plays an essential role in 
downregulation of bacterial-induced BPIFA1 expression, which could result in 
eosinophilic CRSwNP. The expression of BPIFA1 can be quantified and used as a 
diagnostic tool for certain upper airway infections, which may have an impact for 
defining treatment outcomes (Tsou et al., 2018). 
Interestingly, BPIFA1 has been described as a key molecule in studies of pulmonary 
infections with immunomodulatory and host-protective functions (Britto and Cohn, 
2015). In human, PLUNC-encoding genes have been mapped to chromosome 20, while 
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in mice to chromosome 2.  In addition, at the complementary deoxyribonucleic acid 
(cDNA) and amino acid levels, murine Bpifa1 and human BPIFA1 shares approximately 
80% of identity. Therefore, it is predicted that mouse and human Bpifa1 may have 
similar functions (Chu et al., 2007). Importantly, several studies have shown that mouse 
Bpifa1 and human BPIFA1 sequences are homologous, and their PLUNC family 
orthologs are rapidly evolving, thus supports the hypothesis of their involvement in host 
defence (Bingle and Bingle, 2000; Bingle et al., 2004; Bingle et al., 2011).  
1.1.1 Antibacterial and host defence functions 
BPIFA1 protein has been identified as a constituent of the respiratory antimicrobial 
response based on its structural similarity to the BPI protein and its profuse expression 
at sites of potential bacterial exposure and infection, such as the oral cavity and 
conductive airways of many mammals including humans (Bingle and Craven, 2002). 
Efficient host defence against microbial invasion requires an innate immune system, 
which has two main characteristics, both rapid and independent of prior exposure, and 
it has been appreciated that several types of secreted proteins play a key role in this 
innate immune response (Hoffmann et al., 1999; Canny and Levy, 2008). There are 
several lines of evidence that suggest BPIFA1-mediated antibacterial function, which is 
an essential aspect of the innate immune response in the respiratory airways. The first 
evidence is its structural similarity to BPI and LPS-binding protein (LBP), which have 
been indicated for their important role in the host defence mechanism against Gram-
negative bacteria (Horwitz et al., 1995; Tobias et al., 1997). Secondly, BPIFA1 is one of 
the short peptides in the subfamily of bactericidal/permeability-increasing fold-
containing family (BPIFA) proteins, which is similar to the N-terminal domains of BPI 
(Figure 1-2). It has previously been shown that peptides derived from this region of BPI 
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express direct bactericidal activity (Elsbach and Weiss, 1993; Capodici et al., 1994; 
Elsbach et al., 1994).  
 
Figure 1-2. Crystal structure of human BPIFA1 and BPI. 
Human BPIFA1 (blue) shares structural similarity with the N-terminal of human BPI (yellow). 
Figure modified from Garland et al., 2013. 
 Anti-Pseudomonas effect  
Research has shown BPIFA1 function against Psuedomonas bacteria. One of these 
studies was performed by Sayeed et al., 2013, who verified the antibacterial function 
of BPIFA1 in acute respiratory infections using a mouse model and Psuedomonas 
aeruginosa and treatment with recombinant human BPIFA1 protein, which showed a 
bacteriostatic effect of BPIFA1 through reduction and inhibition of bacterial growth. 
This inhibition occurred because of BPIFA1 induced bacterial cell permeability. On the 
other hand, removal of BPIFA1 enhanced the recovery and growth of P. aeruginosa. 
Furthermore, the same study identified a novel function for BPIFA1 as a 
chemoattractant that enhances the migration of macrophages and neutrophils after its 
binding to bacteria. 
Lukinskiene et al., 2011 investigated the role of BPIFA1 in prevention of lung 
infection with P. aeruginosa in mice. The authors used transgenic mice (Scgb1a1-
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BPIFA1) in which BPIFA1 was given and directed to the respiratory epithelium using the 
Secretoglobin Family 1A Member 1 (Scgb1a1) promoter. Results of this study showed 
expression of BPIFA1 in respiratory epithelial cells of trachea, bronchi and bronchioles, 
and in the bronchoalveolar lavage fluid (BALF). In vitro, BALF samples from transgenic 
mice showed higher antibacterial activity compared to those of wild-type mice. 
Interestingly, Scgb1a1-BPIFA1 transgenic mice showed enhanced survival and bacterial 
clearance after in vivo challenge with P. aeruginosa, which was associated with a 
reduction in cytokine levels and neutrophil infiltration. All these data indicate the 
antibacterial activity of BPIFA1 in respiratory bacterial infections, which indicates 
critical involvement of this protein in the innate immune response of the airway 
epithelium.   
Interestingly, Britto et al., 2013 studied the role of Bpifa1 in host defence through 
their in vitro and in vivo experiments, and found that regulation of Bpifa1 expression is 
highly affected by exposure to microorganisms. Although under steady-state 
conditions, concentrations of Bpifa1 were high in secretions of the lower respiratory 
tract, this high concentration was notably decreased during respiratory infection as a 
response to infection of the epithelial layers. In this study, in vivo experiments included 
intratracheal infection of C57BL/6J mice using 5x104 colony-forming units (CFU) of P. 
aeruginosa and 1x105 of Streptococcus pneumoniae; animals were euthanised after 4 h 
or 3 days, respectively. In addition, IAV was intranasally administrated and mice were 
euthanised at 7 days post-infection (dpi). IH and western immunoblotting were used to 
assess expression of Bpifa1 in lung sections and tissue homogenates of naive C57BL/6J 
mice, which showed abundant production of Bpifa1 in the respiratory epithelium 
particularly in trachea and proximal bronchi. In contrast, there was a significant 
reduction of Bpifa1 levels in BALF tested by enzyme-linked immunosorbent assay 
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(ELISA) of mice with pneumonia induced by P. aeruginosa, S. pneumoniae and IAV. In 
order to determine the effects of infection on Bpifa1 expression over time, C57BL/6J 
mice were intranasally administrated the Gram-negative endotoxin LPS. At 3 h post-LPS 
administration, the Bpifa1 level in the BALF was found to be increased as shown by 
ELISA, followed by a reduction with a nadir at 24 h and continued below the normal 
concentration for 48 h. As also the Bpifa1 ribonucleic acid (RNA) expression in lung 
tissue decreased post-LPS administration. This decline in Bpifa1 concentration was 
associated with an obvious increase in neutrophilic infiltration, proposing a correlation 
between Bpifa1 and inflammation. All these variations in Bpifa1 may serve as a 
regulator of inflammation and mucociliary clearance, which assist in host protection. 
Bpifa1 fluctuation is perhaps crucial in the rapid stimulation of innate immune 
responses and to trigger the subsequent inflammatory responses, therefore acting as a 
monitor of both innate and adaptive immunity. 
Moreover, Britto et al., 2019 investigated a novel immunomodulatory effect of 
Bpifa1 in triggering inflammation and regulation of neutrophil recruitment into the 
lung. In this study, wild-type and knock out Bpifa1 (Bpifa1-/-/ KO) mice were inoculated 
intranasally with LPS from P. aeruginosa and euthanised at different time points. 
Results showed a significant reduction of neutrophils in Bpifa1-/- mice in comparison to 
wild-type mice in the lung and airways at 8- and 24-hours post-infection (hpi). 
Furthermore, Bpifa1-/- mice exhibited a significant lower degree of inflammation in the 
peribronchial and alveolar compartments compared to wild-type mice. Additionally, to 
address the mechanism of impaired neutrophil recruitment into the lung of Bpifa1-/- 
mice, the authors found that IFN gamma (IFN-ƴ) expression was significantly lower in 
Bpifa1-/- than in wild-type mice as shown by reverse transcriptase-polymerase chain 
reaction (RT-PCR) in lung samples from both groups at 0, 8 and 24 hpi. This reduced 
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expression of IFN-ƴ inhibits neutrophil accumulation through limitation of IFN-
mediated cytokine induction. Thus, both Bpifa1 and IFN-ƴ act in a harmonised way to 
modulate inflammatory responses in the lung.   
  Anti-Mycoplasma effect 
Several studies have determined the host defence mechanism and anti-
inflammatory functions of Bpifa1 during Mycoplasma pneumoniae infection, a 
prominent respiratory pathogen (Chu et al., 2007). Their experiment in vivo using 
mouse models and in vitro using cultures of normal human primary bronchial epithelial 
cells showed that Bpifa1 protein has anti-bacterial function through inhibition of M. 
pneumonia growth, and an anti-inflammatory effect through inhibition of the 
production of epithelial IL-8 (a chemokine that is involved in the host defence against 
bacterial infection via recruiting neutrophils) induced by M. pneumonia-derived 
lipoproteins. It was also found that normal mouse and human large airway epithelial 
cells express high levels of BPIFA1. Although M. pneumonia infection increases Bpifa1 
expression, IL-13 significantly decreases Bpifa1 expression and clearance of these 
bacteria. This suggests that BPIFA1 acts as a host defence protein against these bacteria 
and the reduction in BPIFA1 expression during an allergic inflammation might 
contribute to the persistence of bacterial infections in allergic conditions of the 
conductive airways.   
Gally et al., 2011, demonstrated further evidence of the in vivo antibacterial 
property of BPIFA1 in host defence against M. pneumoniae by inhibiting growth and 
bacterial adherence. This role was uncovered by using Bpifa1-/- mice, which showed a 
significant increase in the lung bacterial load compared with wild-type mice. 
Furthermore, they found that in addition to its antibacterial action, Bpifa1 modulates 
the innate immune response through enhancing lung leukocytes (neutrophils 
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activation). They tested human peripheral blood neutrophils treated with recombinant 
BPIFA1 protein, directly followed by M. pneumoniae infection for 2 h. Results showed 
infection with M. pneumoniae stimulated neutrophil elastase activity, and BPIFA1 
further increased the neutrophil elastase activity. One of the interesting results of this 
study was not only the in vivo function of Bpifa1 observed in the knockout model, but 
the transgenic mouse model which was used to overexpress human BPIFA1 in the 
airway epithelium. This overexpression of human BPIFA1 in mouse airways resulted in 
the doubling of Bpifa1 protein in bronchoalveolar lavage fluid (BAL), which significantly 
inhibited M. pneumoniae infection and associated pulmonary inflammation. The 
findings of this study suggest that mouse Bpifa1 and human BPIFA1 share similar 
antibacterial and immunomodulatory activities. Therefore, Bpifa1 deficient and BPIFA1-
transgenic mouse models can be useful for further investigations into the role of BPIFA1 
in other bacterial infections under specific disease conditions that affect humans such 
as chronic obstructive pulmonary disease, asthma and cystic fibrosis. 
1.1.1.3 Anti-Klebsiella effect 
Liu et al., 2013 revealed that Bpifa1 is an endogenous surfactant and has a 
significant role in the maintenance of the low surface tension in respiratory epithelial 
secretions, an activity that enhances anti-biofilm defences at the mucosal surfaces. 
Using an in vivo approach, the authors found increased susceptibility of Bpifa1-/- mice 
to Klebsiella pneumoniae infection, with significantly more bacterial CFUs in both lungs 
and BALF in comparison to wild-type mice particularly at 24 and 48 hpi. In addition, 
Bpifa1-/- mice exhibited more intense peribronchial inflammation and airway lumen 
leukocyte accumulation at 48 hpi, which are both features of severe pneumonia. 
Furthermore, they demonstrated through an in vitro experiment using human and 
murine cultured tracheal and bronchial airway epithelia that BPIFA1 is critically 
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essential for maintenance of low surface tension in airway epithelial secretions. 
Moreover, they indicated that recombinant BPIFA1 significantly inhibited K. 
pneumoniae biofilm formation on respiratory airway epithelia.  Based on these results, 
it is proposed that BPIFA1 is a necessary component of the respiratory mucosal innate 
immune defence and a multifunctional protein with potential host defence roles that 
include direct inhibition of bacterial growth, anti-biofilm activity, LPS binding and 
modulation of neutrophil activity as well as facilitation of mucociliary clearance. These 
observations into airway epithelial defences against bacterial infection may help inform 
subsequent therapeutic approaches. 
1.1.2 Anti-viral function  
Little is known about the antiviral activity of Bpifa1, although several studies have 
investigated this role. Leeming (2010) found that Bpifa1 has an anti-inflammatory 
function in the lung during MHV-68 infection. During the acute stage after intranasal 
infection of wood mice (Apodemus sylvaticus) with MHV-68 she showed, by using IH for 
Bpifa1, that the expression of this protein was significantly decreased in bronchioles of 
infected mice at 7 dpi compared to mock-infected mice. This suggested that this protein 
contributes to an effective immune response. While at later stages of the infection, 
there was a significant increase in the expression of Bpifa1 in the bronchi and 
bronchioles, most obvious in the bronchioles. This finding was associated with the 
resolution of the inflammatory reaction, which might occur due to involvement of 
Bpifa1 (Leeming, 2010). 
In another study, Leeming et al., 2015 have shown modulation of Bpifa1 
expression levels after MHV-68 infection, which clearly suggests its role in the host 
defence. The authors examined the differential temporal and spatial expression of this 
protein and its products in airways during MHV-68 infection of wood mice (Apodemus 
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sylvaticus). This examination demonstrated that Bpifa1 is produced and stored in 
granules within club cells, and its expression was decreased in bronchioles at 7 dpi, 
consistent with release of stored protein during the acute phase of MHV-68 virion 
production and damage of epithelial cells. However, the expression of Bpifa1 was 
increased throughout the entire respiratory tract in response to the infection at 14 dpi, 
and was associated with mucus production in club cells. Additionally, this increase in 
Bpifa1 expression may indicate a specific role in the resolution process of the infection 
(Leeming et al., 2015). 
Additionally, an inhibitory effect of BBIFA1 has been shown on the replication of 
Epstein-Barr virus (EBV), a membrane-bound herpesvirus in lymphoblastoid cell, in the 
respiratory epithelium. Zhou et al., 2008 used three EBV-transformed B cell lines 
treated with BPIFA1. The authors found that BPIFA1 is able to enhance the disruption 
and apoptosis of EBV-infected B cells as well as a significant decrease in the total EBV 
deoxynucleic acid (DNA) in vitro after 7 days of treatment with BPIFA1. These 
observations revealed the inhibitory role of BPIFA1 on the potential oncogenicity of this 
virus in the respiratory epithelium (Zhou et al., 2008).  
In another study, Zhang et al., 2003 investigated the decreased expression of 
BPIFA1 in biopsy samples of nasopharyngeal carcinoma (NPC), which has been shown 
to be linked to EBV infection and some genetic factors (Hildesheim and Levine, 1993). 
The authors suggested that loss of BPIFA1 expression might be involved in the 
development of NPC. In addition, BPIFA1 gene polymorphisms are also associated with 
susceptibility to EBV-associated NPC (He et al., 2005).  
More recently, Akram et al., 2018 have investigated the potential role of Bpifa1 
against IAV, and modulation of the protein levels after viral infection. The study 
included both in vivo and in vitro approaches, in which mice were infected intranasally 
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with 103 plaque forming units (PFU) of IAV X-31 and showed that Bpifa1-/- mice had 
higher viral loads in the lung peaking at 5 dpi, compared to wild-type C57BL/6J mice. 
Additionally, in vitro experiments using mouse tracheal epithelial cells (mTEC) infected 
with 0.1 PFU per cell of IAV showed a higher number of cells expressing IAV nuclear 
protein (NP) in cell cultures derived from Bpifa1-/- mice than in cultures derived from 
wild-type C57BL/6J mice at 24 and 48 hpi. Notably, more weight loss was observed in 
Bpifa1-/- than in wild-type C57BL/6J mice particularly at 6 dpi. In addition, using IH the 
authors showed a significant decrease in Bpifa1 positive cells in trachea and bronchi 
sections at 7 dpi compared to mock-infected animals. This study indicated that Bpifa1 
inhibited the binding and entry of IAV into airway epithelial cells, and this investigation 
supports the hypothesis that Bpifa1 has an essential role in the host mucosal defence 
against this virus (Akram et al., 2018). Whether Bpifa1 has any effect on the 
pathogenesis of other respiratory viruses is still unclear and of interest. It is obvious that 
Bpifa1 inhibits viral infections by limiting the spread of virus into the airways. It is 
thought that Bpifa1 achieves this by inhibiting the entry of virus into cells, decreasing 
the nuclear import of IAV nuclear protein complexes, and thereby limiting the number 
of infected cells, particularly during the early stages of IAV infection (Akram et al., 2018). 
1.1.3  Other functions 
Garcia-Caballero et al., 2009, reported an additional function for BPIFA1, i.e. that 
it can regulate the epithelial sodium channel (ENaC) of the airways, which plays a key 
role in salt and liquid homeostasis. This regulation occurs through direct extracellular 
binding to this channel, which results in preventing its cleavage and activation. The 
authors tested this role in vitro using human bronchial epithelial cell cultures and 
Xenopus laevis oocytes. Knockdown of BPIFA1 resulted in a failure of the cultured cells 
to regulate the activity of ENaC and the volume of the airway surface liquid. This 
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inactivation was restored by adding recombinant BPIFA1 (rBPIFA1) to the airway 
surface liquid. Moreover, another study carried out by Rollins et al., 2010 found that 
BPIFA1 potently inhibited ENaC activity by ~70%, while two other PLUNC family 
members, BPIFA2 (SPLUNC2) and BPIFB1 (LPLUNC1) which are also expressed in airway 
epithelia did not significantly inhibit this sodium channel. This inhibition was due to the 
ability of BPIFA1 to reduce the number of ENaC multimers at the plasma membrane, 
which led to a significant reduction in ENaC currents (Garcia-Caballero et al., 2009). 
Furthermore, Gakhar et al., 2010 found for the first time that BPIFA1 possesses 
surfactant-like activity, through an in vitro experiment using purified recombinant 
BPIFA1 and primary cell cultures of human nasal and bronchial airway epithelia. This 
study indicated that BPIFA1 plays a role in lowering surface tension in the upper 
airways. Additionally, the study showed the ability of BPIFA1 for in vitro inhibition of 
biofilm formation of the opportunistic pathogen P. aeruginosa, which can cause lethal 
chronic respiratory infections in patients with cystic fibrosis and bronchiectasis (Lyczak 
et al., 2002). This finding suggests that one of the biological functions of BIPFA1 protein 
may be the prevention of chronic infections on mucosal surfaces.  
Another interesting role of BPIFA1 is its effect on mucociliary clearance and 
homeostasis in the upper respiratory airways. A study performed by McGillivary and 
Bakaletz, 2010, demonstrated that BPIFA1 functions to maintain homeostasis of the 
upper airway and is critical for the protection of the middle ear during bacterial otitis 
media (OM). OM is a disease wherein commensal bacteria present in the paediatric 
nasopharynx move up to the Eustachian tube (ET) and penetrate the middle ear cavity, 
particularly after or concurrent with upper airway infection with viruses such as 
influenza virus type A (Heikkinen and Chonmaitree, 2003). The in vivo cohort study was 
performed in chinchillas, which were intranasally administrated small interfering 
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ribonucleic acid (siRNA). The siRNA was designed to knock down the expression of 
chinchilla ortholog of human BPIFA1 (cBPIFA1) in the airway. One day later, the animals 
were transbullarly challenged with bacteria called nontypeable Haemophilus influenza 
(NTHI), the main causative agent of OM. While the authors found no significant 
difference in the bacterial load in the collected middle ear effusions after 2 and 4 days 
of siRNA treatment, the reduction in cBPIFA1 expression had a notable impact on ET 
function as indicated by a marked defect in the ability of the ET to maintain appropriate 
middle ear pressure (MEP) or mediate effective mucociliary clearance, compared to 
control groups. Therefore, this study presented evidence that the diminished cBPIFA1 
expression with ET dysfunction observed in animals was due to the function of the 
protein as a biological surfactant. In other words, the surfactant property of cBPIFA1 
was necessary for homeostasis of the upper airways, and thus defence of the middle 
ear. In addition, a histological approach was used in this study to investigate the 
underlying mechanism for the dysfunction of ET. Animals, which received control siRNA 
and were challenged with NTHI bacteria exhibited inflammatory cells infiltration in the 
lumen of the ET. In contrast, animals, which received cBPIFA1 siRNA, showed a more 
pronounced influx of immune cells, mucus and cellular debris accumulation in the 
lumen of ETs. Hyperplasia of goblet cells was also obvious in the epithelial layer, and 
the increase in goblet cells number possibly contributed to the increased amount of 
mucus in the lumen of the ET (McGillivary and Bakaletz, 2010). The decrease in 
surfactant activity in the respiratory airways can lead to increased mucin production 
(Glasser et al., 2008); therefore, these observations suggested that ET dysfunction in 
chinchillas with NTHI-induced OM subsequent to silenced cBPIFA1 expression was 
because of the reduction of surfactant activity in this tubal organ (McGillivary and 
Bakaletz, 2010).  
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A further interesting function of Bpifa1 is in the modulation of macrophage 
function and the inhibition of eosinophil infiltration of the airways, through reducing 
eotaxin-2 production in alveolar macrophages (AM). In a study performed by 
Thaikoottathil et al., 2012, in which Bpifa1-/- and wild-type C57BL/6 mice were 
sensitised by intraperitoneal administration of ovalbumin (OVA) on day 0 and 7 before 
being challenged with aerosolised 1% OVA or saline for 30 minutes (min) on three 
consecutive days. Data from this study showed that OVA-sensitised/challenged Bpifa1-
/- mice exhibited increased airway inflammation, which was determined by quantifying 
the total leukocyte and eosinophil numbers in the BALF. In addition, eotaxin-2 protein, 
which has a chemotactic effect on eosinophils (Lloyd, 2002), was significantly higher in 
BALF and whole-lung tissue in Bpifa1-/- compared to wild type mice, and eotaxin-2 
protein concentrations were positively correlated with the eosinophilic inflammation in 
both strains. As a conclusion, Bpifa1 concentrations are reduced in allergic murine 
lungs, and deficiency of Bpifa1 significantly exacerbates an eosinophilic inflammation in 
the airways along with increased eotaxin-2 production in the lung tissue and in AMs 
(Thaikoottathil et al., 2012). These findings could be used to attenuate eosinophilic 
inflammation in patients suffer from allergic asthma (Newcomb and Peebles, 2009; 
Huang et al., 2011; Thaikoottathil et al., 2012).   
 Influenza viruses  
1.2.1 Classification, structure and subtyping 
Influenza viruses belong to the Orthomyxoviridae family; the name is derived from 
the Greek orthos, which means "standard, correct," and myxa, which means "mucus" 
(Cheung and Poon, 2007). This family contains six genera; Influenzavirus A, 
Influenzavirus B, Influenzavirus C, Thogotovirus, Isavirus, and Quarajavirus (Nuñez and 
Ross, 2019). Members of this family cause highly contagious and rapidly spreading 
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acute respiratory infections, which can spread from animal to person as well as from 
person to person (Boggess, 2019). Beside the three main types of influenza virus, A, B, 
C, a fourth subtype, type D, has recently been isolated from swine and cattle (Hause et 
al., 2013; Collin et al., 2015). However, only types A and B seem to have the ability to 
cause annual epidemics in humans (Hay et al., 2001; Barberis et al., 2016). Both IAV and 
influenza B virus (IBV) contain eight negative-sense, single-stranded viral RNA (vRNA) 
gene segments (Palese and Schulman, 1976; McGeoch et al., 1976) (Figure 1-3A). Unlike 
IAV and IBV, influenza C virus (ICV) and influenza D virus (IDV) only contain seven vRNA 
gene segments, as the haemagglutinin-esterase-fusion (HEF) protein vRNA replaces the 
haemagglutinin (HA or H) and the neuraminidase (NA or N) vRNAs (Hause et al., 2014).  
Structurally, the IAV virion is composed of a host-derived lipid membrane, called 
an envelope, which is decorated on the surface with the viral surface membrane 
proteins HA, NA, and to a lesser extent the matrix 2 (M2) protein (Harris et al., 2006). 
The matrix 1 (M1) protein supports the viral envelope from the inside, and from the 
inside, the eight vRNAs exist as individual viral ribonucleoprotein (vRNP) complexes. 
Each single vRNP, which is responsible for transcription and replication of the virus, is 
composed of a vRNA that is wrapped around various copies of the viral NP and bound 
by an individual copy of the heterotrimeric viral polymerase, consisting of three 
subunits: polymerase acidic (PA), polymerase basic 1 (PB1) and PB2 (Arranz et al., 2012; 
Te Velthuis and Fodor, 2016). The polymerase binds the vRNAs at a helical hairpin 
structure that arises from the base pairing between the conserved 5′ and 3′ extremities 




Figure 1-3. Schematic structure of IAV’s genome. 
A. IAV genome consists of eight vRNA gene segments. The 5′ and 3′ untranslated regions (UTRs) 
which contain the viral promoters are illustrated as a line, and the box represents the coding 
region within each vRNA. B. Diagram of an IAV. The viral membrane proteins HA, NA, and M2 
are illustrated alongside with the eight vRNPs and the matrix protein M1 that supports the viral 
envelope. A single vRNA gene segment is illustrated wrapped around numerous NP copies with 
the conserved promoter regions in the 5′ and 3′ UTRs forming a shape similar to a helical hairpin 
which is bound by a single heterotrimeric viral RNA-dependent RNA polymerase (PA, PB1 and 
PB2). Figure adapted from Dou et al., 2018. 
  Subtyping of IAV is possible based on two main factors, the genetic and antigenic 
properties of the surface glycoproteins HA and NA which enhance viral entry and 
release. There are 18 HA subtypes (H1-H16 in wild waterfowl, and H17 and H18 in bats) 
and 11 NA subtypes (N1–N9 in wild waterfowl, and N10 and N11 in bats) have been 
identified in IAV isolated from aquatic birds which circulate in humans and animals 
(Krossøy et al., 1999; Tong et al., 2012; Tong et al., 2013; McAuley et al., 2019; Nuñez 
and Ross, 2019).   
1.2.2 Influenza virus host range reservoirs  
Aquatic birds are the main viral reservoirs of IAV in nature; however, IAV 
constantly circulate and periodically infect other hosts outside of the main host 
reservoir (Parrish et al., 2015). Sustained influenza virus outbreaks have been reported 
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in several mammalian species, including humans, horses, seals, pigs and minks, as well 
as in poultry. Recently, IAV strains have been shown to emerge in domestic dogs 
(Parrish et al., 2015; Parrish and Voorhees, 2019). In addition, these strains have been 
identified in bats; however, the exact origin is still unclear (Figure 1-4) (Mänz et al., 







Figure 1-4. IAV reservoirs. 
Wild aquatic birds are the natural reservoir of IAV, from these birds the virus can be transmitted 
to other hosts, including humans, pigs, chickens, wild flying birds, seals, whales, dogs, cats, 
horses and bats. Figure adapted from Mänz et al., 2013.  
1.2.3 Life cycle of influenza virus 
The first step of the influenza virus life cycle is recognition and binding of the HA 
protein on the surface of the virion to the sialic acid (SA)-linked host cell-surface 
receptors, of which there are two subtypes; α2, 3-linked SA receptor and α2, 6-linked 
SA receptor (Figure 1-5). After binding, viral entry occurs through receptor-mediated 
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endocytosis (Lakadamyali et al., 2004). Upon entry, the viral and endosomal 
membranes bind to each other under low pH conditions, resulting in membrane fusion 
(Huang et al., 1981; Hu et al., 2015). Subsequently, the viral genome is released into the 
cytoplasm of the infected cell, and it migrates to the nucleus, where it is transcribed 
and replicated. Following genome replication, the viral segments associate with NP to 
form vRNPs, which are transported to the cytoplasm for packaging with the aid of M1 
protein and the non-structural protein 2 (NS2). M1 protein associates with newly 
assembled vRNPs in the nucleus and accompanied them to the cytoplasm through the 
nuclear pores. During viral entry into a new host cell, M1 protein dissociates from the 
RNPs, enabling them to enter the nucleus (Martin and Heleniust, 1991). NS1, in 
contrast, is a multifunctional protein, which plays key roles in enhancement of viral 
gene expression and the antagonism of host cellular innate immune responses (Pereira 
et al., 2018). This protein is abundantly expressed in infected cells and included in the 
virion (Shaw et al., 2008; Hutchinson et al., 2012; Hutchinson et al., 2014). The 
assembled vRNPs translocate to the cell membrane alongside the viral envelope 
proteins HA, NA, M1 and M2, where they bud from the cell and form virus particles 
(Leser and Lamb, 2005). Finally, NA mediates the release of the newly made virus 
particles from the host cell through the cleavage of SA from the surface of the infected 
cell, causing spreading of the virus to adjacent host cells (Gamblin and Skehel, 2010; Shi 





Figure 1-5. Life cycle of IAV. 
IAV binds to SA-linked receptors, and entry is mediated via endocytosis. Within the host cell, 
viral and endosomal membranes fuse at low pH conditions, which causes the release of the 
segmented viral genome into the cytoplasm. Subsequently, the viral genome is translocated to 
the nucleus, where it is transcribed and replicated. After synthesis process in the cytoplasm, 
viral proteins are assembled into vRNPs in the nucleus. M1 and NS2 proteins mediate the export 
of the vRNPs into the cytoplasm. Assembly of virus particles occurs at the cell membrane, and 
the newly generated progeny virus is then released from the cells. Figure modified from Shi et 
al., 2014. 
1.2.4  Pathogenesis of IAV 
IAV are responsible for severe infections of the respiratory system in humans and 
animals. Every year, approximately 3-5 million people experience serious influenza 
infection, and around 250,000-500,000 succumb to the disease (WHO, 2009; Edwards 
et al., 2019). In general, there are two phases of the pathogenesis following IAV 
infection. The first phase starts immediately after infection; its course lasts between 1 
and 3 days and determines the virus titre peak, and thus the level of inflammation. 
Based on these two features, the second phase either does lead to virus control or can 
cause severe disease characterised by acute respiratory distress syndrome and in some 
cases death. Both host and viral factors are important in determination of the clinical 
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disease and outcome of influenza pathogenesis. Host factors include sex, age, immune 
status, microbiome and genetic diversity, all influence the clinical course and outcome 
of the infection (Gounder and Boon, 2019). 
It has been reported that several important IAV-encoded proteins are associated 
with pathogenesis of the viruses and the host immune response against viral infection. 
The first protein, HA, is the most abundant virus surface and multifunctional 
glycoprotein that attaches to the target host cell and cause cellular fusion and viral entry 
(Zhang et al., 2013). HA recognises SA receptors on the target host cells. This step is the 
most essential one in the entire process of IAV invasion into an organism (Gao et al., 
2009; Xu et al., 2010). As mentioned before, there are two common cellular receptors 
in Influenza viruses: α2, 3-linked SA receptor and α2, 6-linked SA receptor (Xiong et al., 
2013). 
The α2, 6-linked SA receptor is predominantly found in the URT of human 
particularly in ciliated respiratory epithelium and mucin-producing goblet cells, while 
α2, 3-linked SA receptor is expressed in the lower respiratory tract (LRT) particularly the 
apical membranes of ciliated airway epithelia of human and mouse and type II alveolar 
epithelial cells (Ibricevic et al., 2006), birds and pigs (Ibricevic et al., 2006; Shinya et al., 
2006; De Graaf and Fouchier, 2014). For this reason, during human infection, human 
derived IAV strains replicate in the upper airways, whereas the replication of avian 
derived IAV strains occurs primarily in the lower airways (Shi et al., 2014). In addition, 
diversity of cell surface receptors contributes to but also represents a barrier against 
influenza virus cross-species and zoonotic transmission (Shi et al., 2014; Chen et al., 
2018).  
Furthermore, HA is the primary target of neutralising antibodies directed against 
the different viral subtypes. Therefore, these epitopes are crucial dominants that affect 
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mutation and recombination mechanisms of the virus (Wang et al., 2016). Because of 
the high variability of HA, IAV can escape from host immune defences and lead to 
seasonal epidemics (Chen et al., 2018). The second major viral envelope glycoprotein is 
NA, which cleaves off SA moieties and promotes the release of progeny virions from 
infected cells, thereby aiding IAV dispersion (Wang et al., 2012). This glycoprotein also 
plays essential roles in the viral infection process and HA-mediated membrane fusion 
through binding to SA receptors (Lin et al., 2010; Zhu et al., 2012).   
IAV is characterised by two main distinct mechanisms of antigenic diversity in the 
viral surface glycoprotein, called “antigenic drift” and “antigenic shift” (Figure 1-6). 
These two mechanisms are responsible for the differences in epidemiological forms, 
known as seasonal and pandemic influenza (Paules and Subbarao, 2017). Antigenic drift 
can be defined as a continuous process that occurs due to gradual accumulation of point 
mutations in the HA and NA genes. Because of these mutations, the virus can escape 
the host immune defences induced by either vaccination or previous natural exposure 
leading to seasonal influenza epidemics (Iwasaki and Pillai, 2014; Paules and Fauci, 
2019). Conversely, antigenic shift occurs sporadically and involves the introduction of a 
novel virus subtype into a human population, against which the majority of this 
population lack immunity. This novel subtype arises from either an IAV of animal origin 
or due to a recombination between human and animal viruses. Zoonotic transmission 
of these new recombinants into the human population can lead to global influenza 
pandemics (Chen and Deng, 2009; Paules and Fauci, 2019). Transmission of avian 
influenza viruses from the natural reservoir (aquatic bird) to mammals involves many 
changes that encourage zoonotic spread. One of these changes is the temperature. 
Decreasing of the optimal temperature of viral replication from 40°C (avian) to 37°C 
(mammalian). Also, changing the site of replication from the digestive system to the 
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respiratory system as well as switching the receptor specificity from α2, 3-linked SA 
receptor to α2, 6-linked SA receptor (Klenk et al., 2013). 
In the human population, one of the main reasons of continuous circulation of 
influenza viruses is the partial protection given by available seasonal influenza vaccines 
against possible arising drifted or shifted influenza strains (Sautto and Ross, 2019). 
During the last century, four influenza pandemics have occurred and caused millions of 
deaths. The H1N1 pandemic in 1918 (Spanish) was the most disastrous, the H2N2 
pandemic in 1957 (Asian), the H3N2 pandemic in 1968 (Hong Kong) and the H1N1 
pandemic in 2009 (Paules and Subbarao, 2017). Each pandemic is due to recombinant 
viruses which have acquired gene segments from natural reservoirs by reassortment, 
which led to expression of innovative genome segment combinations to which most of 
the human population had little or no immunity (Webster and Govorkova, 2014). 
In addition, avian influenza viruses (H5N1, H7N9 and H9N2), swine (H1N1, H1N2 
and H3N2), and infection with other zoonotic influenza viruses have led to more human 
infections and life loss in comparison with the past decade (WHO, 2016). Presently, 
there is an increase demand to develop more powerful broadly-reactive or universal 
influenza vaccine with high level of protection against newly introduced potential 
seasonal and pandemic strains (Jazayeri and Poh, 2019). Developments in structural 
analysis have shown the presence of common antigenic epitopes on hemagglutinins 
across all influenza strains which could be utilised to produce a universal vaccine. 
Therefore, the need for a universal vaccine at the present is a public health priority 





Figure 1-6. Schematic diagram of influenza viral antigenic drift and shift to escape host 
immunity. 
Antigenic drift occurs due to genetic mutations, particularly in the HA protein gene. This allows 
an influenza virus to escape from recognition by neutralising antibodies. This change leads to 
seasonal epidemic outbreaks. Antigenic shift results in the introduction of a new virus subtype 
into the human population. This novel subtype, when efficiently transmitted from human to 
human, can cause a pandemic outbreak in the naïve human population due to absence of 
antibodies against the new subtype. Dotted lines mean direct transmission of influenza viruses 
from animals to humans. Figure modified from Van de Sandt et al., 2012. 
1.2.5  Modelling of IAV transmission using mice 
IAV transmission from an infected individual (index) to a non-infected 
susceptible individual (contact) occurs through the inhalation of viral particles either in 
the form of large droplets (>20 µm) or in the form of aerosols (<5 µm) shed from the 
respiratory tract (Tellier, 2009). In addition, transmission occurs via direct (body-to-
body contact) and indirect contact, the later with infectious fluids and contaminated 
objects, respectively. Transmission through droplets takes place when the infected 
individual releases contagious droplets through coughing or sneezing; these move a 
short distance and come into contact with another individual’s mucous membranes, 
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such as nasal or oral mucosa, and conjunctiva. With droplets larger than 10 µm tend 
not to remain suspended in the air, this type of transmission is not affected by 
procedures such as control of room pressure or special air handling (Bridges et al., 
2003). On the other hand, airborne transmission occurs with infectious droplet nuclei; 
these have a diameter of less than 5 µm and are therefore able to stay suspended in 
the air and to be spread by air currents through a facility or in a room to be taken or 
inhaled by a susceptible individual (Schürmann and Eggers, 1983; Bridges et al., 2003). 
Several models have been used to study IAV transmission including guinea pig, 
ferret and human models. One of the drawbacks of using these models is that they are 
difficult to manipulate, which explains the general lack of understanding about the 
individual’s impact on viral transmission (Ortigoza et al., 2018). This knowledge gap can 
be overcome with the use of mice (Mus musculus), which are the most widely known 
and used laboratory animal model for influenza virus research. The reasons for this are 
mainly practical. The mouse is a convenient animal model in terms of cost, size and 
maintenance requirements, and the availability of species-specific reagents, together 
with the option to genetically manipulate mice provides a system in which the host 
response to the infection can be studied in depth and in detail (Bouvier and Lowen, 
2010). The mouse model is often an excellent choice for preliminary evaluations of drug 
or vaccine efficacy and safety (Krishnakumar et al., 2019). However, there are some 
disadvantages of using this model; it is sometimes unsuitable to answer specific 
virological questions, and data obtained in mice can be difficult to translate to the 
human situation. Examples are the susceptibility of mice to human and other influenza 
viruses, the signs of disease in mice and the transmission of influenza viruses in mice 
(Bouvier and Lowen, 2010; Krishnakumar et al., 2019).  
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Several animal studies have been performed to identify factors affecting the 
transmission of influenza virus. Loosli et al., 1943 studied the effects of humidity on the 
ability of influenza viruses to infect mice in a non-ventilated room with constantly 
agitated air. They found that mice became infected with influenza 24 h after the virus 
was first aerosolised into the room at a relative humidity of 17–24%, although the 
percentage of infected mice decreased over time. In addition, the authors found that 
when the floor was vigorously swept the infectivity was enhanced at 22 h after influenza 
virus introduction, suggesting that desiccation (dryness) of the virus does not eliminate 
infectivity (Edward, 1941) Whether sufficient numbers of virus-laden particles can 
remain viable to infect humans in a similar setting is unknown. 
Mouse experiments by Schulman, 1967 and 1968 showed a strong reverse 
correlation between air exchange and infection rate, regardless of whether infected 
and non-infected mice were physically separated. It was found that non-infected mice 
when kept in the same cage with infected mice become infected with the same 
effectiveness as those kept in a separate, adjacent cage that allowed droplet nuclei and 
droplet (i.e., airborne) transmission to occur between cages but not through direct 
contact. Furthermore, Infectious particles produced by infected mice in a size of <10 
µm in diameter were found by air sampling, leading to the conclusion that airborne 
transmission of droplet nuclei might have occurred (Schulman, 1967). However, it is still 
unclear whether these results can be extrapolated to humans, especially those with 
previous antibody levels to influenza virus. 
The respiratory tract epithelium is an essential site of interaction between a living 
host and its surrounding environment; therefore, this epithelium has both protective 
and adaptive functions that help it to act as a barrier to different environmental factors 
that may be harmful to the living host (Al-Sayed et al., 2017). The replication of 
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influenza viruses occurs in the epithelial cells throughout the respiratory system, and 
the virus can be recovered from both the upper and lower parts of the respiratory tract 
of people naturally or experimentally infected (Qi et al., 2011).  
Edenborough et al., 2012 investigated the effect of close contact in IAV 
transmission using mice as a model. The experiment included intranasal infection of 
male BALB/c mice with 104.5 PFU IAV H1N1 and H3N2 strains, in which two mice were 
infected and housed separately for 6 h. Later, these infected mice were introduced to 
three non-infected mice. Afterwards, the infectious viral titre was measured in nasal 
turbinates, trachea and lung tissue samples, as well as the antibody response 
determined in sera samples using the haemagglutination inhibition (HI) assay at 4 dpi. 
The authors found a lack of viral replication and antibody response in the all non-
infected contact mice with all examined H1N1 strains. However, all contact mice 
exposed to H3N2 strains showed viral loads in the respiratory system and antibodies in 
the sera. This model might have a beneficial effect in pilot studies to find out the efficacy 
of curative interference that target to minimise contact-dependent transmission of IAV 
H3N2 subtype (Edenborough et al., 2012). 
  Immune response against IAV  
1.3.1 Innate immunity  
The first line of defence against viral infection is the innate immune response, 
which is rapid but non-specific and lacks memory. The innate immune system consists 
of physical barriers, secreted proteins such as mucins and collectins (which include 
surfactant proteins A and D), phagocytic cells, cytokines, interferons (IFN) and IFN-
stimulated genes (ISG); these also provide the initial defence against IAV infection (Holt 
et al., 2008; Chen et al., 2018).  
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Several cell types are involved in the innate immune response against IAV (Figure 
1-7). The first target of IAV are the ciliated epithelial cells of the respiratory airways (Wu 
et al., 2016). These cells produce chemotactic and antiviral molecules that rapidly 
recruit innate effector cells to initiate immune responses. These are monocytes, natural 
killer (NK) cells, and neutrophils. All cell types exhibit their own unique mechanisms 
through which they interact with virus-infected cells in order to minimise viral 
replication. In addition, they induce cells of the adaptive immune response for antigen-
specific immunity and memory. IL-1 and tumour necrosis factor-alpha (TNF-α) from 
monocytes and neutrophils activate endothelial adhesion molecules, which provoke 
migration of the cells of the innate immune response, blood borne dendritic cells (DC), 
macrophages, NK cells and neutrophils to the site of infection (Tripathi et al., 2015; 
Chen et al., 2018).  
Following IAV infection, the first type of leukocytes that are recruited into the lung 
are neutrophils and monocytes/macrophages, which therefore constitute the majority 
of infiltrating cells in the lung during influenza infection and play crucial roles in the 
virus clearance process, before the onset of an adaptive immune response (La Gruta et 
al., 2007; Tavares et al., 2017). Macrophages and neutrophils produce proinflammatory 
cytokines, including IL-1α, IL-1β, IL-18 and TNF-α (La Gruta et al., 2007; Nüssing et al., 
2018). In non-inflamed alveoli, i.e. also with initial viral exposure, AMs are the primary 
mononuclear phagocytes, and are the first cells of the host immune system to 
encounter inhaled antigens and pollutants. AMs are the most abundant cells of the 
innate immune response in the distal lung, which are located on the luminal surface of 
alveolar space (Joshi et al., 2018). AMs maintain the immunological homoeostasis and 
host defence in the lung, and they exhibit regulatory functions by non-specific ways of 
defence such as phagocytic activity, secretion of antimicrobials, IFN-γ, nitric oxide (NO) 
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and TNF-α (Byrne et al., 2015). For this reason, these cells act as the dominant 
scavenger cells in the lower part of the respiratory tract, and with appropriate 
stimulation, these cells produce proinflammatory cytokines and chemokines. In 
addition, AMs play a critical role in limiting the spread of IAV (Nathan, 1987; Tumpey et 
al., 2005). During infection, activated AMs phagocytose IAV-infected epithelial cells and 
therefore limit viral dissemination and determine the subsequent adaptive immune 
response (Tumpey et al., 2005; Nüssing et al., 2018).  
Neutrophils are one of the first-responders and rapidly recruited cells into the 
lungs during IAV infection (Wang et al., 2008; Camp and Jonsson, 2017). Neutrophils 
also contribute to the release of chemokine receptors (CR), which are important for the 
recruitment and stimulation of leukocytes. These are CCR1, CCR2, CCR3, CCR5, CXCR1, 
CXCR3, and CXCR4 in lung-recruited neutrophils. The activation of these induced CRs 
help in the modulation of neutrophil phagocytic activity and ligand-specific neutrophil 
migration (Tavares et al., 2017; Rudd et al., 2019). Neutrophils can be also involved in 
IAV-induced immunopathology because of an overwhelming recruitment of highly 
stimulated neutrophils through induction of neutrophil extracellular traps (NETs) and 
release of extracellular histones (Ramos and Fernandez-Sesma, 2015; Rudd et al., 2019).  
Additionally, NK cells are innate immune response cells and essential cytotoxic 
lymphocytes to eliminate IAV infection. It has been shown that NK cells play a role in 
lysis of IAV-infected cells, which is mediated by the binding of HA viral protein to the 
NKp44 and NKp46 receptors (Mendelson et al., 2010). NK cells target and lyse the IAV-
infected cells that express HA on their surface as a recognition signal through the 
activating receptor NKp46, which leads to target cell killing (Guo et al., 2011). 
Another important cell type involved in the innate immune process is DCs. They 
are professional antigen presenting cells (APC) and form an essential bridge between 
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the innate and adaptive immune systems during IAV infection. DCs initiate the adaptive 
immune response when naïve and memory T cells recognise the viral antigens 
presented by DCs. During the time of IAV infection, conventional dendritic cells (cDC) 
migrate from the lung into the draining lymph nodes (Heer et al., 2008), in which cDCs 
present IAV antigens to T cells and trigger a virus-specific CD8+ cytotoxic T lymphocyte 
(CTL) response, together with the help of CD4+ T, which enforce both cellular and 
humoral immune responses (Hintzen et al., 2006; GeurtsvanKessel et al., 2008; 
Koutsakos et al., 2019).   
In addition, the innate immune response includes an extremely robust antiviral 
effect mediated by IFNs, which have the ability to limit the early viral dissemination and 
consequently shape the adaptive immunity approach by secretion of their cytokines. 
IFNs are a family of cytokines with multifunctional effect, which are secreted by host 
cells. IFNs consist of 130-170 amino acids and have a molecular weight of 20-100 kDa. 
The mammalian IFNs are classified into three types according to amino acid sequence 
homology and the type of receptors that they use; these are type I, II  and type III IFNs 
(Randall and Goodbourn, 2008; Wang et al., 2017). Type I IFN includes 13 IFN-α smaller 
subtypes, and single subtypes for IFN-β, IFN-κ, IFN-ε, IFN-ω, IFN-δ and IFN-τ (Wang et 
al., 2017). Type III IFN includes IFN-λ1, IFN-λ2 and IFN- λ3; also known as IL-29, IL-28A 
and IL-28B respectively (Wang et al., 2017). Expression of type I and III interferons is 
activated in all cell types through recognition of viral molecules, particulary nucleic 
acids, by endosomal and cytoplasmic receptors (Fensterl and Sen, 2009). IFN-ƴ is the 
only member of the type II IFN family and is primarily produced by NK cells and T cells. 
This production is activated by IL-12 and IL-18 released from DCs and macrophages 
(Fensterl and Sen, 2009; Ramos and Fernandez-Sesma, 2015). IFN-ƴ has been 
extensively studied with respect to its expression and role in immune function 
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regulation. IFN-ƴ demonstrates immunomodulatory effects through enhancement of 
antigen processing and presentation, leukocyte trafficking, and influencing cellular 
proliferation and apoptosis (Kak et al., 2018). This gene has been also extensively 
characterized in many mammalian species, making it one of the most widely cloned 
immunoregulatory genes (Savan et al., 2009). It is implicated that IFN-ƴ regulates 
Bpifa1, Britto et al., 2013 showed that IFN-ƴ potentially inhibits Bpifa1 mRNA 
expression in mTECs cultured with 10 ng/ ml IFN-ƴ for 48 h using qPCR. Also, the authors 
found that IFN-ƴ reduced Bpifa1 protein secretion using ELISA at 48 h and 10 days. This 
effect was due to the direct effect of IFN-ƴ on airway epithelial cells. It was shown 
that IFN-ƴ decreased Bpifa1 mRNA expression after 24 hours in in vitro using polyp 
tissue samples from adult patients with chronic rhinosinusitis with nasal polyps 
(CRSwNP) treated with IFN-ƴ (Wei et al., 2014).  
On the other hand, Britto et al., 2019 showed a novel mechanism by which IFN-ƴ 
and Bpifa1 work in a synchronised programme to sense PAMP and trigger inflammatory 
responses to pathogen signals in the lung. The authors found that reduction of IFN-ƴ 
mRNA expression at 24 h in Bpifa1-/- mice intranasally administered LPS from P. 
aeruginosa compared with wild-type C57BL/6 mice led to reduction of 
polymorphonuclear cells (PMN) during acute inflammation of lung tissue by 
downregulation of IFN-stimulated cytokines and IFN-stimulated genes (ISG). Therefore, 
reduction of Bpifa1 dampens PMN cells recruitment through its effect on IFN signaling 
pathways. Reduced IFN signaling after downregulation of Bpifa1 limits recruitment of 
PMN cells and may aid as a protective mechanism to limit exaggerated PMN cells 









Figure 1-7. Innate and adaptive arms of the immune system during influenza virus infection. 
Influenza virus infection causes stimulation of the cells of the innate immunity, such as 
macrophages and neutrophils, which in turn produce pro-inflammatory cytokines, including IL-
1α, IL-1β, IL-18 and TNF-α leading to the recruitment of other leukocytes. Furthermore, these 
cells stimulate APCs by providing them with critical signal molecules. APCs subsequently present 
influenza virus antigens to CD8+ and CD4+ T cells for efficient viral removal. CD4+ T cells play a 
key role by providing assistance to CD8+ T cells and antibody-producing B cells to boost the 
antiviral response. Figure modified and adapted from Nüssing et al., 2018. 
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1.3.2 Adaptive immunity 
The second arm of the host defence against IAV is the adaptive immunity (Figure 
1-7). Unlike the innate immune response, adaptive immunity is pathogen-specific and 
has a delayed onset. It involves two main types of cells, B cells (responsible for humoral 
immunity; virus-specific antibodies) and T cells (responsible for cell-mediated 
immunity; cellular immunity). These cells are antigen-targeted memory cells, capturing 
and neutralising pathogenic microorganisms, representing a highly specific response in 
order to produce better protection to subsequent infections (Maines et al., 2008; Hillion 
et al., 2019). 
 Humoral immunity 
The humoral immunity against influenza viruses is mediated by B cells, and acts 
through the production of antibodies, also called immunoglobulins (Ig) to diverse 
influenza antigens. The most important antibodies are the HA-specific antibodies as 
these neutralise and overcome IAV to prevent disease. In addition, generated 
antibodies have the ability to bind to the surface of infected cells and stimulate either 
antibody-dependent cell-mediated cytotoxicity (ADCC) or complement activation 
(Waffarn and Baumgarth, 2011; Van de Sandt et al., 2012; Lam and Baumgarth, 2019).  
The humoral immune system, both mucosal and systemic, play a crucial role in 
immunity against influenza virus infection, and the cell-mediated immune response is 
principally effective in removing virus-infected cells. The primary port of entry for many 
microorganisms including influenza virus is the mucosal surfaces (Chen et al., 2018). 
Therefore, the mucosal immune system provides the first line of defence against 
microbes at the mucosal membranes of the host, apart from the innate immune 
response. Secretory immunoglobulin A (SIgA), and to some extent, IgM, function as the 
main antibodies at these surfaces by neutralising invading mucosal microorganisms, 
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thus preventing virus entry and replication. IgM appears early in the course of an 
infection and is always the first immunoglobulin to be produced during humoral 
immune response because IgM can be expressed without isotype switching and its level 
in the serum peaks ~ 7-10 days after infection/ immunisation (Greenfield, 2014). IgM 
molecules are pentamers in structure and as a result of the large size of the pentamers, 
IgM is predominantly found in blood and to a lesser extent, lymph fluid. Additionally, 
this pentameric structure makes IgM effective in activating the complement system. 
The rapid production of IgM and its efficient activation of the complement system are 
crucial in controlling of bloodstream infections (MacLennan et al., 1997; Janeway et al., 
2001).   
  IgA and IgG antibodies play key roles in the immune response against influenza 
virus infection (Lamm, 1997). Both immunoglobulins can be detected within 10-14 days 
after primary influenza virus infection (Cox et al., 2004). IgA contributes to protection 
in the upper respiratory system and serum IgG to protection in the lower regions (Cox 
et al., 2004; Bahadoran et al., 2016). IgA is the predominant immunoglobulin isotype 
neutralising antibody to influenza virus in the nasal secretions (Mazanec et al., 1995). 
IgA exists in two forms, monomeric and dimeric and the main role of this 
immunoglobulin is neutralisation of viruses, bacteria and toxins, and is predominantly 
present in mucosal surfaces such as the upper respiratory tract, providing the first line 
of defence in mucosal immunity at the primary entry of influenza virus infection 
(Greenfield, 2014; Muramatsu et al., 2014). The main anatomical locations of IgA 
synthesis and secretion are the respiratory epithelium, the gut, the lactating breast and 
other exocrine glands, for example the salivary and tear glands. IgA-secreting plasma 
cells are found mainly in the connective tissues called the lamina properia, which lies 
immediately below the basement membrane of many surface epithelia. From these 
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locations, IgA immunoglobulins can be transported across the epithelial layer to its 
external surface, for instance, to the bronchi or the lumen of the gut (Janeway et al., 
2001). On the other hand, IgG is the main isotype of immunoglobulins which is crucial 
for the systemic immunity, and is the principle isotype in the blood and the extracellular 
fluid and is secreted as a monomer that is small in size (Janeway et al., 2001). In contrast 
to IgM, IgG immunoglobulins are produced following subsequent class switching and 
antibody maturation (MacLennan et al., 1997). 
 IgG opsonizes microbes for phagocytosis by phagocytic cells and efficiently 
activates the complement system. On the other hand, IgA is less robust than IgG in 
opsonising microbes and is a weak stimulator of the complement. Not surprising, as IgG 
acts primarily in the body tissues, where molecules and accessory cells are available, 
while IgA acts primarily on epithelial surfaces, where complement and phagocytic cells 
are not commonly existing, and thus mainly operates as a neutralising antibody 
(Janeway et al., 2001). In the nasal washes and upon primary infection, IgA, IgG and IgM 
specific to HA have been identified using ELISA (Murphy et al., 1973; Murphy and 
Clements, 1989).   
In the murine family, there are four types of IgG antibodies including IgG1, IgG2a, 
IgG2b and IgG3. This classification is based on the immunological, biological and 
physiochemical characteristics of the IgGs (Nisonoff et al., 1975; Tizard, 2009; Gomes et 
al., 2019). While it has been shown that IgG plays a key role in the prevention of 
influenza virus infection and may inhibit its pathogenesis through reduction of its 
replication in the infected lung (Seibert et al., 2013), little is known about the IgG sub-
class response during influenza virus infection (Balkovic et al., 1987).  
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 Cellular immunity 
Infection with IAV elicits a cellular immune response including two types of   T cells, 
generally known as CD8+ T and CD4+ T cells. These cells have distinct but fundamental 
and important roles in the process of immune response regulation and eventual viral 
removal respectively (Van de Sandt et al., 2012; Bahadoran et al., 2016). 
During IAV infection, naïve CD8+ T cells are activated by DCs that have migrated 
from the lung tissue to the draining lymph nodes, particularly to the T cell zone, 
resulting in T cell proliferation and differentiation of CD8+ T cells into CTLs (Ho et al., 
2011; Kreijtz et al., 2011; Chen et al., 2018). Furthermore, other molecules are involved 
in the development and differentiation process of CD8+ T cells into CTLs during viral 
antigen stimulation, such as IFN-γ and IL-2 (Whitmire et al., 2005; Pipkin et al., 2010). 
CTLs then migrate towards the site of infection, where they can recognise and remove 
IAV-infected cells and prevent the production and dissemination of new progeny virus 
(Nakanishi et al., 2009). 
The second important cell type of adaptive immunity against IAV infection is CD4+ 
T cells, which are also called T-helper (Th) cells. They have the ability to target IAV-
infected epithelial cells through major histocompatibility complex (MHC) class II and 
induce expression of this complex in epithelial cells especially in murine models (Brown 
et al., 2012; McKinstry et al., 2012). The most significant contribution of IAV-specific 
CD4+ T cells is their ability to prompt antiviral B cell responses including antibody class 
switching, affinity maturation and the formation of long-lasting plasma cells (Kim et al., 
2011).  
Similar to CD8+ T cells, activation of CD4+ T cells during IAV infection occurs by 
migrated DCs in the draining lymph nodes (Ingulli et al., 1997). It is well accepted that 
CD4+ T cells are able to direct CD8+ T cells responses through secreting different types 
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of cytokines (Chen et al., 2018). However, the actual functions of these cells to promote 
and regulate CD8+ T cell responses against IAV infection remain enigmatic, as there is 
evidence that initiation of primary CD8+ T cell response to IAV infection can occur 
independently of CD4+ T cells in mice (Belz et al., 2002; La Gruta and Turner, 2014). 
  Diagnosis, treatment and prevention strategies  
Influenza virus remains one of the potential global health concerns in the current 
century, and it is well established that seasonal influenza infections and pandemic 
outbreaks cause high morbidity and mortality rates associated with serious economic 
burdens (WHO, 2014). In many cases, clinical examination of influenza virus infection is 
challenging because of the wide range of influenza symptoms especially in severity and 
their similarity with other respiratory virus infections (Dwyer et al., 2006). Histological 
changes in most cases of influenza virus infection are non-specific and the histological 
analysis alone is insufficient for a specific accurate diagnosis (Travis et al., 2002). 
Typically, diagnosis of influenza virus infection requires other supportive diagnostic 
techniques, for example isolation of the virus, serologic assays, rapid diagnostic tests 
including RT-PCR, IH or in situ hybridization as confirmative techniques (Taubenberger 
and Layne, 2001). Viral infections with non-fatal influenza strains predominantly involve 
the upper part of the respiratory system and the trachea, while fatal cases of influenza 
virus infection usually show significant evidence of pneumonia (Taubenberger and 
Morens, 2008). 
Vaccines and antiviral drugs are considered the most efficient means to prevent 
or treat influenza virus infections (Das et al., 2010). During the last seven decades, 
vaccination approaches have been used in order to protect people from influenza 
complications, particularly those who are at high risk of the severe infection. Current 
vaccination with inactivated influenza viruses fails to generate cross-protection against 
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pandemic, seasonal and avian viruses. However, these vaccination regimens trigger 
strain-specific antibody immune responses directed against the viral HA protein 
(Nüssing et al., 2018). Presently, two types of vaccines are used to fight seasonal 
influenza virus; live attenuated influenza vaccine (LAIV) which is able to induce 
protective mucosal immunity and trivalent inactivated vaccines (TIV) which stimulate a 
primarily humoral immune response (Fischer II et al., 2014; Ryan et al., 2018). 
Unfortunately, due to rapid virus evolution, vaccines need to be re-formulated and re-
administered most years. In addition, these vaccines do not provide protection against 
novel pandemic influenza strains (Krammer and Palese, 2015) and resistance against 
antiviral drugs is emerging and is considered a major concern (Zaraket et al., 2010). At 
present, NA inhibitors (zanamivir and oseltamivir) are used globally for treatment and 
prophylaxis purposes of influenza virus illness and are currently recognised by the 
World Health Organization (WHO) as the only antiviral agents (Gubareva et al., 2000; 
WHO, 2010). Pandemic influenza strains emerge sporadically because of co-infection 
with multiple virus strains in hosts. This co-infection can lead to genetic re-assortment 
of genes (antigenic shift) and are a substantial global health concern. Because of 
antigenic drifts and shifts, influenza viruses can easily escape the antiviral drug and 
immune neutralisation activity and these newly produced subtypes are a substantial 
global health concern (Wright et al., 2007; Zeng et al., 2017). As a result, it is important 
to understand how innate and intrinsic mechanisms modulate and trigger influenza 
virus infection and how these may be used to develop novel therapeutic interventions. 
  Aims of this thesis 
The aims of this work were to investigate further other possible functions of 
Bpifa1. The influence of Bpifa1 in the transmission of IAV was investigated using a 
murine transmission model in which transmission was attempted between infected and 
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non-infected wild-type C57BL/6J and Bpifa1-/- mice. To assess whether Bpifa1 has any 
effect on the adaptive immune response during IAV infection, the adaptive immune 































  Tissue culture 
Two cell lines were used throughout this thesis, human embryonic kidney 293T 
cells (HEK 293T; epithelial cells) (Graham et al., 1977) and Madin-Darby canine kidney 
cells (MDCK) (Dukes et al., 2011). Both cell lines were maintained in Dulbecco’s 
modified Eagles medium/high glucose (DMEM) (Sigma, D6429), supplemented with 
10% volume per volume (v/v) foetal bovine serum (FBS) (Sigma, F9665), 1% L-glutamine 
(Sigma, G7513) and 1% penicillin-streptomycin (Sigma, P0781). Cells were incubated in 
a humidified atmosphere at 37°C, in 5% CO2 incubator (SANYO, MCO175). They were 
cultured in sterile T175 cm2 tissue culture flasks (Corning Incorporated, 431079) and 
were passaged regularly when approaching confluence. Medium was removed from the 
flask and cells washed three times with pre-warmed (to 37°C) sterile Dulbecco’s 
phosphate-buffered saline (PBS) (Sigma, D8662). Cells were detached by the addition 
of 5 ml of 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) (1X) (Life technologies, 
25200-072). After a short incubation period (5-10 min), 5 ml fresh medium was added 
to re-suspend the cells. The 293T cells were then pelleted by centrifugation at 475 x 
gravity (x g) for 5 min. The supernatant was decanted and the cell pellet resuspended 
in 10 ml fresh medium. From this 10 ml amount, a small sample of the cell suspension 
(10 μl) was mixed with an equal volume of 0.4% trypan blue (Sigma, T8154) and the cell 
density calculated using 10 μl and a haemocytometer. Suitable numbers of cells were 
then seeded in new flasks or plates as required. 
  Molecular cloning of Bpifa1  
2.2.1  Preparation of target DNA 
In order to study Bpifa1, the full-length complementary DNA (cDNA) of the gene 
was cloned and expressed. Using Luria-Bertani (LB) broth and agar, one Nunc™ cell 
culture Petri dish (Thermo Fisher, 168381) was cultured; which contained ampicillin 
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(Sigma, A5354) in a concentration of 50 µg/ml with Mus musculus palate, lung and nasal 
epithelium associated fully sequenced cDNA clone (GenBank, Accession No.; BC054375) 
(reSource, IRAVp968E10103D) (host species. E. coli; host strain: DH10B TonA) and 
incubated at 37°C overnight (Stuart® orbital incubator, SI500). Then, five bacterial 
colonies were chosen from this dish and inoculated into 5 separate tubes, containing 3 
ml of LB broth supplemented with ampicillin and mixed thoroughly using a sterile loop. 
These tubes were placed in an incubator with shaking 200 revolutions per minute (rpm) 
overnight at 37°C (Labnet Incubator Shaker, 311DS). Each sample was divided into two 
parts, 1.5 ml for DNA extraction using QIAprep Spin Miniprep Kit (QIAGEN, 27104) and 
1.5 ml for glycerol stocks which were made by adding 250 μl of 60% (v/v) sterile glycerol 
(Sigma, G2025) to 750 μl of bacterial culture in a cryotube and then vortexed and stored 
at -80°C for long-term storage. 
2.2.2  Small scale purification of plasmid DNA (mini preparation) 
Using QIAprep Spin Miniprep Kit (QIAGEN, 27104), bacterial overnight cultures 
containing transformed bacteria in LB medium were pelleted by centrifugation at 6800 
x g for 3 min at room temperature (RT). The supernatants were discarded and the 
pellets resuspended in 250 μl Buffer P1 and transferred to a microcentrifuge tube. To 
this 250 μl, Buffer P2 was added and mixed thoroughly by inverting the tube 4-6 times 
until the colour turned blue, followed by incubation at RT for no more than 5 min. 
Following this, 350 μl Buffer N3 was added and mixed immediately and thoroughly by 
inverting the tube 4-6 times until the solution became colourless. 
The cells were then centrifuged at 15,616 x g for 10 min, 800 μl supernatant 
were collected and transferred to the QIAprep 2.0 spin column by pipetting and 
centrifuged at 15,616 x g for one min, and the flow-through was discarded. Then, the 
QIAprep 2.0 spin column was washed by adding 500 μl Buffer PB and centrifuged at 
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15,616 x g for one min and the flow-through was discarded. Another washing of the 
QIAprep 2.0 spin column was performed by adding 750 μl Buffer PE and centrifuged at 
15,616 x g for one min and the flow-through was discarded. After that, the QIAprep 2.0 
spin column was transferred to the collection tube provided by the kit, and another 
centrifugation was applied at 15,616 x g for one min to remove residual wash buffer. 
The QIAprep 2.0 spin column was placed in a clean 1.5 ml microcentrifuge tube and 
DNA was eluted by adding 50 μl Buffer EB [10 mM (millimolar) Tris-Cl, pH 8.5] to the 
centre of the QIAprep 2.0 spin column. After leaving it standing for one min, the tube 
was stored at -20°C until use.  
2.2.3 Conventional PCR and preparation of DNA 
After DNA extraction by using Miniprep as mentioned in section 2.2.2, 
amplification of DNA was performed by PCR using the primers listed in Table 2-1 
(Eurofins Genomics) to add restriction sites.  
Table 2-1. Primers used in PCR 
 
Reactions were carried out in 0.1 ml thin walled 8-strip PCR tubes (Starlab, 
A1402-3800), with a total reaction mixture of 20 µl as shown in Table 2-2. Standard 
reactions were set up by using the KOD XL DNA Polymerase kit (Novagen®, 71087-3) 
comprising 2 μl of 10X PCR buffer for KOD XL DNA Polymerase (Novagen®, 71157), 2 μl 
of deoxynucleoside triphosphates (dNTPs) (2 mM each) (Novagen®, 71154), and 0.8 μl 
of each of the forward and reverse primers in a concentration of 100 picomole 














(pmol)/μl, 0.2 μl KOD XL DNA Polymerase (Novagen®, 71662) in a concentration of 2.5 
Units (U)/μl , 12.2 μl nuclease-free water (Ambion®, AM9937) and 2 μl of the target DNA 
sample per each well.  
Table 2-2. Standard PCR reaction setup 
Component Volume/ sample (µl) 
10X buffer for KOD XL DNA Polymerase 2 
dNTPs (2 mM each) 2 
Forward primer (F) 0.8 
Reverse primer(R) 0.8 
KOD XL DNA Polymerase (2.5 Unit/μl) 0.2 
Nuclease-free water 12.2 
Template DNA 2 
Total volume 20 
 
Reaction mixtures were prepared in a Captair® Biohood (Erlab) in which 
elimination of DNA contamination by exposure to ultraviolet light (UV) was performed 
prior to use. PCR reactions were carried out in a T100™ thermal cycler (BIO-RAD, Catalog 
# 186-1096). The thermal cycling parameters were as follows: 1) denaturation at 94°C 
for 30 sec; 2) annealing at 66°C for 30 sec; 3) extension at 72°C for 30 sec, followed by 
further 29 cycles of steps 1) to 3); 4) final extension at 74°C for 10 min. After that, the 
samples were electrophoresed through 1% weight per volume (w/v) agarose gels.  
2.2.4  Agarose gel electrophoresis 
Portions of 10 μl from the PCR products were mixed in a ratio of 1:6 with blue 
orange 6X loading dye (Promega, G 190 A) and were then electrophoresed through 1% 
w/v agarose gels (Molecular Grad4, Bioline, BIO-41025) containing fluorescent nucleic 
acid gel stain 10:100,000 v/v SYBR® Safe DNA gel stain (Invitrogen, S33102) in 1X Tris-
acetate-EDTA (TAE) buffer (40 mM Tris-base, 20 mM glacial acetic acid, 1 mM EDTA pH 
8.0).  
Then, the solution was poured carefully to avoid the occurrence of air bubbles 
into the plastic tray after sealing its ends with adhesive laboratory tape. The comb was 
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then inserted before the agarose solidified completely. After that, the adhesive tape 
and comb were withdrawn gently and gels were placed horizontally in plastic 
electrophoresis tanks (BioRad, UK), filled with 1X TAE buffer and ran at 100 voltage 
(Volts), 250 milliampere (mA) and 100 watt (W) for 50 min. Gels were then documented 
under ultraviolet light using the gel analysis tool of ChemiDoc™ Touch Imaging System 
(BIO-RAD, Catalog # 170-8370), images taken and target DNA bands sizes compared 
with 1 kilobase (kb) DNA marker (Bioline, BIO-33053).       
2.2.5  Extraction of DNA for Bpifa1  
Extraction of DNA samples was performed by using PureLink™ Quick Gel 
Extraction Kit (Invitrogen, K210012). Initially, a minimal area of gel containing the DNA 
fragment of interest was excised by a clean, sharp disposable scalpel (Swan-Morton®, 
0501) and placed in a clean 1.5 ml Eppendorf tube and ~600 μl gel solubilisation Buffer 
L3 were added to the excised gel. This tube with the gel slice and Buffer L3 was placed 
into a 50°C heat block that was equilibrated to this temperature before start and 
incubated for 10 min. During the incubation, the tube was inverted every 3 min to mix 
and ensure gel dissolution. After the gel slice appeared dissolved, the tube was 
incubated for an additional 5 min. After that, one gel volume of isopropanol was added 
to the dissolved gel slice and mixed well. The dissolved gel piece was pipetted into a 
Quick Gel Extraction Column inside a wash tube and centrifuged at >12,000 x g for one 
min, the flow-through was discarded and the column placed into the wash tube. After 
that, 500 μl Wash Buffer (W1) containing ethanol were added to the column. Then, the 
column was centrifuged at >12,000 x g for one min and the flow-through was discarded 
and the column was placed into the wash tube. To remove ethanol, the column was 
centrifuged at 16,873 xg for 2 min and then the flow-through was discarded. For DNA 
elution, the column was placed into a recovery tube and 50 μl Elution Buffer (E5) was 
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added to the centre of the column and the tube was incubated for one min at RT. 
Following this step, the tube was centrifuged at >12,000 x g for one min and the purified 
DNA was stored at 4°C for immediate use or at -20°C for long-term storage. 
2.2.6  Restriction digest reaction and purification of the DNA  
After that, Bpifa1 cDNA was cloned into pVR1255 vector (Figure 2-1) (Norman et 
al., 1997) between NotI and BamHI sites using the restriction digest technique. This was 
performed in a total volume of 20 μl (Table 2-3) containing 11 μl of nuclease-free water, 
2 μl of 1X NEB 3.1-buffer (New England Biolabs, B7203S) 10X concentrate, 1 μl of NotI 
(  ) (New England Biolabs, R0189S) in a concentration of 10,000 
U/ml, 1 μl of BamHI ( ) (New England Biolabs, R0136S) in a 





Figure 2-1. Annotated structure of pVR1255. 
Red arrows denote genes with the direction of transcription shown. Kanamycin resistance is 
encoded in the plasmid. NotI and BamHI were used to excise the LUX gene in order to insert the 
Bpifa1 gene.  
 





























































Nuclease-free water 11 11 
1X NEB 3.1-buffer 2 2 
Enzyme (NotI) 1 1 
Enzyme (BamHI) 1 1 
PCR product /vector 5 5 
Total volume 20 20  
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The mixtures were incubated for 2 h at 37°C. After digestion, 2 μl of 10X buffer 
(invitrogen, PIN Y01371) and 1 μl of calf intestinal alkaline phosphatase (CIAP) (invitrogen, 
18009-027) in a concentration of 1 U/µl were added and samples were incubated further 
20 min at 37°C.  
 Purification of the Bpifa1 PCR products and pVR1255 vector was performed using 
the QIAquick® PCR Purification Kit (QIAGEN, 28104) in which 5 volumes Buffer PB were 
added to one volume of the PCR product/vector and mixed. To bind DNA, a QIAquick 
column was placed in a 2 ml collection tube provided in the kit, the sample was applied to 
the QIAquick column and centrifuged at 17,900 x g for one min, the flow-through was 
discarded, and the QIAquick column was placed in the same tube. Following this, a 
washing step using 750 μl Buffer PE was added to the QIAquick column and centrifuged 
at 17,900 x g for one min and the flow-through was discarded and the QIAquick column 
was placed in the same tube. After that, the QIAquick column was centrifuged once more 
in the provided 2 ml collection tube at 17,900 x g for one min to remove residual wash 
buffer. To elute DNA, each QIAquick column was placed in a clean 1.5 ml microcentrifuge 
tube and 50 μl Buffer EB (10 mM Tris-Cl, pH 8.5) were added to the centre of the QIAquick 
membrane. The column was let stand for one min and then centrifuged at 17,900 x g for 
one min and stored at 4°C until the next step. 
2.2.7 Ligation reaction and transformation of plasmids 
The ligation reaction was performed on a total volume of 20 μl; using 1 μl 
plasmid, 4 μl DNA fragment, 1 μl of T4 DNA ligase (Invitrogen,15224-017) in a 
concentration of 1U/µl, 4 μl of 5X T4 ligase buffer (Invitrogen, PIN Y90001), and 10 μl of 
nuclease-free water. The ligation mixture was incubated overnight at 4°C in a beaker of 
water. Ligation samples were transformed using One Shot® TOP10 chemically 
competent E. coli (Invitrogen, C404010) following the manufacturer’s instructions. 
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Initially, one vial of One Shot® TOP10 chemically competent cells was thawed for each 
transformation. Then, 5 μl of the DNA were added to a vial of One Shot® cells and mixed 
gently and the vials were incubated on ice for 30 min. Cells were heat-shocked for 30 
sec at 42°C without shaking using a water bath (Grant instruments, Cambridge Ltd, 
England). After that, the vials were immediately removed from the 42°C bath and 
placed on ice for 2 min. Aseptically, 250 μl of pre-warmed super optimal broth with 
catabolite repression (S.O.C.) medium (Invitrogen, 15544-034) were added to each vial. 
The vials were capped tightly and shaken horizontally at 37°C for 1 h at 200 rpm in a 
shaking incubator (Labnet Incubator Shaker, 311DS). Then, 20 μl of S.O.C. medium were 
spread over pre-warmed agar plates supplemented with 30 µg/ml kanamycin sulphate, 
and 40 μl from each transformation were spread over pre-warmed agar plates and the 
agar plates were incubated at 37°C overnight. 
After the overnight incubation, several colonies from the kanamycin sulphate agar 
plates were grown in 15 ml falcon tubes containing 3 ml LB broth supplemented with 
30 µg/ml kanamycin sulphate. Incubation took place overnight at 37°C, with 200 rpm 
shaking. A sample from each falcon tube was streaked out on a kanamycin sulphate 
agar plate, which was then incubated overnight at 37°C. The remaining bacteria were 
pelleted by centrifugation at 6,800 x g for 3 min at RT (15–25°C) (Centrifuge 5810 R, 
Eppendorf), and plasmid DNA was extracted using QIAprep® Spin Miniprep Kit (QIAGEN, 
27104) as mentioned before (see section 2.2.2). Furthermore, another restriction 
reaction and 1% gel electrophoresis were performed as mentioned before in sections 
2.2.6 and 2.2.4 to confirm the insertion of the DNA of interest. Several clones were sent 
to and sequenced at Source Bioscience (Rochdale, UK) using specific primers (Table 2-
4). Data were aligned using Basic Local Alignment Search Tool (BLAST) on the National 
54 
 
Centre for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/) 
to confirm the correct sequence and orientation of recombinant Bpifa1-pVR1255. 




2.2.8 Large scale purification of plasmid DNA (Maxi preparation) 
To purify larger quantities of DNA, the EndoFree® Plasmid Maxi Kit (10) (QIAGEN, 
12362) was used. Either a single colony grown on a selective LB agar plate or ~5 μl 
partially thawed glycerol stock was placed in a 10 ml falcon tube containing LB medium 
supplemented with 30 μg/ml kanamycin sulphate and incubated with rotation (200 
rpm) at 37°C for 4-8 h using an orbital incubator (SANYO). This culture was then added 
to 90 ml LB medium supplemented with 30 μg/ml kanamycin sulphate in a 1 litre flask 
and incubated at 37°C in an orbital shaker at 200 rpm overnight. The overnight LB 
culture was then centrifuged at 6,000 x g for 15 min at 4°C using high speed centrifuge 
(Avanti® J-E Centrifuge, Beckman Coulter) and the pellet was completely resuspended 
in 10 ml buffer P1 (50 mM Tris-Cl, pH 8.0; 10 mM EDTA, 100 μg/ml RNase A). The 
bacteria were then lysed by adding 10 ml buffer P2 (200 mM NaOH, 1% [w/v] SDS) and 
mixed thoroughly by inverting the tube 4-6 times, then incubated at RT for 5 min until 
the solution turned blue. During the incubation, the QIAfilter Cartridge cap was screwed 
onto the outlet nozzle of the QIAfilter Cartridge and placed in a 50 ml falcon tube. Then, 
10 ml chilled buffer P3 (neutralisation buffer; 3.0 molar (M) potassium acetate, pH 5.5) 
was added to the lysate and mixed thoroughly by inverting the tube 4-6 times until the 
lysate was completely colourless. 





After that, the lysate was poured into the barrel of the QIAfilter Cartridge and 
incubated at RT for 30-45 min. The cap was removed from the QIAfilter Cartridge outlet 
nozzle, the plunger was gently inserted into the QIAfilter Cartridge, and the cell lysate 
was filtered into a 50 ml falcon tube. To this, 2.5 ml buffer ER was added to the filtered 
lysate and mixed by inverting the tube approximately 10 times, and incubated on ice 
for 30 min. A QIAGEN-tip 500 was equilibrated by applying 10 ml buffer QBT [750 mM 
sodium chloride (NaCl); 50 mM 4-morpholinopropanesulphonic acid (MOPS), pH 7.0; 
15% isopropanol (v/v), 0.15% triton® (v/v)] and the supernatant was added and the 
column allowed to empty by gravity flow. After 30 min incubation, the filtered lysate 
was applied to the QIAGEN tip and allowed to enter the tip and then washed twice with 
30 ml buffer QC [1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v)] prior to DNA 
elution with 15 ml buffer QN [1.6 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v)]. 
To precipitate the DNA, 10.5 ml isopropanol (Sigma, I9516) was added to the eluted 
DNA and mixed, then the mixture centrifuged at 15,000 x g for 30 min at 4°C and the 
supernatant carefully removed. The resulting pellet was washed with 5 ml of 70% 
ethanol (Sigma, E7023) and centrifuged again at 15,000 x g for 10 min. The supernatant 
was carefully removed without disturbing the pellet. The pellet was air-dried for 5-10 
min and the DNA dissolved in 1 ml tris-EDTA (TE) buffer (10 mM Tris, pH 8.0; 1 mM 
EDTA).  
2.2.9 Measurement of DNA concentration 
The yield DNA concentration was calculated using UV spectrometry and 
measured using Qubit® dsDNA BR reagent *200X concentrate in the dimethyl sulfoxide 
(DMSO) Kit (Life technologies invitrogen, Q32850) following the manufacturer’s 
manual. The Qubit® working solution was prepared by diluting the Qubit® dsDNA BR 
reagent (Component A) 1:200 in Qubit® dsDNA BR buffer (component B) using a clean 
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1.5 ml Eppendorf tube (STAR LAB, S1615-5500). Then, 190 μl of Qubit® working solution 
were loaded into each of the tubes used for standards 1 (Component C) and 2 
(Component D) using thin-walled, clear, 0.5 ml PCR tubes (Axygen® PCR-05-C tubes; 
VWR, part No. 10011-830). After that, 10 μl of each Qubit® standard were added to the 
appropriate tube, 199 μl of the Qubit® working solution were loaded into individual 
assay tubes and 1 μl of the DNA sample was added, and then mixed by vortexing for 2-
3 sec, so that the final volume in each tube after adding each sample was 200 μl. All 
tubes were incubated at RT for 2 min and the DNA concentration of the samples was 
calculated using the following equation: 





Where: QF value = the value given by the Qubit® 2.0 Fluorometer, x = the number of 
microliters of sample added to the assay tube. 
  In vitro expression of recombinant Bpifa1-pVR1255 using mammalian 
expression vector 
2.3.1 Maintenance of cell cultures 
  HEK 293T cells were maintained as described in section 2.1.  
2.3.2  In vitro transfection 
In order to express Bpifa1-pVR1255, pVR1255 promoter-based vector, designed 
for in vivo gene therapy was used as a negative control. Initially, the recombinant 
Bpifa1-pVR1255 was concentrated using the EndoFree® Plasmid Maxi Kit (QIAGEN, 
12362) as described in section 2.2.8. Following this, the DNA concentration was 
measured using the Qubit® dsDNA BR reagent *200X concentrate in DMSO Kit (Life 
technologies invitrogen, Q32850) as described in section 2.2.9. HEK 293T cells were 
grown in T175 cm2 tissue culture flasks (Corning Incorporated, 431079) containing 30 
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ml DMEM (Sigma, D6429) supplemented with 10% FBS (Sigma, F9665), 1% penicillin-
streptomycin (Sigma, P4458) and 1% L-glutamine (Sigma, G7513). 
The experiment carried out using 2 ml culture media containing 2x105 cells/well 
were seeded into a six well plate (Corning Incorporated, 3516) and incubated at 37°C, 
5% CO2 overnight. Transfections were performed when cells were 50-60% confluent 
using two Eppendorf tubes (STAR LAB, S1615-5500) labelled as A and B.  
The experiment included three Eppendorf tubes labelled as (A) contained 86 µl of 
2X 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)/well [(280 mM NaCl, 
1.5 mM HEPES, 1.5 mM sodium phosphate dibasic (Na2HPO4); pH 7.05-7.12)]. In 
addition, another three Eppendorf tubes labelled as (B) (86 µl total volume) were 
prepared; the first tube contained 1.28 µg/ml (1.3 µl) Bpifa1-pVR1255, the second tube 
contained 0.3 µg/ml (5.7 µl) pVR1255 as a negative control and the third tube contained 
1.6 µg/ml (1 µl) pEGFP-C1 (BD Bioscience Clontech, #6084-1) as a control for 
transfection efficiency. The content of each tube was mixed separately with nuclease-
free water and freshly prepared and filtered 2M calcium chloride (CaCl2) (Sigma, C5670), 
which was prepared by mixing it with nuclease-free water and filtered using 0.2 um 
Minisart® syringe filter (Sartorius, FC121) (Table 2-5). After that, the content of tube B 
was added to tube A in a drop wise fashion using a sterile filter tip, and incubated for 
30 min at RT. Then, 172 µl of culture media were taken and the transfection solution 
(172 µl total volume) was added in a drop wise fashion to the cells and then incubated 




Table 2-5. In vitro transfection of recombinant Bpifa1-pVR1255 using calcium phosphate 
 
 
2.3.3  Proteins analysis  
 Collection of cells and supernatants 
After 24 h  incubation, 2 ml supernatants were collected from Bpifa1-pVR1255 
and pVR1255 wells in a 15 ml falcon tube (Corning Incorporated, 430791) followed by 
centrifugation at 4°C for 5 min at 1902 x g (Mistral 3000i, Sanyo, UK) and then 50 µl 
from each supernatant was mixed with 10 µl of 2X sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer [3.8ml distilled water 
(DW), 50 µl of 1M Tris; pH 6.8, 10 µl of 20% SDS (Sigma, L3771), 2 µl of 2-
mercaptoethanol (Sigma, M3148), 10 µl of glycerol (Sigma, G2025) and 5 µl of 
bromophenol blue (Sigma, B8026)] and stored at -20°C. For the preparation of cell 
pellets, cells were scraped off the wall of the culture plates using a 25 cm cell scraper 
(VWR, blade width 20 mm,734-2602) after adding 500 µl of PBS. Cells were pelleted by 
centrifugation at 4°C for 5 min at 832 x g  (Microfuge® 22R Centrifuge, Beckman 
Coulter™), PBS was decanted and the pellets were re-suspended in the remaining PBS 
(± 50 μl). An equal volume of 2X SDS-PAGE loading buffer was added and cells were 
denatured by sonication using a Vibra-Cell™ Ultrasonic Liquid Processor (Sonics, VCX 
130) for 5 sec at selected pulsing cycle 20 and amplitude 45%, and then heating at 95°C 
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centrifugation at 3099 x g (Centrifuge 5418, Eppendorf) for 30 sec before storage at -
20°C.  
  Pre-preparation of SDS-PAGE 
Using AE 6530 mPAGE (ATTA corporation, Japan), two plain glass plates and two 
1 mm glass plates were cleaned with 70% ethanol using white dry wipes (Kimtech 
Science, 7552). One 1 mm gasket was laid with its convex side upside on the glass plate 
and the plain glass plate was overlaid and clamped together with the pair of clips on the 
sides to form two assembled gel casts and stood vertically on a level flat. 
15% resolving gel (approximately 15 ml for two gels) was prepared [5 ml of 1.5 M 
Tris pH 8.8, 7.5 ml 30% acrylamide (Sigma, A3699), 2.4 ml of DW, 75 µl of 20% SDS 
(Sigma, L3771), 75 µl 10% ammonium persulfate (Sigma,A3678); prepared as 0.05 g 
dissolved in 450 µl DW and 25 µl of N,N,N′,N′- Tetramethylethylenediamine 
(TEMED) (Sigma, T9281)], mixed in a universal tube and loaded followed by loading of 
1 ml of DW on the top of the gel and left at least 30 min for separating gels to 
polymerise. After polymerisation of separating gels, the overlaid water was discarded 
by tilting the glass plate sandwich and the empty space between the two plates was 
dried using paper tissue (Kimtech Science, 7552). Then, a stacking gel solution (5 ml for 
two gels) was prepared [620 µl of 0.5 M Tris pH 6.8, 833 µl of 30% acrylamide, 3.817 ml 
DW, 25 µl of 20% SDS, 50 µl of 10% ammonium persulfate and 5 µl TEMED] and gently 
introduced to the level about 2 mm lower than the notch of the 1 mm glass plate to 
avoid trapping air bubbles at its teeth. Then, a 1 mm 12-well comb was carefully 
inserted between the glass plates to avoid any air bubbles and left for about 30 min to 
allow the stacking gel to polymerise. The comb was gently removed by slowly pushing 
it up. The clips were removed and gaskets were slowly pulled to the outside. Two gel 
holders were prepared and gel sandwiches were placed on the gel holders, with their 
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plain surfaces facing the gel holders. The humps of the gel holders were pushed with 
the thumbs while holding the core assembly with other fingers until it clamped with a 
click. 
After that, about 400 ml of running buffer prepared from 100 ml of 10X Tris-
glycine [30 g Trizma®base (Sigma, T6066), 144 g glycine (Sigma, G8898) dissolved in DW 
and the volume completed to one litre], 5 ml of 20% SDS and 895 ml of DW were gently 
poured into the lower buffer chamber with care to avoid raising air bubbles, and the 
core assembly was slowly lowered into the lower buffer chamber. About 70-80 ml of 
running buffer was gently poured in the upper buffer so the level of the buffer was 2-3 
mm lower than the top of the glass plates. Air bubbles were removed from the sample 
wells by using a microliter syringe needle (Hamiltor Bonaduz AG, CH-7402), then the 
samples (10 µl) and Spectra™ multicolour broad range protein marker (Thermo 
Scientific™, #26634) (10 µl) were applied using gel saver II tips (Starlab, I 1022-0000) 
and run at 60 V, 200 mA and 100 W for 2 h, then at 100 V, 250 mA and 100 W for 2 h.  
 Western immunoblotting 
Proteins were transferred with cold condition using ice packs from the SDS-
PAGE gel onto a Polyvinylidene difluoride membrane (PVDF membrane; Immobilon®-P, 
IPVH 00010) to prepare a western immunoblotting sandwich (Figure 2-2) using an 
Amersham Pharmacia Biotech electrophoresis power supply (IEC, 18-1130-01) at 200 V, 
350 mA and 100 W for 1 h and 15 min in transfer buffer (100 ml of 10X Tris-glycine, 200 
ml methanol and 700 ml DW). Immunodection of proteins was performed as follows: 
membranes were incubated overnight in 5% blocking buffer (w/v) [(2.5 g skimmed milk 
powder (Marvel) in 50 ml of 1X Tris-buffered saline-tween 20 (TBST) [100 ml 10X Tris-
buffered saline (TBS) (50 g NaCl (Sigma, S7653), 200 ml 1M Tris-HCl, pH 7.6 in a total 
volume of 1 litre DW), 900 ml DW and 1 ml tween 20 (Sigma, P1379)] with agitation at 
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4°C. Membranes were then incubated with the primary and secondary antibodies 
diluted in 1X TBST with dried skimmed milk at RT and agitating for two and one h 
respectively. Washing of the membranes was performed using 30 ml of 1X TBST three 
times for 10 min, each with agitating. Antibody binding was visualised using clarity™ 
western ECL substrate (BIO-RAD, #170-5060) in a ratio of 1:1 [consisting of two 
reagents; clarity western peroxide reagent and clarity western luminol/enhancer 
reagent] and compared to a Spectra™ multicolour broad range protein marker (Thermo 
Scientific™, #26634), the band density was measured using the gel analysis tool of the 
ChemiDoc™ Touch Imaging System (BIO-RAD, Catalog # 170-8370).   
 
Figure 2-2. Preparation of western immunoblotting sandwich 
 
 Antibodies and their concentrations 
All tested samples were analysed by 15% SDS-PAGE. For Bpifa1-pVR1255 in vitro 
expression, rabbit anti-mouse Bpifa1 antibody (Musa et al., 2012) was used as a primary 
antibody in a dilution of 1:5,000, and horseradish peroxidase (HRP) goat anti-rabbit IgG 
antibody (peroxidase) (Vector Laboratories, PI-1000) as a secondary antibody in a 
dilution of 1: 5,000. For the in vivo expression of Bpifa1-pVR1255 (pilot experiments and 
testing of BAL samples), the primary and secondary antibodies were used in a dilution 
of 1:500 and 1:1,000, respectively. For the in vivo expression of BPIFA1 in the pilot 
experiments, rabbit anti-human BPIFA1 antibody (kindly provided by Professor Colin 
Bingle, University of Sheffield) was used as a primary antibody in a dilution of 1:500, 
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and HRP goat anti-rabbit IgG antibody (peroxidase) (Vector Laboratories, PI-1000) as a 
secondary antibody in a dilution of 1:1,000. 
For the in vivo expression of pMSCV-IRES-GFP (third pilot experiment), green 
fluorescent protein [GFP (B-2)], a mouse monoclonal IgG2a (kappa light chain) (Santa 
Cruz Biotechnology, sc-9996) was used in a dilution of 1:1,000, and anti-mouse IgG 
(whole molecule)-peroxidase antibody produced in goat (Sigma, A4416) was used as a 
secondary antibody in a dilution of 1:10,000. 
  In vivo experiments   
2.4.1 Viruses 
Two strains of IAV were used in this study, A/X-31 (X-31, H3N2) and A/Puerto 
Rico/8/34 [A/PR/8/34 (PR8, H1N1) (Kilbourne, 1969; Baez et al., 1980). Both were 
propagated in the allantoic cavity of 9-day-old embryonated chicken eggs and titred by 
plaque assay on MDCK cells (Matrosovich et al., 2006). The X-31 strain contains the six 
internal segments of PR8 but expresses H3N2 surface proteins, while PR8 expresses 
H1N1 surface proteins (Kilbourne, 1969; Lamb and Krug, 1996). PR8 is a mouse-adapted 
influenza virus that is known to cause severe infection in mice. On the other hand, X-31 
causes mild to moderate illness in mice, despite containing the six internal genes of PR8 
(Rutigliano et al., 2014). Different doses of both viruses were used throughout the 
study. For IAV X-31, doses of 10, 102 and 103 PFU were used for the immune response 
experiments, and 5x104 PFU dose was used for the transmission experiments to ensure 
occurrence of virus transmission from the infected (index) mice to the non-infected 
(contact) mice. While for IAV PR8, doses of only 50 and 103 PFU were used in the 




The mouse work was reviewed and approved by the local University of Liverpool 
Animal Welfare Committee and performed under UK Home Office Project Licences 
I2EF4E56C and 70/8599. Mice were specified pathogen-free (SPF) and maintained 
under barrier conditions in individually ventilated cages (IVC) (Techniplat, GM500) 
subjected to a 12 h light/dark cycle. Food and water were provided ad libitum. The 
generation of the transgenic Bpifa1-/- mice is described elsewhere (Akram et al., 2018). 
Briefly, transfection of wild-type C57BL/6J mouse embryonic stem cells was performed 
by using a conditional targeting vector for Bpifa1 which includes exons 2 and 3 (Genious 
Targeting Laboratory, Inc., Ronkonkoma, NY). 
These embryonic stem cells were microinjected into BALB/c blastocysts. The 
resulting chimeras with a high percentage of black coat colour were mated to wild-type 
C57BL/6J mice to generate F1 heterozygous offspring. Correctly targeted F1 mice 
contained a Neo-selection cassette, three lox-P sites and two FRT sites. Deletion of the 
Neo-cassette was achieved by breeding with a heterozygous wild-type C57BL/6J 
background FLP+/- mouse (Jackson Laboratories, JAX; stock# 003800). Due to these FLP 
mice are heterozygotes (homozygotes are embryonic lethal), the resulting F2 mosaic 
mice were screened for the FLP transgene presence and deletion of the Neo cassette. 
After breeding with wild-type C57BL/6J mice, the resulting F3 generation was also 
screened for the absence and deletion of FLP transgene of the Neo cassette. This mouse 
was bred with another heterozygous FLP-/- and Neo-/- F3 offspring to produce a 
homozygous floxed F4 mouse without the FLP transgene and without the Neo cassette 
(Bpifa1loxP). 
In order to generate a systemic Bpifa1-/- mouse, Bpifa1loxP mice were mated with a 
mouse containing the Cre-recombinase transgene under the control of hCMV IE 
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promoter (CMV-Cre, formally B6.C-Tg (Tg (CMV-Cre)1Cgn/J; JAX Stock No: 006054). 
After that, Bpifa1loxP and Bpifa1-/- mice were deposited at the MRC Mammalian Genetics 
Unit (Harwell, UK; FESA: 5217 and 5945 respectively) and then transferred from there 
to the University of Liverpool (Akram et al., 2018). The C57BL/6J strain was selected for 
use as the background as this is a widely used, well characterised inbred strain (Ward 
et al., 2001; Zevnik et al., 2014), which is known to be susceptible to IAV infection 
(Eisfeld et al., 2019). 
 Bpifa1-/- mice were bred at the University of Liverpool under UK Home Office 
Project Licence 70/8378. Wild-type sex- and age-matched C57BL/6J control mice (8-12 
weeks old) were purchased from Charles River (Margate, UK).  
 Phenotyping of Bpifa1-/- mice 
Phenotyping of mice has been carried out previously (Akram et al., 2018). As 
BPIFA1 has previously been implicated in the inhibition of sodium transport by the ENaC 
in airway epithelia of human (Garcia-Caballero et al., 2009) and the surfactant 
properties of airway secretions (Gakhar et al., 2010), knocking out the Bpifa1 gene may 
affect these important functions in the transgenic mice. Previous gross examination 
showed no differences and histological examination of the gastrointestinal, 
cardiovascular, lymphoid, endocrine, reproductive organs and the central nervous 
system also revealed no differences. Furthermore, no phenotypical differences were 
seen between wild-type C57BL/6J and Bpifa1-/- mice in other tissues such as the trachea, 
bronchi and lower respiratory tract. The only noted difference was in the parotid, 
submandibular and sub-lingual salivary glands, minor tongue (von Ebner’s) gland, 
Zymbal’s gland, Harderian gland and lacrimal gland. These tissues exhibited eosinophilic 
granules within the epithelium of the convoluted tubules of the submandibular salivary 
glands, which are prominent in male mice only, were less striking in the male Bpifa1-/- 
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mice than in wild-type C57BL/6J mice. In addition, tissues from the upper and lower 
tract were examined using haematoxylin and eosin (HE), Alcian blue (AB), periodic acid-
Schiff (PAS) and IH for Bpifa1. Results of IH showed that tissues from Bpifa1-/- were 
consistently negative for Bpifa1.  
These differences are unlikely to contribute to the observed differences in IAV 
pathology that have been previously published (Akram et al., 2018). 
2.4.3 Virus infection of mice 
Animals were randomly assigned into multiple groups, anaesthetised lightly 
with ketamine (Ketavet, Zoetis UK Ltd) by intramuscular injection (IM) and inoculated 
intranasally with different IAV doses (depending on the experiment) diluted in sterile 
PBS. Mice were euthanised by cervical dislocation at variable time points after infection. 
Blood, BAL, nasal wash and several tissue samples were removed immediately for 
downstream processing. 
2.4.4  Pilot experiments of in vivo expression  
 First pilot experiment: mouse Bpifa1 and human BPIFA1 in vivo 
expression/over-expression 
  In order to assess the ability of wild-type C57BL/6J and Bpifa1-/- mice to express 
recombinant mouse Bpifa1 and human BPIFA1 (kindly prepared and provided by N. 
Moyo), a pilot experiment was set up using a total of 14 mice (6 wild-type C57BL/6J and 
8 Bpifa1-/- mice). The two plasmids were concentrated using Amicon® ultra-0.5 
centrifugal filter devices (Ultracel 30K, Cat. No. UFC503024) following the 
manufacture’s protocol. Briefly, 200 μg of each plasmid was used in a final volume of 
500 μl using nuclease-free water. Then the Amicon® Ultra-0.5 device was inserted into 
one of the microcentrifuge tubes, and each sample (500 μl) was added to the Amicon® 
Ultra filter device and capped. The tubes were centrifuged at 14,000 × g for 5 min. After 
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that, the assembled devices were removed from the centrifuge and the Amicon® Ultra 
filter device was separated from the microcentrifuge tube. Subsequently, 400 μl of 
nuclease-free water were added into each tube. To recover the concentrated solute, 
the Amicon® Ultra filter devices were placed upside down in a clean microcentrifuge 
tube and centrifuged for 1 min at 1,000 × g to transfer the concentrated plasmid from 
the device to the tube.  
After that, the two plasmids were mixed separately with in vivo-jetPEI® delivery 
reagent (Polyplus transfection® The Delivery Experts, 201-50G), a linear 
polyethylenimine that mediates efficient nucleic acid delivery to tissues, and diluted 
with 10% D+ glucose solution (Polyplus transfection® The Delivery Experts, 701-10) 
following the manufacturer’s instructions (Figure 2-3). Initially, the plasmids were put 
into two Eppendorf tubes and made up in clean nuclease-free water at a concentrated 
amount of >2,000 ng/μl, and then plasmids and in vivo-jetPEI were diluted separately 
into 5% glucose (final concentration) and vortexed gently. This was followed by adding 
the in vivo-jetPEI to the plasmids all at once, immediate vortexing and gently 
centrifugation. Then, the tubes were incubated for 15 min at RT before performing the 
injection. Mice were then intranasally inoculated with 20 µg in 50 µl final volume 
plasmid/in vivo-jetPEI mix per mouse; three wild-type C57BL/6J mice were inoculated 
either with Bpifa1 or BPIFA1 each, and four Bpifa1-/- mice with either Bpifa1 or BPIFA1 
each. Two days post-administration, mice were euthanised and lung tissue samples 
were collected, homogenised to evaluate the mouse Bpifa1 and human BPIFA1 




Figure 2-3. Plasmid/in vivo-jetPEI® complex preparation. 
Adapted from in vivo-jetPEI® manual. 
 
Lung tissue samples (~100 mg) were put in 15 ml falcon tubes separately on dry 
ice and chipped into tiny pieces. Then, 500 µl of RIPA lysis buffer (Radio 
ImmunoPrecipitation Assay) were added, followed by 20 µl of protease inhibitor 
cocktail (Sigma, P8465). The samples were left on wet ice and mixed thoroughly for 30-
40 min, then sonicated using a Vibra-Cell™ Ultrasonic Liquid Processor (Sonics, VCX 130) 
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were transferred into Eppendorf tubes and centrifuged at 16873 x g for 15 min at 4°C. 
Then, 20 µl supernatant were mixed with 20 µl sample buffer and tested by western 
immunoblotting (see 2.3.3.3). 
  Second pilot experiment: mouse Bpifa1 and human BPIFA1 in vivo 
expression 
In this experiment, eight Bpifa1-/- mice were used to assess the ability of these 
mice to express recombinant mouse Bpifa1 and human BPIFA1. Mice were treated by 
intra-nasal inoculation of 20 µg in 50 µl final volume plasmid/in vivo-jetPEI mix per 
mouse (four were inoculated with Bpifa1 and four with BPIFA1) as described in section 
2.4.4.1. Mice were euthanised two days post-administration and lung tissue samples 
were collected, homogenised as described in 2.4.4.1 and analysed for Bpifa1/ BPIFA1 
expression by western immunoblotting (see 2.3.3.3). 
In this pilot experiment, the MiraCLEAN®Endotoxin removal kit (Mirus, 
MIR5900) was used to remove the bacterial endotoxin. The EndoGO Extraction Reagent 
was warmed to RT and vortexed before use. The DNA samples were diluted to 0.5-1.0 
mg/ml using TE buffer in Eppendorf tubes (STAR LAB, S1615-5500). Then, 0.1X sample 
volume of MiraCLEAN® buffer was added to the DNA samples which were subsequently 
vortexed to mix, and the tubes were incubated in an ice bath for at least 5 min and then 
vortexed. After that, 0.03X sample volume of the EndoGO extraction reagent was added 
to each tube and the tubes were briefly vortexed and incubated in the ice bath for 5 
min with intermittent vortexing at least twice. Then, the tubes were incubated in the 
50°C water bath for 5 min. They were centrifuged at RT for 30 sec at 14,000 x g using a 
standard bench microcentrifuge (Thermo Scientific, Heraeus Fresco 17). The tubes were 
gently removed from the centrifuge and tilted carefully, and the upper colourless 
aqueous phase (containing the DNA) was transferred, using a pipette and a standard 
69 
 
tip, to a new tube and placed in the ice bath. Two rounds of extraction were performed. 
Then, the DNA was precipitated with two volumes of cold 100% ethyl alcohol (Sigma, 
E7023) and the tubes were incubated at -20°C for 30 min, followed by centrifugation at 
14,000 x g at 4°C for 20 min. The supernatant was removed and the pellet was washed 
with 1 ml of 70% ethanol. After that, the tubes were centrifuged at 14,000 x g at 4°C for 
20 min. The supernatant was removed and the pellet was resuspended in 500 µl of TE 
buffer and then stored at 4°C until use.  
  Third pilot experiment: in vivo expression of pMSCV-IRES-GFP 
In this experiment, eight Bpifa1-/- mice were used to assess the ability of these 
mice to express pMSCV-IRES-GFP (Addgene, plasmid 20672), which encodes the GFP 
reporter gene (Figure 2-4). Mice were treated by intra-nasal inoculation of 20 µg in 50 
µl final volume plasmid/in vivo-jetPEI mix per mouse as described in section 2.4.4.1. 
Mice were euthanised two days post-administration and lung tissue samples were 
collected, homogenised as described in section 2.4.4.1, and analysed for pMSCV-IRES-
GFP expression by western immunoblotting (see 2.3.3.3). In this pilot experiment, the 
MiraCLEAN®Endotoxin removal kit (Mirus, MIR5900) was used as described in section 
2.4.4.2. In addition, pMSCV-IRES-GFP was concentrated using Amicon® ultra-0.5 




Figure 2-4. Annotated structure of pMSCV-IRES-GFP. 
Black arrows denote genes with the direction of transcription shown. Ampicillin resistance is 
encoded in the plasmid in addition to the GFP reporter gene. Restriction digest sites are 
displayed. 
 
2.4.5  IAV transmission experiments 
 Design of animal experiments  
In order to investigate the transmission of IAV between infected and non-
infected wild-type C57BL/6J and Bpifa1-/- mice, ten female wild-type C57BL/6J and ten 
Bpifa1-/- mice were used in two specific experiments following previous protocols 
(Edenborough et al., 2012) and as shown in Figure 2-5. For infection, the IAV X-31 strain 
was used, a mouse-adapted H3N2 strain that generates a sub-lethal infection (Huang et 
al., 2013), which models most IAV-associated infections in humans and allows analysis 
over an extended time course (Akram et al., 2018). In the transmission experiments 1 
and 2, four wild-type C57BL/6J and four Bpifa1-/- mice were infected intranasally with 
5x104 PFU of IAV X-31 (H3N2) at day 0 (index mice). Six hours later, two infected index 
wild-type C57BL/6J and two Bpifa1-/- mice (ear-clipped for identification) were 
introduced to naïve mice (i.e. to three wild-type C57BL/6J and three Bpifa1-/- mice per 
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IVC; contact mice), distributing the animals to a total of four cages. In transmission 
experiment 1, two wild-type C57BL/6J index mice were introduced to three wild-type 
C57BL/6J contact mice, and two Bpifa1-/- index mice to three Bpifa1-/- contact mice per 
IVC. In transmission experiment 2, two wild-type C57BL/6J index mice were introduced 
to three Bpifa1-/- contact mice and two Bpifa1-/- index mice to three wild-type C57BL/6J 
contact mice per IVC. The IVCs were left off the ventilation system for 24 h and then 
placed back onto the ventilation rack. Mice were weighed daily and euthanised at day 
4 post-infection/exposure. The left lung and the entire soft palate and nasal turbinates 
were sampled for analysis of virus titres using plaque assay and MDCK cells (see 2.4.5.3).  
Based on the results of transmission experiments 1 and 2, another transmission 
experiment; transmission experiment 3 was set up (Figure 2-6), in which eight wild-type 
C57BL/6J mice were infected intranasally with 5x104 PFU of IAV X-31 each at day 0. Six 
hours later, two wild-type C57BL/6J index mice were introduced to either three wild-
type C57BL/6J contact mice or three Bpifa1-/- contact mice per IVC (four cages in total). 
The IVCs were left off the ventilation system for 24 h and then placed back onto the 
ventilation rack. Mice were weighed daily, and all infected (index) wild-type C57BL/6J 
and three wild-type C57BL/6J contact and three Bpifa1-/- contact mice were euthanised 
at day 4 post-infection/exposure. From all euthanised animals, tissues were collected 
for histological and immunohistological examinations (see 2.4.5.2). At day 16 post-
infection/exposure, the remaining six contact mice (three wild-type C57BL/6J and three 
Bpifa1-/- mice) were euthanised, and blood, BAL as well as nasal wash samples were 
collected for determination of antibodies levels. Mice were bled from the heart or 
kidney and the blood samples were incubated at 37°C for 30 min, and then at 4°C for 
two h. After centrifugation at 832 x g for 5 min at 4°C, serum was collected and stored 
at -20°C until use. BAL and nasal wash samples were obtained by inserting a catheter 
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into a small opening in the trachea immediately after euthanasia; the lung was flushed 
2-3 times with 500 µl PBS. BAL and nasal wash samples were centrifuged at 832 x g for 
5 min at 4°C and stored at -20°C until use. 
 
 
Figure 2-5. Experimental design of the transmission experiments 1 and 2. 
Each experiment included a total number of ten female wild-type C57BL/6J and ten Bpifa1-/- 
mice. At day 0, four wild-type C57BL/6J and four Bpifa1-/- mice were infected intranasally with 
5x104 PFU IAV X-31 (H3N2) [index mice (I)]. Six hours later, two index mice per cage were 
introduced to three naïve mice [contact mice (C)]. In transmission experiment 1, the following 
scheme was applied: 2x wild-type C57BL/6J index to 3x wild-type C57BL/6J contact mice, and 
2x Bpifa1-/- index to 3 x Bpifa1-/- contact mice per IVC (four cages total). In transmission 
experiment 2, the following scheme was applied: 2x wild-type C57BL/6J index to 3x Bpifa1-/- 
contact mice and 2x Bpifa1-/- index to 3x wild-type C57BL/6J contact mice per IVC (four cages 
total). The IVCs were left off the ventilation system for 24 h and then put back onto the 
ventilation rack. All mice were weighed daily and euthanised at day 4 post-infection/ exposure. 
Lungs and nasal tissues were sampled for analysis of virus titres using plaque assay and MDCK 






Figure 2-6. Experimental design of the transmission experiment 3. 
Transmission experiment 3 included a total number of ten female wild-type C57BL/6J and ten 
Bpifa1-/- mice. At day 0, eight wild-type C57BL/6J mice were infected intranasally with 5x104 
PFU IAV X-31 (H3N2). Six hours later, two wild-type C57BL/6J index mice per cage were 
introduced and mixed with either three wild-type C57BL/6J contact or Bpifa1-/- contact mice per 
IVC (four cages total). The IVCs were left off the ventilation system for 24 h and then put back 
onto the ventilation rack. Mice were weighed daily, and all wild-type C57BL/6J index and three 
wild-type C57BL/6J contact and three Bpifa1-/- contact mice were euthanised at day 4 post-
infection/exposure and tissues were collected for histological and immunohistological 
examinations. At day 16 post-infection/ exposure, the remaining six contact mice (three wild-
type C57BL/6J and three Bpifa1-/- mice) were euthanised, and blood, BAL as well as nasal wash 





 Sample collection and preparation 
For histological and immunohistological examinations, heads, salivary gland and 
mandibular lymph node (ln), thoracic organs [lung, trachea, bronchial ln, thymus, 
mediastinal adipose tissue], mesenteric ln and spleen with surrounding mesenteric 
adipose tissue were sampled and the tissues fixed in 10% buffered formalin. 
 Determination of infectious virus titres by plaque assay 
MDCK cells were maintained as described in section 2.1. The plaque assay was 
performed to determine infectious virus titres in lung and nasal tissue samples 
homogenised with a TissueLyser LT machine (QIAGEN, Catalog No.85600). Initially, 2 ml 
safe-lock microcentrifuge tubes (Eppendorf, 0030120094) that each contained one 
stainless steel bead (QIAGEN, 69989) were added using TissueLyser single-bead 
dispenser 5 mm (QIAGEN, 69965) and placed on dry ice for at least 15 min before 
homogenising the samples, while the insert of the TissueLyser LT Adapter was kept at 
RT. Then, frozen lung/ nasal tissue samples were excised by using disposable scalpels 
(Swan-Morton®, 0501) and 200-300 mg tissue samples were transferred into the 
precooled tubes and incubated for another 15 min on dry ice. The tubes were placed 
into the insert of the TissueLyser LT Adapter and incubated at RT for 2 min to avoid 
freezing of the 500 µl of DMEM (serum free medium) that later were then added 
immediately to each tube. The tubes were placed into the base of the TissueLyser LT 
Adapter, which is attached to the TissueLyser LT. The lid of the TissueLyser LT Adapter 
was placed over the insert, and the knob was screwed until the lid was securely 
fastened. The TissueLyser LT was operated for 4-6 min at 30 Hertz (Hz) (oscillation). 
Tubes were then centrifuged at 370 x g for 5 min at 4°C. The supernatants were 
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withdrawn with sterile filter tips and transferred into labelled cryotubes that were 
stored at -80°C until use. 
Six well tissue culture plates (Corning Incorporated, 3516) were seeded with 
2x106/ml MDCK cells in 2 ml DMEM supplemented with 10% FBS, 1% L-glutamine and 
1% penicillin-streptomycin per well and were incubated overnight at 37°C, 5% CO2 in an 
incubator (SANYO, MCO175) to achieve 95-100% confluence. Subsequently, 10-fold 
serial dilutions of virus stock (10-1-10-5) in ice-cold DMEM only supplemented with 1 
µg/ml trypsin-tosylamido-phenylethyl-chloromethyl ketone (TPCK)-treated 
(ThermoFisher, 20233) were prepared in 7 ml polystyrene Bijou containers in a 1:1,000 
dilution of 1 mg/ml stock. Then, 1 ml from each prepared serial dilution (10-1-10-5) was 
used in duplicate; tips were changed with each dilution. Plates were incubated for one 
h at 37°C, 5% CO2 using virus incubator (SANYO, MCO-17AIC) and agitated every 10-15 
min to ensure coverage. The viral inocula were removed and 2 ml of overlay medium 
consists from 2.4% Avicel (FMC BioPolymer, RC-581) mixed with 2X overlay medium 
[(20% of DMEM low glucose (10X) (Sigma, D2429), 4% 1M HEPES Solution (Sigma, 
H0887), 2% L-glutamine, 2% penicillin-streptomycin, 2% of 7.5% sodium bicarbonate 
(NaHCO3) (Sigma, S5761) and 70% of double processed tissue culture water (Sigma, 
W3500)] in a 1:1 ratio were added per well. The overlay medium was supplemented 
with TPCK-treated trypsin (1:1,000 dilution of 1 mg/ml stock) immediately prior to 
overlaying the cells. Plates were incubated for 3 days until plaques were visible.  
The overlay was removed by aspiration and the wells were washed twice with 
PBS and then fixed with ice-cold acetone: methanol (60:40) for 10 min at RT, left 
standing for complete air-drying and then stained with crystal violet (Sigma, C3886) for 
approximately 10 min. Plaques were then counted microscopically using a light 
microscope (Motic, ST-30 Series) to determine the plaque forming units (PFU) per 
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sample, which were calculated from the average PFU obtained in five different dilutions 
of the sample, each performed in duplicate. The infectious titre was determined as the 
average result of two separate titrations and the titre was calculated using the following 
formula:  
𝑇𝑖𝑡𝑟𝑒 (𝑃𝐹𝑈/𝑚𝑙) =
(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛)
1 𝑚𝑙 𝑖𝑛𝑜𝑐𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 
2.4.6  IAV vaccination/ challenge experiment 
 Experimental design 
In order to assess the vaccination/ challenge response to IAV in wild-type 
C57BL/6J and Bpifa1-/- mice, an experiment was set up to analyse the response to re-
challenge after vaccination one month earlier. The experiment included three groups 
of six mice for each strain and one group as a control group (mock-infected), which 
received no treatment, 36 mice in total (18 wild-type C57BL/6J mice and 18 Bpifa1-/- 
mice) (Figure 2-7). On day 0, 24 mice (12 wild-type C57BL/6J and 12 Bpifa1-/- mice) were 
lightly anaesthetised with ketamine and infected intranasally with either 103 PFU IAV X-
31 or 50 PFU IAV PR8 or mock-infected. At 24 dpi, blood samples were collected from 
the tail vein of live mice and prepared as described in section 2.4.5.1 to determine the 
IgG level in the serum. At 28 dpi, all mice (36 total) were challenged by intranasal 
infection with 103 PFU IAV PR8. Animals were weighed daily until the end of the 
experiment (i.e. 28 days pre-challenge and 5 days post-challenge). At 33 dpi (5 days 
post-challenge), mice were euthanised by cervical dislocation. BAL samples were 
collected and prepared as described in section 2.4.5.1 to determine the IgA level. The 





Figure 2-7. Experimental design of IAV vaccination/challenge experiment. 
Three groups of six mice from each strain and one group as a control group (mock-infected), 36 
mice in total (18 wild-type C57BL/6J mice and 18 Bpifa1-/- mice). On day 0, six wild-type C57BL/6J 
mice and six Bpifa1-/- mice were lightly anaesthetised with ketamine and infected intranasally 
with either 103 PFU IAV X31 or 50 PFU IAV PR8, respectively. At 24 dpi, blood samples were 
collected from the tail vein of live mice for determination of IgG levels. At 28 dpi, all mice (36 
total) were challenged with 103 PFU IAV PR8. At 33 dpi, mice were euthanised, BAL samples and 
lung tissues were collected for determination of IgA level and infectious virus titres, 
respectively. Also, body weight was recorded daily until the end of the experiment (i.e. 28 days 
pre-challenge and 5 days post-challenge). 
 
 Determination of infectious virus titre 
Infectious virus titres were determined by plaque assay on MDCK cells as described 
in section 2.4.5.3, using 200 mg of homogenised lung tissue.  
2.4.7  IAV antibody experiments 
 Design of animal experiments  
In order to assess the production of antibodies in IAV infected wild-type 
C57BL/6J and Bpifa1-/- mice, three experiments were set up. In antibody experiment 1, 
six wild-type C57BL/6J mice and six Bpifa1-/- mice were infected with 103 PFU IAV X-31 
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at day 0. Blood, BAL and nasal wash samples were collected after euthanasia at 35 dpi 
and prepared for serology (see 2.5.1.2). In antibody experiment 2, six wild-type 
C57BL/6J and six Bpifa1-/- mice were infected with 103 PFU IAV X-31 at day 0. Blood, BAL 
and nasal wash samples were collected at 7 and 14 dpi from euthanised animals and 
prepared for serology (three mice from each strain at each time point). From all animals, 
heads, salivary gland and mandibular ln, thoracic organs [lung, trachea, bronchial ln, 
thymus, mediastinal adipose tissue], mesenteric ln, and spleen with surrounding 
mesenteric adipose tissue were sampled and the tissue fixed in 10% buffered formalin 
for histological and immunohistological examinations.  
In antibody experiment 3, 12 wild-type C57BL/6J and 12 Bpifa1-/- mice were 
infected with two logs virus dose lower than the dose used in the antibody experiments 
1 and 2, i.e. 10 and 102 PFU IAV X-31. Six mice from each dose group (three mice from 
each strain) were euthanised by cervical dislocation at 7 and 14 dpi, respectively. Blood, 
BAL and nasal wash samples were collected and prepared for serology. Furthermore, 
tissues were collected for histological and immunohistological examinations (see 
2.4.5.2).  
 Western immunoblotting 
In order to confirm the species of mice and to ensure that no mixing of mice 
during their breeding and preparation for the antibody experiments had occurred, 15% 
SDS-PAGE was set up as described in section 2.3.3.3 to confirm the in-vivo expression 
of Bpifa1 using BAL samples collected from infected mice with 103 PFU IAV X-31 at 7 dpi 
(3 samples from each mouse strain). Rabbit anti-mouse Bpifa1 was used as a primary 
antibody in a 1:500 dilution, and HRP goat anti-rabbit IgG antibody (peroxidase) (Vector 





Enzyme immunotests [enzyme immunoassay (EIA), ELISA] are quantitative 
analytical methods that show antigen-antibody reactions through change in the colour 
yield, using an enzyme linked conjugate and enzyme substrate. They serve to identify 
the presence and concentration of different antibodies and antigens in biological fluids. 
ELISA is one of the most sensitive, simple and a rapid technology available and is mainly 
a plate-based assay designed and used for detecting and quantifying antigens or 
antibodies against bacteria and viruses. ELISA can be divided into four main types: 
direct, indirect, sandwich and competitive (Hornbeck, 2001; Kohl and Ascoli, 2014).    
 IAV X-31 and PR8 antigens preparation 
To prepare the antigens required for the ELISA, a monolayer of MDCK cells in a 
T175 cm2 flask was washed twice with serum free DMEM (10 ml each). Then, 60 ml 
DMEM supplemented with TPCK-treated trypsin in a 1:1,000 ratio were prepared and 
kept on ice; 5 ml of the prepared cold media were then added to each flask. Then, 250 
µl of IAV X-31 X/E1 [112807, F/T 110810] in a titre of 1024 using hemagglutination assay 
and 50 µl of IAV PR8 [wild-type (WT)] virus stocks in a titre of 108 PFU/ ml using plaque 
assay were added respectively into each separate flask (two flasks for each virus) and 
incubated for 2 h at 37°C, 5% CO2. After that, 25 ml of the prepared cold media were 
added to each flask and the flasks incubated for 24-48 h at 37°C, 5% CO2 to ensure a 
substantial cytopathic effect (CPE). At the end of the incubation period, the infected 
cells were washed three times with PBS to remove DMEM and scraped into 1 ml PBS 
containing 10 µl protease inhibitor cocktail (Sigma, P8465) and then transferred to an 
Eppendorf tube and three cycles of freezing-thawing (on dry ice) with mild vortexing to 
disperse cell debris were applied. After that, 1 ml of cells debris was spread onto a 
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sterile tissue culture dish, placed in Hoefer UVC 500 box inside the hood, and irradiated 
using 300 mJ/cm2. Then, the UV-inactivated preparation was diluted to 50 ml with 
borate buffered saline (BBS) (Sigma, 08059) and stored at -20°C until use. A dilution of 
1:5 (2 ml antigen were added to 8 ml BBS per plate) was used as an optimal 
concentration for the ELISA. 
  ELISA technique and antibody detection  
96-well Nunc MaxiSorp flat bottom ELISA plates (ThermoFisher, 442404) were 
coated with 100 µl of UV inactivated virus in BBS and left in a sealed Tupperware box 
overnight at 4°C. For all the IAV antibody experiments, IAV X-31 antigen was used in 
coating the plates, while for the vaccination/ challenge experiment, IAV PR8 antigen 
was used. The following day, the antigen solution was discarded and the plate(s) were 
washed three times with PBS tablets [(Sigma, P4417) dissolved in DW; one tablet in 200 
ml DW], followed by blocking with PBS containing 1% bovine serum albumin (BSA) 
(Sigma, A7906) using 200 µl per well and incubation in an INCU-Line incubator (VWR, 
S/N 12-11922) at 37°C for one h. After that, plates were washed using PBS with 0.05% 
tween 20 (Sigma, P1379) for five times. The test samples were diluted in PBS with 1% 
BSA and 0.05% tween 20, and 200 µl from each sample were applied in the first row of 
wells and titrated in serial dilutions in PBS with 1% BSA and 0.05% tween 20. For serum 
samples, the dilution started from 1:40, and for BAL and nasal wash samples started 
from 1:5. Plates were incubated for one h at 37°C in a sealed Tupperware box.  
Plates were washed five times using PBS with 0.05% tween 20. Then, 100 µl of 
several anti-mouse Ig subtypes HRP (diluted as above in PBS with 1% BSA and 0.05% 
tween 20) were added per well and plates incubated for one h at 37°C in a sealed 
Tupperware box, then washed five times using PBS with 0.05% tween 20 and once with 
tap water. For this purpose, anti-mouse IgA (α-chain specific)-peroxidase antibody 
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produced in goat (Sigma, A4789), anti-mouse IgG (ƴ-chain specific)-peroxidase 
produced in goat (Sigma, A3673) and anti-mouse IgM (μ-chain specific)-peroxidase 
antibody produced in goat (Sigma, A8786) secondary antibodies were used in a dilution 
of 1:3,000, 1:3,000 and 1:4,000, respectively. In addition, anti-mouse IgG sub-classes (ƴ-
chain specific)-peroxidase antibody produced in rabbit were used as follows: anti-IgG1 
(Sigma, SAB3701171; 1:150,000), IgG2a (Sigma, SAB3701178; 1:90,000), IgG2b (Sigma, 
SAB3701185; 1:65,000) and IgG3 (Sigma, SAB3701192; 1:75,000). In addition, negative 
samples (containing only the secondary antibody) and blank samples (neither primary 
nor secondary antibody; incubation only with the diluent buffer) were included.  
100 µl of pre-warmed (to RT) of TMB (tetramethylbenzidine) ELISA substrate 
standard solution (Interchim, UP664781) were added per well and plates were 
incubated in the dark at RT for 30 min. 100 µl of 0.5 M hydrochloric acid (HCl) 
(Honeywell Fluka™, 320331) were added per well to stop the reaction and the optical 
density (OD) was read at 450 nanometre (nm) using a microplate absorbance reader 
(Infinite F50) and Tecan Magellan-data analysis software for F50 V 7.0.   
2.5.2  Serological detection of IAV infection by microneutralisation assay 
  The microneutralisation assay for influenza virus described below is based on the 
hypothesis that serum-neutralising antibodies to influenza viral HA inhibit the infection 
of MDCK cells with virus. Serial dilutions of sera need to be pre-incubated with a 
standardised amount of virus before the addition of MDCK cells. After overnight 
incubation, the MDCK cells are fixed and the presence of IAV NP protein in infected cells 
is detected by ELISA. An overview of the microneutralisation assay is shown in Figure 2-
8. The protocol is divided into three parts (WHO, 2013): 
Part I: Determination of the tissue culture infectious dose (TCID50) 
Part II: Virus microneutralisation assay 
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Part III: ELISA 
 
Figure 2-8. Parts of the microneutralisation assay. 
Figure adapted from WHO (2013). 
 
 Virus titration and determination of TCID50 
2.5.2.1.1 Virus dilution 
The TCID50 of IAV X-31 virus was determined as described by the World Health 
Organization (WHO, 2013) (Figure 2-9). Initially, the virus was diluted 1:100 in dilution 
buffer [82.9% of DMEM, 1% of 100X penicillin-streptomycin, 13.4% of 7.5% BSA, 2.5% 
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of 1M HEPES buffer solution and 0.2% of trypsin-TPCK-treated (1mg/ml)] in a 
polystyrene Bijou container as working stock. Then, 100 μl of diluent buffer were added 
to all wells, except column A1-D1 of a 96-well tissue culture plate (Falcon®, 353072), 
followed by 146 μl virus (1:100 dilution of working stock) added to column A1-D1 from 
which 46 μl were transferred serially from columns 1 to 12 using ½ log10 dilutions; tips 
were changed with each dilution. The dilutions were 10-2, 10-2.5, 10-3…10-7.5. 
 
Figure 2-9. Experimental design of TCID50. 
Figure adapted from WHO (2013). 
 
2.5.2.1.2 Preparation of MDCK cells 
A monolayer of MDCK cells (70–95% confluency) in T175 cm2 flask was washed 
with each 10 ml PBS three times to remove FBS. Then, 5 ml trypsin-EDTA was added to 
enhance their detachment, and another 5 ml trypsin-EDTA was added to cover the cell 
monolayer, and the flask was incubated at 37°C, 5% CO2 until the monolayer was fully 
detached (approximately 5-10 min). After that, 5 ml DMEM supplemented with 10% 
FBS, 1% L-glutamine and 1% penicillin-streptomycin were added and gently mixed to 
resuspend and break up clumps of cells. The content of the flask was then transferred 
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to a 15 ml falcon tube. Cells were pelleted by centrifugation at 211 x g for 10 min at 
20°C, and the supernatant was decanted. Cells were resuspended in diluent buffer (10 
ml per trypsinised flask) and 1.5 x 105 cells/ml were used. Then, 100 µl diluted cells were 
added to each well of the microtiter plate and the plates incubated for 18–20 h at 37°C 
in 5% CO2. After that, the medium was removed from the microtiter plate and each well 
was washed with 200 μl PBS which was then removed without allowing wells to dry out. 
Then, 100 μl of freshly made 80% cold acetone in PBS was added per well and the plate 
covered with the lid and incubated at RT for 10–12 min. The fixative was removed and 
the plate left to air dry.   
2.5.2.1.3 Determination of TCID50 for microneutralisation assay 
ELISA was performed as follows: Plates were washed five times with PBS and 
0.05% tween 20. The primary antibody (anti-IAV NP monoclonal) (ATCC®, HB-65™, H16-
L10-4R5) from hybridoma (B lymphocyte) was diluted 1:1,000 in PBS with 1% BSA and 
0.05% tween 20, and 100 μl diluted primary antibody were added to each well. Plates 
were covered and incubated for one h at 37°C in a sealed Tupperware box in an INCU-
Line incubator (VWR, S/N 12-11922). After that, plates were washed five times with PBS 
with 0.05% tween 20. The secondary antibody, anti-mouse IgG (ƴ-chain specific)-
peroxidase antibody produced in goat (Sigma, A3673) was diluted 1:3,000 in PBS with 
1% BSA and 0.05% tween 20, and 100 μl diluted secondary antibody were added to each 
well. Plates were covered and incubated for one h at 37°C in a sealed Tupperware box. 
After that, plates(s) were washed five times with PBS with 0.05% tween 20 and once 
with tap water. 100 µl of warm TMB ELISA substrate standard solution (Interchim, 
UP664781) were added per well, and plates were incubated in the dark at RT for 30 
min. 100 µl of 0.5 M HCL were added per well to stop the reaction and the plates were 
read at 450 nm using a microplate absorbance reader (Infinite F50). 
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The mean absorbance (OD450) of the control cell wells was calculated. Any test 
well with an OD450 greater than twice the average of OD450 of the control cell wells 
was scored positive for virus growth. Once all test wells were scored positive or negative 
for virus growth, the TCID50 of the virus was calculated. 
2.5.2.1.4 Calculation of TCID50 
The TCID50 of the virus was calculated using the Reed-Muench method (Reed 
and Muench, 1938). The number of positive and negative wells at each dilution was 
calculated. Then, the cumulative numbers of positive and negative wells were 
calculated. After that, the ratios at each dilution were calculated by dividing the number 
of positives by the number of positives plus negatives wells. The percentage of positive 
wells was calculated by converting each of the ratios to percentages. The proportional 
distance between the dilution showing >50% positives and the dilution showing <50% 
positives were calculated as follows: 
% 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑤𝑒𝑙𝑙 > 50% − 50𝑥0.5 (𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)
% 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑤𝑒𝑙𝑙 > 50% − % 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑤𝑒𝑙𝑙 < 50%
 
The virus working dilution is 200 times the log10 virus dilution at the cut-off point 
determined by the Reed-Muench method. 200 times the virus dilution at the cut-off 
point yields a virus working dilution that contains 100X TCID50 in 50 μl. The 
microneutralisation TCID50 was calculated by adding the proportional distance to the 
dilution showing >50% positive well.  
 Virus microneutralisation assay 
2.5.2.2.1 Preparation of test sera  
Mouse sera were treated with receptor destroying enzyme (II) (RDE) (DENKA 
SEIKEN, 370013) before use. Under sterile conditions, each specimen serum was added 
to the RDE solution in a ratio of 1:3, and mixed thoroughly. Then, the mixtures were 
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heated at 37°C using water bath (Clifton, Scientific Laboratory Supplies) for 18-20 h for 
the reaction to take place. This was followed by further heating at 56°C using a water 
bath (Grant, SUB) for 30-60 min to deactivate the RDE. Then, 50 μl of diluent buffer 
were added to each well of the plate. Furthermore, an additional 40 μl of diluent buffer 
were added to each well in row A that contained samples, followed by adding 10 μl of 
heat-inactivated sera (in duplicate), which included negative serum and sera samples 
to Row A (1 serum/well except control wells). Two-fold serial dilutions were performed 
by transferring 50 μl from one row to the next (A to H).  
2.5.2.2.2 Addition of virus 
After determining the virus titre by TCID50, the virus was diluted to 100 TCID50 
per 50 μl (200 TCID50/100 μl) in diluent buffer (5 ml/plate). Then, 50 μl diluted virus 
were added to each well except for the control cell wells. 50 μl diluent without virus 
was added to control cell wells for negative cell control. In addition, back-titration was 
set-up starting with the virus test dilution (100 TCID50), and additional serial 2-fold 
dilutions were prepared with diluent. The virus-serum mixtures were gently agitated, 
and incubated for 1 h at 37°C, 5% CO2.  
2.5.2.2.3 Addition of MDCK cells 
MDCK cells were prepared as described in section 2.5.2.1.2, and 100 μl cells 
containing 1.5x104 cells were added to each well of the plate. Plates were incubated 




Figure 2-10. Microneutralisation assay experimental design. 
Figure adapted from WHO (2013).   
 
 
The medium was removed from the microtiter plate and each well was washed 
with 200 μl PBS which was then removed without allowing wells to dry out. Then, 100 
μl of freshly made 80% cold acetone in PBS were added per well and the plate was 
covered with the lid and incubated at RT for 10–12 min. Then, the fixative was removed 
and the plate left to air dry. 
 ELISA 
ELISA was performed as described in section 2.5.2.1.3. 
 Data analysis 
Calculations of the virus neutralising antibody end point titre of each serum 
sample were determined using the equation below:  
X = (Average OD of VC wells-Average OD of CC wells)/2 + (Average OD of CC wells), 
where X = 50% of specific signal (i.e. 50% of the cells are infected). All values below this 
value are positive for neutralisation activity. VC means virus + MDCK cells, while CC 
means cells control wells.  
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 Statistical analysis 
 
Infectious virus titres were analysed using t-test with Mann-Whitney U test or One-
way analysis of variance (ANOVA) with Tukey's post-hoc Multiple Comparison Test. 
Body weights and ELISA results were analysed by two-way analysis of variance with 
Bonferroni post-test. Error bars were presented as the standard error of the mean 
(SEM) using GraphPad Prism version 5.03. For all figures, *p <0.05, **p <0.01, ***p 
<0.001 and p value >0.05 was considered statistically not significant. 
 Histological and immunohistological examinations   
2.7.1  Tissue preparation 
Tissue samples and heads were fixed in 10% buffered formalin for approximately 
48 h and then transferred into 70% ethanol and shipped to the Laboratory for Animal 
Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of 
Zurich, Switzerland for further processing. Heads were skinned and coronal sections 
were prepared with a diamond saw (Exakt, Norderstedt, Germany) to produce 
approximately 1.8 mm (1.5–1.8 mm, depending on the size of the head) thick tissue 
slices. The first cut was placed behind the tip of the nose, the second immediately in 
front of the eyes, the third behind the eyes, and the fourth at a level immediately behind 
the caudal aspect of the cortical hemisphere, producing six tissue slices (Figure 2-11A). 
Slices were placed into the histology cassette with the cut surface down, the cassette 
closed and incubated in RDF Mild Decalcifier (CellPath Ltd., Newtown, Powys, UK) for 
7-10 days at RT on a shaking table until the tissue was fully decalcified. The frontal (i.e. 
anterior) part of the nasal cavity and vomeronasal organ (VNO) are located in the first 
section (Figure 2-11B and C), nasal-associated lymphoid tissue (NALT) is located in the 
second section (Figure 2-11D), while trigeminal ganglia are located in sections 3, 4 and 
5 (Figure 2-11E). Bpifa1 is expressed in respiratory epithelium (squamous epithelium) 
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within the anterior part of the nasal cavity, in some Bowman’s glands and Bowman’s 
gland ducts, and in non-ciliated cells. Also, Bpifa1 is expressed in the epithelium and 
submucosa of the nasopharynx and is secreted into the nasal cavity (Musa et al., 2012; 
Seshadri et al., 2012), which was detected by the high concentrations in nasal lavage 
fluid (Bingle and Craven, 2002; Casado et al., 2005).   
 
Figure 2-11. Mouse head processing and resulting tissue sections.  
A. An overview showing the six tissue slices prepared by coronal sections to lamellate the head 
(numbers), scale bar=10 mm. B. Higher magnification of section 1 from A shows the frontal 
nasal epithelium (arrows) and the mid nasal epithelium (arrowhead), scale bar= 250 µm. C. High 
magnification of section 1 from A shows the location of the VNO (arrows), scale bar= 250 µm. 
D. Higher magnification of section 2 from A shows the location of the NALT (arrows), scale bar= 
500 µm. E. Higher magnification of section 3 from A shows a trigeminal ganglion (arrow), scale 




Tissues (see section 2.4.5.2) were trimmed and placed into histology cassettes. 
Heads and tissues were then routinely paraffin wax embedded. Consecutive sections 
(3-5 µm) were prepared using standard microtomes, and were subjected either to 
staining for histological examination or to immunohistological protocols. 
2.7.2  Histological examination  
 Sections were routinely deparaffinised and stained with haematoxylin and eosin 
(HE). A detailed histological examination was undertaken by both the PhD student and 
the supervisor Professor Dr Anja Kipar on the stained slides and/or the digitalised slides 
prepared using a digital slide scanner (NanoZoomer-XR C12000; Hamamatsu, 
Hamamatsu City, Japan). 
2.7.3  Immunohistological staining 
Immunohistology served to detect IAV antigen and to identify T cells (CD3+), B 
cells (CD45R+) and macrophages (Iba-1+). For immunohistological staining, sections 
were placed on positively charged slides and dried overnight at 37°C. After routine 
deparaffinisation, sections underwent antigen retrieval. For the detection of CD45R and 
Iba-1, this was done by incubation for 20 min at 98°C in a pressure cooker in citrate 
buffer [pH 6.0 (Dako, S2031)], for the detection of IAV antigen, in basic buffer [pH 9.0 
(EDTA-buffer)] (Table 2-6). Slides were then rinsed with DW. Antigen retrieval for the 
detection of CD3 is separately described below. 
For the detection of IAV, CD45R and Iba-1, slides were put into TBS-tween buffer 
and all further steps undertaken in a Dako-Autostainer. The programme setup for the 
Dako-Autostainer was as follows:1) incubation with the primary antibodies diluted in 
dilution-buffer (Dako, S2022) and incubated for 1 h at RT; 2) rinsing with wash-buffer 
TBS-tween (Dako, 3006); 3) blocking with peroxidase blocking buffer (Dako, S2023) for 
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10 min at RT; 4) rinsing with TBS-tween; 5) incubation with secondary 
antibodies/detection systems diluted in dilution-buffer for 30 min at RT (for Iba-1, this 
requires subsequent incubation with an interim/bridging antibody and the detection 
system; see Table 2-6); 6) rinsing with TBS-tween; 7) incubation with DAB (3,3′-
diaminobenzidine) (Dako, K3468) for 10 min at RT; 8) removal from Autostainer, rinsing 
with DW; 9) counterstaining for 2 sec with haematoxylin (modified to Gill 2; Merck, 
1.05175.0500); 10) rinsing with tap water; 11) dehydration (70%, 95%, 100%, xylene); 
12) covering with Tissue-Tek-Film (covering-machine, Sysmex). 
For the detection of CD3, the Discovery XT machine (Ventana) was used. This 
included pre-treatment (antigen retrieval) with EDTA, pH 8.4 (CC1 solution; Ventana, 
950-124), followed by incubation for 1 h at 37°C with the primary antibody diluted in 
dilution buffer (Ventana, 251-018). After blocking of nonspecific binding using the 
Chromomap-DAB-Kit (Ventana, 760-159), and incubation with the secondary antibody 
for 16 min, slides were counter stained with haematoxylin for 4 min. They were then 
removed from the machine and cover slipped as above.  
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Table 2-6. Summary of methods used for immunohistology 
Antigen Pre-treatment Blocking reagent Primary antibody Secondary antibody/detection 
system 





Goat-anti Influenza A (virions) 
1:200, 1 h 
(Meridian, B65141G) 
Rabbit anti Goat HRP 
1:100 
(Dako, P0160) 
CD3 CC1 Solution 
(EDTA, pH 8.4) 
(Ventana, 950-
124) 
Inhibitor ChromoMap  
(Ventana, 760-159) 
Rabbit anti-mouse/human 
CD3 (clone SP7)  
1:900, 1 h 
(Spring Bioscience, M3074)  
OMap anti-Rabbit HRP 
 (760-4311) 






Rat-anti mouse CD45R 
1:800, 1 h 
(BDPharmingen, 553084) 





Envision+System HRP Rabbit 
(Dako K4003) 
Iba-1 Citrate buffer pH 
6.0 




Rabbit anti-rat/human Iba-1 
1:750, 1 h 
(Wako, 019-19741) 
Envision+System HRP Rabbit 














Chapter 3. In vitro and in vivo expression experiments 






As mentioend previously that Bpifa1 possesses anti-viral function against MHV-68 
infection (Leeming, 2010; Leeming et al., 2015) and IAV (Akram et al., 2018). 
Furtherrmore, previous results in the laboratory have shown that there is a difference 
in susceptibility to IAV  between wild-type C57BL/6J and Bpifa1-/- mice. Therefore, the 
aim of this chapter was to restore the expression of Bpifa1 in Bpifa1-/- mice and to 
confirm these observations by complementation of Bpifa1 in trans. This would also 
allow for the analysis of Bpifa1 mutants and human BPIFA1 in mice. Bpifa1 was cloned 
and expressed in vitro in HEK 293T cells, and it was attempted to express both mouse 





 In vitro expression of recombinant Bpifa1-pVR1255 using mammalian 
expression vector 
3.2.1  Conventional PCR and preparation of target DNA 
Amplification of the DNA (the full-length cDNA of Bpifa1) was performed by PCR 
using the primers specific for Bpifa1 (Table 2-1), that added restriction sites. Results 
showed the expected size for the targeted DNA at 837 bp for Bpifa1 as shown in (Figure 
3-1).  
 
Figure 3-1. PCR amplification of Bpifa1. 
Bpifa1 cDNA was amplified by PCR using specific primers and analysed by agarose gel 
electrophoresis.  The size of the product was estimated using a 1 kb DNA marker (Bioline, BIO-
33053). 
 
3.2.2  Cloning of Bpifa1  
The amplified Bpifa1 cDNA fragment was digested using NotI and BamHI and 
cloned into pVR1255 between the NotI and BamHI sites as described in sections 2.2.6 
and 2.2.7. Several clones were then tested using Miniprep as described in section 2.2.2. 




to confirm the insertion of Bpifa1. Several clones with inserts of the correct size (Figure 
3-2) were sequenced [Source Bioscience (Rochdale, UK)] using specific primers as 
shown in Table 2-4. Sequencing confirmed the correct insertion and integrity of the 
Bpifa1 cDNA in the pVR1255 vector, now designated Bpifa1-pVR1255. 
 
Figure 3-2. Restriction enzyme analysis of pVR1255 clones containing Bpifa1. 
Miniprep DNAs with NotI and BamHI were analysed by agarose gel electrophoresis. The sizes of 
the fragments were estimated using a 1 kb DNA marker (Bioline, BIO-33053). The vector 
pVR1255 was used as a negative control.  
 
3.2.3  In vitro expression of recombinant Bpifa1-pVR1255 by transient transfection  
In order to express Bpifa1, a stock of the Bpifa1-pVR1255 plasmid was prepared 
using an EndoFree® Plasmid Maxi Kit as described in section 2.2.8. HEK 293 T cells were 
transfected using calcium phosphate method when they were 50-60% confluent (see 
section 2.3.2).  
For analysis, Bpifa1-pVR1255 was used alongside an empty pVR1255, as a negative 




out as shown in Table 2-5. After 24 h incubation, the efficiency of in vitro transfection 
was assessed using the pEGFP-C1 transfected cells by taking images using a 
fluorescence culturet microscope (Olympus ®, CK40) (Figure 3-3). Supernatants and cell 
pellets were collected from the Bpifa1-pVR1255 and pVR1255 transfected cells and 
plasmid expression was confirmed by SDS-PAGE and western immunoblotting. 
 
Figure 3-3. Analysis of transfection efficiency using pEGFP-C1. 
HEK 293T cells were grown to 50-60% confluence and transfected with pEGFP-C1 using calcium 
phosphate and visualised using a UV microscope after 24 h. Transfection efficiency was 
estimated by comparing the numbers of pEGFP-C1-positive and negative cells. A. A bright field 
of HEK 293T cells. B. pEGFP-C1. Scale bars= 10 µm. 
 
3.2.4  Western immunoblotting 
Proteins were analysed using 15% SDS-PAGE and western immunoblotting as 
described in section 2.3.3.3 using rabbit anti-mouse Bpifa1 antibody as a primary 
antibody and HRP goat anti-rabbit IgG antibody (peroxidase) as a secondary antibody. 
Results showed expression of Bpifa1-pVR1255 with a molecular weight of 25 kDa in 
both supernatant and cell pellet samples (Figure 3-4). This result confirms the 





Figure 3-4. In vitro expression of Bpifa1-pVR1255 in both supernatant and cell pellets of HEK 
293T cells. 
HEK 293T cells were transfected with plasmids (as labelled). After 24 h, samples of supernatant 
and pellet were analysed by SDS-PAGE and western immunoblotting. Molecular weights were 
estimated by comparison with multicolour broad range protein marker. A characteristic 25 kDa 
single band was observed in both supernatants and cell pellets samples of HEK 293T cells.  
 
 Pilot experiments of in vivo expression 
3.3.1  First pilot experiment: mouse Bpifa1 and human BPIFA1 in vivo 
expression/over-expression 
In the first pilot experiment, we wanted to assess the ability of both wild-type 
C57BL/6J and Bpifa1-/- mice to express recombinant mouse Bpifa1 and human BPIFA1. 
A plasmid expressing Bpifa1 (Bpifa1-pVR1255) was constructed as described in the 
previous section. A similar expression construct for BPIFA1 was made previously (N. 
Moyo and J.P. Stewart, unpublished). These two plasmids were concentrated using 
Amicon® ultra-0.5 centrifugal filter devices and mixed separately with in vivo- jetPEI® 
delivery reagent as described in section 2.4.4.1 and shown in Figure 2-3. A total number 
of 14 mice (three wild-type C57BL/6J mice were intranasally inoculated either with 
mouse Bpifa1 or human BPIFA1 each, and four Bpifa1-/- mice with either mouse Bpifa1 




plasmid/in vivo-jetPEI mix per mouse. Immediately after administration, the mice went 
into shock and had to be resuscitated, given oxygen and warmed on a heat pad. A 
number of the mice succumbed to shock. Two days post-administration, mice were 
euthanised and lung tissue samples were collected, homogenised (see 2.4.4.1) and 
analysed for Bpifa1/ BPIFA1 expression by using western immunoblotting (see 2.3.3.3). 
Results of this pilot experiment showed no in vivo expression of Bpifa1 in Bpifa1-/- mice 
(Figure 3-5B). In addition, no in vivo expression of BPIFA1 in wild-type C57BL/6J and 
Bpifa1-/- mice was seen (Figure 3-5C and D). The only in vivo expression was identified 
in two wild-type C57BL/6J mice, which is expected (Figure 3-5A). However, one wild-
type C57BL/6J mouse (sample number 2) did not show any expression which might be 
attributed to the sample processing. A disadvantage of using western immunoblotting 
technique in this pilot experiment was our inability to distinguish between endogenous 
and transfected Bpifa1. To improve the experimental design, negative control samples 
from non-transfected wild-type C57BL/6J mice could be used. In addition, plasmid 
constructs which express Bpifa1 tagged with V5/6XHIS-TAG could be used to 





Figure 3-5. In vivo expression of mouse Bpifa1 and human BPIFA1. 
Mice were inoculated by intra-nasal route using 20 µg of plasmid in 50 µl final volume 
plasmid/in vivo-jetPEI mix per mouse. Two days post-administration, mice were euthanised and 
lung tissue samples were collected, homogenised and analysed for mouse Bpifa1 and human 
BPIFA1 expression by using western immunoblotting. A. In vivo expression of Bpifa1 in wild-
type C57BL/6J mice (n=3). B. In vivo expression of Bpifa1 in Bpifa1-/- mice (n=4). Rabbit anti-
mouse Bpifa1 was used as a primary antibody in a dilution of 1:500, and HRP goat anti-rabbit 
IgG antibody as a secondary antibody in a dilution of 1: 1,000. C. In vivo expression of BPIFA1 in 
wild-type C57BL/6J mice (n=3). D. In vivo expression of BPIFA1 in Bpifa1-/- mice (n=3). Rabbit 
anti-human BPIFA1 antibody was used as a primary antibody in a dilution of 1:500, and HRP 
goat anti-rabbit IgG antibody as a secondary antibody was used in a dilution of 1:1,000. The first 
lane shows the molecular weight markers. This figure shows no in vivo expression of Bpifa1 in 
Bpifa1-/- mice as well as no in vivo expression of BPIFA1 in Bpifa1-/- mice, which were 
administered both mouse Bpifa1 and human BPIFA1. In addition, no in vivo expression of BPIFA1 
in wild-type C57BL/6J mice, which were administered human BPIFA1. The only identified in vivo 





3.3.2 Second pilot experiment: mouse Bpifa1 and human BPIFA1 in vivo expression  
In the previous pilot experiment, mice appeared to suffer endotoxic shock after 
administration of the transfection mix. In the second pilot experiment, only Bpifa1-/- 
mice were used to assess the ability of these mice to express recombinant mouse Bpifa1 
and human BPIFA1. In addition, MiraCLEAN®Endotoxin removal kit was used for the 
extensive removal of bacterial endotoxins from DNA as described in section 2.4.4.2. 
The experiment included eight mice total; four were inoculated with Bpifa1 and 
four with BPIFA1 by intra-nasal route using 20 µg of plasmid in 50 µl plasmid/in vivo-
jetPEI mix per mouse. Mice were euthanised after two days of administration and lung 
tissue samples were collected, homogenised (see 2.4.4.1) and analysed for Bpifa1/ 
BPIFA1 expression by using western immunoblotting (see 2.3.3.3). Furthermore, a 
positive control sample was included which was derived from a single wild-type 
C57BL/6J mouse which tested positive for Bpifa1 expression in the first pilot 
experiment. In this pilot experiment, no in vivo expression of recombinant mouse 









Figure 3-6. In vivo expression of mouse Bpifa1 and human BPIFA1. 
Mice were inoculated by intra-nasal route using 20 µg of plasmid in 50 µl final volume 
plasmid/in vivo-jetPEI mix per mouse. Two days post-administration, mice were euthanised and 
lung tissue samples were collected, homogenised and analysed for mouse Bpifa1 and human 
BPIFA1 expression by using western immunoblotting. A. In vivo expression of Bpifa1 (n=4), 
rabbit anti-mouse Bpifa1 was used as a primary antibody in a dilution of 1:500, and HRP goat 
anti-rabbit IgG antibody as a secondary antibody in a dilution of 1: 1,000. The positive (+ve) 
control is a sample from a single wild-type C57BL/6J mouse, which tested positive for Bpifa1 
expression in the first pilot experiment. B. In vivo expression of BPIFA1 (n=3); rabbit anti-human 
BPIFA1 antibody was used as a primary antibody in a dilution of 1:500, and HRP goat anti-rabbit 
IgG antibody as a secondary antibody was used in a dilution of 1:1,000. The first lane shows the 
molecular weight markers. No in vivo expression of mouse Bpifa1 and human BPIFA1 was 
observed in Bpifa1-/- mice.  
 
3.3.3 Third pilot experiment: in vivo expression of pMSCV-IRES-GFP 
In the previous experiments, no mouse Bpifa1 or human BPIFA1 expression had 
been seen after in vivo administration of plasmids. To assess the feasibility of the in vivo 
transfection technique, Bpifa1-/- mice were only used to assess their ability to express 
the GFP reporter plasmid pMSCV-IRES-GFP. The experiment included eight mice total, 
which were inoculated by the intra-nasal route using 20 µg of plasmid in 50 µl 
plasmid/in vivo-jetPEI mix per mouse. Two days post-administration, mice were 
euthanised and lung tissue samples were collected, homogenised (see 2.4.4.1) and 
analysed for pMSCV-IRES-GFP expression by using western immunoblotting (see 




2.4.4.2). In addition, pMSCV-IRES-GFP was concentrated using Amicon® ultra-0.5 
centrifugal filter devices as described in section 2.4.4.1. Results of this pilot experiment 
showed no in vivo expression of pMSCV-IRES-GFP in Bpifa1-/- mice (Figure 3-7). 
 
Figure 3-7. In vivo expression of pMSCV-IRES-GFP. 
Mice were inoculated by intra-nasal route using 20 µg of plasmid in 50 µl final volume 
plasmid/in vivo-jetPEI mix per mouse. Two days post-administration, mice were euthanised and 
lung tissue samples were collected, homogenised and analysed for pMSCV-IRES-GFP expression 
by using western immunoblotting. GFP (B-2)], a mouse monoclonal IgG2a was used as a primary 
antibody in a dilution of 1:1,000, and anti-mouse IgG (whole molecule)–peroxidase antibody 
produced in goat was used as a secondary antibody in a dilution of 1:10,000. The first lane 
shows the molecular weight markers. No in vivo expression of pMSCV-IRES-GFP was observed 
in Bpifa1-/- mice. 
 
In summary, in this study, we were able to clone and express Bpifa1 in in vitro using 
HEK 293T cells (Figures 3-2 and 3-4) in a characteristic molecular weight of 25 kDa, that 
is supported by other studies (LeClair et al., 2004; Britto et al., 2013). However, 
limitations are evident such as we were unable to detect both mouse Bpifa1 and human 
BPIFA1 proteins in Bpifa1-/- mice by western immunoblotting in the first pilot 




respectively, suggesting either that the protein is difficult to express, or that the 
expressed protein is produced at low levels below the limit of detection by western 
immunoblotting. In addition, we were unable to detect BPIFA1 protein in wild-type 
C57BL/6J mice (Figure 3-5C). Therefore, alternatively, quantification of RNA by using 
RT-PCR would be a potentially more sensitive approach to detect the in vivo expression 
for future studies.    
GFP expression can be used as an evidence to illustrate and assess gene expression 
and protein localisation in living organisms (Chalfie et al., 1994). We were unable to 
express pMSCV-IRES-GFP in vivo using Bpifa1-/- mice in the third pilot experiment (Figure 

















Chapter 4. Role of Bpifa1 in the  







Mice have not until relatively recently been thought of as transmitting IAV. 
However, recent publications have indicated that, under the right conditions they can 
be suitable in vivo models to study influenza virus transmission. In addition, a larger 
number of mice can be used in experimental work, which is an essential factor for 
transmission studies and consequent data analysis (Rigoni et al., 2010). The aim of this 
chapter was to establish the transmission model and investigate whether Bpifa1 has 





 Virological characteristics of experimental infection 
4.2.1 Infection of mice 
To assess the role of Bpifa1 in the transmission of IAV between infected and non-
infected wild-type C57BL/6J and Bpifa1-/- mice, two transmission experiments were set 
up. The experimental strategy follows that of (Edenborough et al., 2012) and is shown 
in Figure 2-5. Wild-type C57BL/6J and Bpifa1-/- mice were used as both the infected 
(index) mice and the non-infected (contact) mice. In transmission experiment 1, wild-
type C57BL/6J index mice were mixed with wild-type C57BL/6J contact mice, and 
Bpifa1-/- index mice were mixed with Bpifa1-/- contact mice. In transmission experiment 
2, wild-type C57BL/6J index mice were mixed with Bpifa1-/- contact mice, and Bpifa1-/- 
index mice with wild-type C57BL/6J contact mice. Following these two transmission 
experiments and based on their results, a third transmission experiment was set up and 
is shown in Figure 2-6, in which wild-type C57BL/6J index mice were mixed with either 
wild-type C57BL/6J contact mice or Bpifa1-/- contact mice. All index mice in the three 
transmission experiments were infected intranasally with 5x104 PFU IAV X-31 (H3N2). 
 Infectious virus titres in lung and nasal tissue samples (for both transmission 
experiments 1 and 2) were measured at 4 dpi by plaque assay using MDCK cells as 
described in section 2.4.5.3. In transmission experiment 3, since it appeared that wild-
type C57BL/6J index mice transmitted IAV more effectively, all wild-type C57BL/6J index 
mice and  three wild-type C57BL/6J and three Bpifa1-/- contact mice were euthanised at 
day 4 post-infection/exposure and tissue samples were collected immediately and 
included: heads, salivary gland and mandibular ln, thoracic organs [lung, trachea, 
bronchial ln, thymus, mediastinal adipose tissue], mesenteric ln, and spleen with 
surrounding mesenteric adipose tissue were sampled and the tissue fixed in 10% 
buffered formalin for histological and immunohistological examinations. Detailed 




Kipar, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, 
Switzerland, and Institute of Infection, Veterinary and Ecological Sciences, University of 
Liverpool. At day 16 pi, the last six contact mice (three wild-type C57BL/6J and three 
Bpifa1-/- mice) were euthanised; blood, BAL and nasal wash samples were collected and 
antibody levels determined. 
4.2.2  Body weight 
The body weight was determined daily for the duration of the experiment (4 days), 
and recorded as the percentage of the starting body weight at day 0. During the 
transmission experiment 1, wild-type C57BL/6J and Bpifa1-/- index mice did not show 
any significant difference in the body weight (Figure 4-1A), whereas a significant 
difference in the body weight was observed between wild-type C57BL/6J and Bpifa1-/- 
contact mice; Bpifa1-/- mice had lost more weight than wild-type C57BL/6J mice at 2, 3- 
and 4-days post-onset of co-housing with index mice from the same strain (Figure 4-
1B). In the transmission experiment 2, no significant difference was observed in the 
body weight between wild-type C57BL/6J and Bpifa1-/- index mice (Figure 4-1C) and 
between wild-type C57BL/6J and Bpifa1-/- contact mice when they were mixed with 
index mice from the other strain (Figure 4-1D). Index mice in the transmission 
experiments 1 and 2 did not show any significant differences in the body weight loss. 
This result is consistent with our previous work in the laboratory (Akram et al., 2018), 
where upon a significant difference in weight loss is detected after 6-7 dpi. Mice in this 
study lost less weight (Akram et al., 2018) which is attributed to the virus dose, which 





Figure 4-1. Body weights of mice in the transmission experiments 1 and 2. 
Mice (numbers for each group are shown in the figure) were infected intranasally with 5x104 
PFU IAV X-31. A. and B., transmission experiment 1; C. and D., transmission experiment 2. Mice 
were weighed daily and the body weights recorded as a percentage of the body weight at day 
0. A. No significant difference in the body weight was seen between wild-type C57BL/6J and 
Bpifa1-/- index mice. B. A significant higher body weight loss in Bpifa1-/- contact mice than wild-
type C57BL/6J mice at 2, 3- and 4-days post-onset of co-housing. C. No significant difference in 
the body weight was seen between wild-type C57BL/6J and Bpifa1-/- index mice. D. No 
significant difference in the body weight was seen between wild-type C57BL/6J and Bpifa1-/- 
contact mice. The results are presented as SEM for each group. Asterisks indicate statistical 
difference [(two-way analysis of variance (ANOVA) with Bonferroni post-test (*P < 0.05, **P 
<0.01)]. 
However, a significant difference in body weight was observed between wild-type 
C57BL/6J and Bpifa1-/- contact in the transmission experiment 3; Bpifa1-/- mice showed 
more weight loss than wild-type C57BL/6J mice at 1, 2, 3- and 4-days post-onset of co-






Figure 4-2. Body weights of mice in the transmission experiment 3 
Mice (numbers for each group are shown in the figure) were infected intranasally with 5x104 
PFU IAV X-31. Mice were weighed daily and the body weights recorded as a percentage of the 
body weight at day 0. A significant higher body weight loss was observed in Bpifa1-/- contact 
mice than wild-type C57BL/6J mice at 1, 2, 3- and 4-days post-onset of co-housing with wild-
type C57BL/6J index mice. The results are presented as SEM for each group. Asterisks indicate 
statistical difference [(two-way analysis of variance (ANOVA) with Bonferroni post-test (*P < 
0.05, ***P < 0.001)].  
 
4.2.3 Infectious virus titre  
The plaque assay was performed on homogenised lung and nasal tissue samples 
from the transmission experiments 1 and 2 to determine the infectious virus titres (see 
2.4.5.3), using 200-300 mg lung/nasal tissue samples and the MDCK cells. In both 
experiments, there were no significant differences in infectious virus titres in the lungs 
of wild-type C57BL/6J and Bpifa1-/- index mice (Figure 4-3A). Surprisingly, this result 
does not concur with our recent published work (Akram et al., 2018), which might be 
due to the difference in the virus dose used. In contrast, the viral titre was significantly 
higher in the nasal tissue of Bpifa1-/- index mice than in wild-type C57BL/6J index mice 
(Figure 4-3B). Interestingly, when both wild-type C57BL/6J and Bpifa1-/- contact mice 
were mixed with wild-type C57BL/6J index mice neither showed significant differences 




higher virus titre in the nasal tissue than wild-type C57BL/6J mice when either were 
mixed with wild-type C57BL/6J index mice (Figure 4-3C). In addition, there was no 
significant difference between wild-type C57BL/6J and Bpifa1-/- contact mice in the virus 
titre of the lung and nasal tissue when they were mixed with Bpifa1-/- index mice (Figure 
4-3D).  
 
Figure 4-3. Infectious virus titres in lung and nasal tissue samples of the transmission 
experiments 1 and 2. 
Mice were infected intranasally with 5x104 PFU IAV X-31. Lung and nasal tissue samples were 
collected at 4 dpi. Virus titre was measured by plaque assay using MDCK cells. The results are 
representative of two separate experiments. A. There is no significant difference in the virus 
titre in the lung between wild-type C57BL/6J and Bpifa1-/- index mice, as shown using t-test with 
Mann-Whitney U test. B. A significant higher virus titre in the nasal tissue is obvious in  
Bpifa1-/- index mice than wild-type C57BL/6J mice, as shown using t-test with Mann-Whitney U 
test at **P value 0.0080. C. There is no significant difference in the virus titre in the lung 
between wild-type C57BL/6J and Bpifa1-/- contact mice, while there is a significant higher virus 
titre in the nasal tissue of Bpifa1-/- contact mice compared with wild-type C57BL/6J contact mice 
using t-test with Mann-Whitney U test at **P value 0.0055. D. No significant differences in the 
virus titre between wild-type C57BL/6J and Bpifa1-/- contact mice in lung and nasal tissue at P 
value 0.1273 using One-way analysis of variance with Tukey's Multiple Comparison test. Index 
and contact mice are indicated with arrows wherein index mice are denoted to the left of the 




  Antibody response to IAV infection 
 
To investigate the immune response in both wild-type C57BL/6J and Bpifa1-/- 
contact mice, samples of blood, BAL and nasal wash samples were collected at day 16 
pi and analysed by ELISA for IAV X-31 specific antibody titres (see 2.5.1.2), i.e. to 
determine the IgA and IgG levels in BAL and nasal wash samples, and the IgG level in 
serum samples. Results showed a weak immune response in IgA level in BAL of wild-
type C57BL/6J mice (Figure 4-4A), however statistically non-significant differences were 
seen between these two groups of mice in their IgA and IgG levels in the collected 
samples (Figure 4-4). Negative control and blank samples were used for data 
comparison. For serum samples, a negative sample from a non-infected (control) wild-
type C57BL/6J mouse at 14 dpi (from 103 PFU IAV X-31 antibody experiment) was used. 
For BAL samples, a negative sample from a non-infected (control) Bpifa1-/- mouse at 14 
dpi (from 103 PFU IAV X-31 antibody experiment) was used. While for nasal wash 
samples, a negative sample from a Bpifa1-/- mouse infected with 10 PFU IAV X-31 at 7 
dpi (which was previously tested negative) was used. Blank samples contained neither 
primary nor secondary antibody; incubation only with the diluent buffer were used as 





Figure 4-4. IgA and IgG levels in BAL, nasal wash and serum of contact mice at 16 dpi. 
Index mice were infected intranasally with 5x104 PFU IAV X-31. BAL, serum and nasal wash 
samples were collected at 16 dpi from both wild-type C57BL/6J and Bpifa1-/- contact mice and 
analysed by virus specific ELISA. A. IgA level in BAL. B. IgG level in BAL. C. IgA level in nasal wash. 
D. IgG level in nasal wash. E. IgG level in serum. The results are presented as SEM for each group. 
All observed differences between groups were not statistically significant, as determined by 
two-way analysis of variance (ANOVA) with Bonferroni post-test. Negative control and blank 






 Histopathological changes 
 
To investigate the inflammatory response to IAV infection and to shed light on its 
potential differences in relation to the observed virological differences (see 4.2.3), the 
respiratory tract, lungs, and lymphatic tissues were harvested at day 4 pi from index 
mice (wild-type C57BL/6J) and contact mice (both wild-type C57BL/6J and Bpifa1-/-). The 
histological and immunohistological findings are listed in detail in Table 1 in the 
Appendix. 
4.4.1  Nasal cavity 
For a detailed assessment of the nasal cavity, the heads (coronal sections) were 
fully examined. All wild-type C57BL/6J index mice (total examined n=8) showed 
sloughing and necrosis of some epithelial cells in the nasal mucosa; this was associated 
with the presence of some cell debris in the lumen of the nasal cavity (Figure 4-5A and 
B). Also, presence of sloughing and necrosis of some olfactory epithelial cells (Figure 4-
5C and D). Research has shown a difference in the expression of Bpifa1 in the sites of 
respiratory and olfactory epithelia. Although there is a complete lack of Bpifa1 
expression in areas of olfactory epithelium, Bpifa1 is predominantly expressed in the 
respiratory epithelium (Musa et al., 2012). IAV antigen was detected in numerous intact 
and degenerating individual respiratory epithelial cells in the nasal cavity (Figure 4-5E 
and F) and occasional neuroepithelial cells of the VNO as well as some neurons in 
trigeminal ganglia. Mild, predominantly mononuclear mucosal infiltration and mild to 
moderate NALT formation was also seen (Figure 4-5G). NALT is represented by a small 
aggregation of organised lymphoid tissue in the nasal mucosa, which is found on both 
sides of the nasopharyngeal duct. This tissue is essential for induction of systemic 





Figure 4-5. Histopathological and immunohistological findings in the nasal cavity of wild-
type C57BL/6J index mice at 4 dpi. 
A-G. Mouse B18-1186. A. Sloughing of some epithelial cells in the nasal mucosa (arrow) with 
presence of cell debris in lumen of nasal cavity (arrowhead), scale bar= 100 µm. B. Higher 
magnification of A. to show degenerating cells (arrow), scale bar= 50 µm. C. Sloughing of some 
olfactory epithelial cells (arrow), scale bar= 100 µm. D. Higher magnification of C. to show 
degenerating cells (arrow), scale bar= 50 µm. E. IAV antigen expression is seen in abundant 
epithelial cells (arrows), scale bar= 250 µm. F. Higher magnification of E. shows IAV antigen 
expression in individual epithelial cells (arrows), scale bar= 50 µm. G. Moderate NALT formation 





At this time point, wild-type C57BL/6J contact mice (total examined n=3) showed 
intact respiratory and olfactory epithelial cells (Figure 4-6A and C), moderate NALT 
formation (Figure 4-6E), and bilateral focal neutrophil infiltration in the VNO. Viral 
antigen expression was not detected in these mice (Figure 4-6G). Bpifa1-/- contact mice 
(total examined n=3) exhibited no histological abnormality in the nasal cavity (Figure 4-
6B and D), and only mild NALT formation (Figure 4-6F). However, they showed focal 
areas with positive intact epithelial cells (mainly cytoplasmic reaction) in the nasal cavity 
(Figure 4-6H). Infected cells were mainly seen in the frontal nasal cavity, their number 





Figure 4-6.  Histological and immunohistological findings in the nasal cavity of contact mice 
at 4 dpi. 
A, C, E and G. Wild-type C57BL/6J mouse (B18-1196); B, D, F and H. Bpifa1-/- mouse (B18-1197). 
In both groups of mice, the nasal cavity did not exhibit any histological changes in both the 
respiratory (A and B), scale bars= 50 µm and olfactory epithelium (C and D), scale bars= 50 µm. 
Mild NALT formation (E and F) (arrows), scale bars= 100 µm. Viral antigen expression is not seen 
in the wild-type C57BL/6J mouse (G), whereas the Bpifa1-/- mouse shows a focal area with 
several positive epithelial cells (H) (arrows), scale bars= 100 µm. A, B, C, D, E, F: HE stain; G, H: 





4.4.2  Lower respiratory tract and lungs 
In some wild-type C57BL/6J index mice (total examined n=8), the trachea was 
histologically unaltered, in others it exhibited several to abundant individual 
apoptotic/necrotic epithelial cells. Viral antigen expression was seen in several intact 
epithelial cells (mouse B18-1190). In other mice, it was seen in numerous intact and 
degenerate/necrotic epithelial cells (mice B18-1191 and B18-1192) and also was rare in 
intact epithelial cells (mouse B18-1193).   
The lungs showed moderate multifocal necrotising bronchiolitis (Figure 4-7A) with 
peribronchiolar lymphocyte dominated infiltration, a multifocal lymphocyte dominated 
vasculitis with evidence of lymphocyte recruitment and perivascular lymphocyte 
dominated mononuclear infiltrates (Figure 4-7B). Around affected bronchioles, alveoli 
exhibited necrosis of epithelial cells (Figure 4-7A). Animals also showed variably sized 
collapsed, consolidated areas with necrotic pneumocytes, type II pneumocyte 
activation and desquamation, and in one mouse (B18-1186); extensive neutrophil and 
lymphocytes accumulations. Viral antigen was detected in intact and degenerating 
individual respiratory epithelial cells, especially in affected bronchioles (Figure 4-7C). 
Alveolar cells (mainly type II pneumocytes) in altered and unaltered alveoli and in 





Figure 4-7. Histopathological and immunohistological findings in the lung of wild-type 
C57BL/6J index mice at 4 dpi. 
A. Mouse (B18-1189), necrotising bronchiolitis (arrow) with necrosis of epithelial cells around 
the bronchiole (arrowhead), scale bar= 50 µm. B. Mouse (B18-1186), perivascular lymphocyte 
dominated mononuclear infiltrates (arrow), scale bar= 50 µm. C. Mouse (B18-1189), IAV antigen 
expression in intact and degenerating epithelial cells of affected bronchioles (arrows), scale 
bar= 100 µm. D. Mouse (B18-1186), IAV antigen in consolidated areas (arrows), scale bar= 100 
µm. E. Mouse (B18-1189), IAV antigen in alveolar cells (arrows), scale bar= 100 µm. A, B: HE 
stain; C, D, E: IH, haematoxylin counterstain. 
 
Wild-type C57BL/6J contact mice (total examined n=3) showed no histological 
changes in the trachea. Their lungs did not exhibit any histological changes apart from 
a mildly increased interstitial cellularity and a few neutrophils (Figure 4-8A). In one 




8C). In contrast, Bpifa1-/- contact mice (total examined n=3) did not only exhibit 
increased interstitial cellularity (Figure 4-8B), but also showed some lymphocyte rolling 
along endothelial cells and some lymphocytes around vessels (Figure 4-8D), focal 
peribronchiolar lymphocyte aggregates, and mild bronchus-associated lymphoid tissue 
(BALT) formation. Trachea was not on any of the sections. Viral antigen expression was 
not detected in trachea and lungs of any contact mice (Figure 4-8E, F). 
 
Figure 4-8. Histopathological and immunohistological findings in the lung of wild-type 
C57BL/6J and Bpifa1-/- contact mice at 4 dpi. 
A. Wild-type C57BL/6J mouse (B18-1196), mild increased in interstitial cellularity (circled), scale 
bar= 50 µm. B. Bpifa1-/- mouse (B18-1197), a dramatic increase in interstitial cellularity (circled), 
scale bar= 50 µm. C. Wild-type C57BL/6J mouse (B18-1196), some lymphocytes around the 
blood vessel (arrows), scale bar= 50 µm. D. Bpifa1-/- mouse (B18-1197), lymphocyte rolling along 
endothelial cells (arrows), scale bar= 50 µm. IAV antigen was not detected in E. Wild-type 
C57BL/6J mouse (B18-1194) and F. Bpifa1-/- mouse (B18-1199), scale bars= 100 µm. A, B, C, D: 




4.4.3  Lymphatic and other tissues 
 Besides the spleen and thymus, lymph nodes (mandibular, bronchial and 
mesenteric lymph nodes) were examined in wild-type C57BL/6J index mice and both 
wild-type C57BL/6J and Bpifa1-/- contact mice. The spleen of index mice showed a white 
pulp comprised of relatively small to moderate sized primary follicles or moderately 
sized secondary follicles and T cell zones. The red pulp was of low to moderate or high 
cellularity and showed mild to moderate extramedullary haematopoiesis (EMH) (Figure 
4-9A). Wild-type C57BL/6J contact mice exhibited moderate to relatively large sized 
secondary follicles with several apoptotic cells and T cell zones, consistent with an 
active immune response (McGaha and Karlsson, 2016). They also showed moderate 
cellularity of the red pulp and mild EMH (Figure 4-9B). The white pulp of Bpifa1-/- contact 
mice showed similar features, i.e. moderate sized secondary follicles with occasionally 
apoptotic cells and moderately sized T cell zones; the red pulp exhibited moderate to 
high cellularity and mild EMH (Figure 4-9C). Viral antigen was not detected in the 






Figure 4-9. Histopathological findings in the spleen of index and contact mice at 4 dpi. 
A. Wild-type C57BL/6J index mouse (B18-1193), small to moderate sized primary follicles 
(arrows) with moderate cellularity of red pulp (circled). B. Wild-type C57BL/6J contact mouse 
(B18-1194), moderate sized follicles (arrows) and moderate cellularity of red pulp (circled). C. 
Bpifa1-/- contact mouse (B18-1197), moderate sized secondary follicles (arrow) with moderate 
sized T cell zone (arrowhead) and moderate cellularity of the red pulp (circled). Scale bars= 250 
µm, HE stain.  
 
The mandibular lymph nodes of index mice exhibited relatively small to large 
follicles and T cell zones (Figure 4-10A), but was overall cell rich, with mild to moderate 
sinus histiocytosis. In wilt-type C57BL/6J contact mice small, indistinct follicles and T cell 
zones were seen (Figure 4-10B), and there was mild to moderate sinus histiocytosis. 
This was similar in Bpifa1-/- contact mice where relatively small follicles and T cell zones 






Figure 4-10. Histopathological findings in the mandibular lymph node of index and contact 
mice at 4 dpi. 
A. Wild-type C57BL/6J index mouse (B18-1191), large follicles (arrows). B. Wild-type C57BL/6J 
contact mouse (B18-1196), indistinct follicles and T cell zones. C. Bpifa1-/- mouse (B18-1199), 
small follicles (arrows) and T cell zone (arrowhead). Scale bars= 250 µm, HE stain. 
Bronchial lymph nodes were not always included in the sections. When present, 
they exhibited indistinct follicles and T cell zones and moderate sinus histiocytosis in 
index mice (Figure 4-11A, B), and mild sinus histiocytosis in wild-type C57BL/6J contact 
mice (Figure 4-11C). In Bpifa1-/- contact mice they were not on the sections. Mesenteric 






Figure 4-11. Histopathological findings in the bronchial lymph node of index and contact 
wild-type C57BL/6J mice at 4 dpi. 
A. Wild-type C57BL/6J index mouse (B18-1189), indistinct follicles and T cell zones, scale bar= 
250 µm. B. Wild-type C57BL/6J index mouse (B18-1192), moderate sinus histiocytosis (arrows), 
scale bar= 50 µm. C. Wild-type C57BL/6J contact mouse (B-18-1196), mild sinus histiocytosis 
(arrow), scale bar= 50 µm. HE stain. 
 
The thymus of index mice showed a thinned cortex (Figure 4-12A), and a cell rich 
medulla with a slight increase in apoptotic lymphocytes. In both contact mice (wild-type 








Figure 4-12. Histopathological findings in the thymus of index and contact mice at 4 dpi. 
A. Wild-type C57BL/6J index mouse (B18-1188), a thinned cortex. B. Wild-type C57BL/6J contact 
mouse (B18-1195), unaltered thymus. C. Bpifa1-/- contact mouse (B18-1198), unaltered thymus. 
Scale bars= 250 µm, HE stain. 
 
 
The mediastinal and mesenteric adipose tissues were examined for the presence 
of lymphocyte accumulations as described in mice after infections (Jackson-Jones et al., 
2016). Some index mice showed several, variably sized, poorly delineated aggregates of 
lymphocytes, macrophages and plasma cells with occasional Mott cells, as well as focal 
dense aggregates of lymphocytes. Contact wild-type C57BL/6J mice showed a few small 
aggregates of lymphocytes and macrophages, and contact Bpifa1-/- mice exhibited a few 
small to several larger aggregates of lymphocytes and macrophages. In none of the mice 
was there any viral antigen expression in any of these tissues.   
In conclusion, IAV transmission occurred from wild-type C57BL/6J index mice to 
Bpifa1-/- contact mice but not from Bpifa1-/- index mice to wild-type C57BL/6J contact 




3). The possible reasons for this interesting result are still unknown and therefore more 
work will be required to further explore and uncover the underlaying mechanisms for 
the future research. However, Bpifa1-/- contact mice were more susceptible to IAV 
transmission and exhibited more viral load and histological changes than wild-type 
C57BL/6J contact mice, particularly in the nasal tissue. From these results, Bpifa1 

















Chapter 5. The immune  







The elicited immune response during influenza virus infection provides a model in 
which the relative contributions of the humoral, cellular and the mucosal immune 
systems can be investigated (Renegar et al., 2004). This immune response includes a 
systemic response (serum), local respiratory response (virus-specific local IgA and IgG 
antibodies in respiratory secretions), along with the cellular immunity (Ghendon, 1990). 
The adaptive immune response is crucial for control and clearance of influenza virus 
infection (Neff-LaFord et al., 2003). Humoral immunity against IAV represented by 
antibodies is highly cross-reactive, i.e. antibodies induced by infection or vaccination 
with one strain usually protect against infection with other related strains (Yu et al., 
2008). 
Neutralising antibodies induced either by infection or vaccination are often 
directed to the globular head of HA molecule (Koel et al., 2013). Long-lasting protection 
by these neutralising antibodies is prevented by continuous antigenic drift in this part 
of HA, and the appearance of antigenically new IAV strains into a serologically naïve 
population (De Jong et al., 2000). However, IAV-induced T cells during seasonal IAV 
infection provide protective immunity against these new viruses. IAV-specific CTLs are 
mainly directed to more conserved internal influenza proteins such as NP, therefore 
they can mediate cross-reactive immunity and provide protection against antigenically 
distinct strains of IAV (Gotch et al., 1987; Van de Sandt et al., 2012; Sridhar et al., 2013). 
 The main gaol of vaccine design is to initiate extremely efficient immunological 
memory without any of the unwanted effects. IAV X-31 (H3N2) and PR8 (H1N1) are 
serologically independent i.e. antibodies produced toward the glycoproteins of one 
virus do not distinguish the other virus. However, antibodies toward the nucleocapsid 




cross-reactive T-cell populations due to the fact that virus-specific T cells can distinguish 
peptides from the shared viral proteins which are common between X-31 and PR8. After 
challenge with IAV PR8, mice that have recovered from the infection must recruit naïve 
B cells to the PR8 glycoproteins, nevertheless they can receive help from cross-reactive 
T cell primed during the former infection (Coleclough et al., 2005).       
Previous work in the laboratory had suggested that as well as directly inhibiting 
IAV infection, Bpifa1 could influence the production of antiviral antibodies. Therefore, 
the aim of this chapter was to investigate further the role of Bpifa1 during IAV infection 


















 Confirmation of in vivo expression of Bpifa1  
In order to confirm the in vivo expression of Bpifa1 and thereby the correct strain 
of mice was used during the IAV antibody experiments and to ensure that no mixing of 
these mice during their breeding and preparation for the experiments had occurred, 
BAL samples (three samples from each mouse strain) previously infected with 103 PFU 
IAV X-31 at 7 dpi were subjected to western immunoblotting (see section 2.3.3.3). The 
results confirmed the in vivo expression of Bpifa1 in the BAL samples of wild-type 
C57BL/6J mice, visible as a characteristic 25 kDa single band, but not in Bpifa1-/- mice 
(Figure 5-1). 
 
Figure 5-1. In vivo expression of Bpifa1 in BAL samples of mice infected with 103 PFU IAV X-
31 at 7 dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; BAL samples were collected and 
analysed by western immunoblotting. Rabbit anti-mouse Bpifa1 was used as a primary antibody 
(1:500), and HRP goat anti-rabbit IgG antibody as a secondary antibody (1: 1,000). The first lane 
shows the molecular weight markers. A characteristic 25 kDa single band was only observed in 






 Effect of Bpifa1 on protective immune responses 
 
Protective anti-IAV antibody responses are mostly directed at the viral HA and NA 
glycoproteins, whereas protective cytotoxic T lymphocytes (CTL) responses are directed 
at internal proteins such as NP and PA (Wiley et al., 1981; Caton et al., 1982; Sridhar et 
al., 2013). IAV strains X-31 and PR8 have different HA and NA types (H3N2 and H1N1, 
respectively) which do not afford cross-protection. However, they have identical 
internal proteins (e.g. NP and PA) and so CTL responses directed against one strain will 
cross-react with the other. By infecting/vaccinating with X-31 and PR8 and then 
challenging with PR8 it is therefore possible to distinguish between CTL and antibody-
mediated protection.  
To assess whether Bpifa1 influence antiviral responses, a vaccination/challenge 
experiment was performed. Here control wild-type C57BL/6J and Bpifa1-/- mice were 
infected at day 0 with either 103 PFU IAV X-31, 50 PFU IAV PR8 or mock- infected (for 
schematic see Figure 2-7). The rationale for using two different virus doses in this 
experiment is that IAV PR8 is mouse-adapted and more lethal than X-31 (Kilbourne, 
1969; Baez et al., 1980; Coleclough et al., 2005), and for the challenge, a lethal dose 
(103 PFU) of IAV PR8 was used to investigate any post-challenge differences between 
these two mice strains with high viral dose. On 24 dpi, blood samples were collected 
from the tail vein of live mice to determine the anti-IAV IgG level in the serum. On 28 
dpi, mice were challenged with 103 PFU IAV PR8. On 33 dpi, mice were euthanised, BAL 
was collected, the thoracic cavity was opened and lung tissue was collected to 
determine the virus titre.  
Weight loss was measured after infection and challenge as a non-invasive clinical 
sign. A significant difference in weight loss was observed between wild-type C57BL/6J 




Bpifa1-/- mice losing more weight (5-10% more than control mice) (Figure 5-2). Infected 
mice generally recovered their original weight by 21 dpi except Bpifa1-/- mice infected 
with X-31 that did not regain their original weight even after 28 days. Thus, infected 
mice all showed clinical signs of IAV disease but recovered and regained all or the 
majority of weight loss. 
 
Figure 5-2. Post-infection (pre-challenge) body weight of mice during the IAV vaccination/ 
challenge experiment. 
Mice were infected on day 0 with either A. 103 PFU IAV strain X-31, or B. 50 PFU IAV strain PR8. 
Also, control groups (mock-infected), which received no treatment from both strains of mice 
for both IAV X-31 and PR8 were included in the experiment. All mice were weighed daily for 28 
days and weights are presented as a percentage of the starting body weight. The results are 
presented as SEM for each group. Asterisks indicate statistically significant differences 
determined by two-way analysis of variance (ANOVA) with Bonferroni post-test (*P < 0.05, **P 
<0.01, ***P < 0.001). The green and blue lines represent the body weights of the control wild-
type C57BL/6J and control Bpifa1-/- mice, respectively. Bpifa1-/- mice either infected with IAV X-





After challenge, mice either infected with IAV X-31 or PR8 were protected from 
significant weight loss post-challenge. Whereas uninfected mice lost weight rapidly and 
had to be euthanised at 5 dpi as they had lost >20% of their original weight. However, 
there was no significant difference in the post-challenge body weight between infected 
and challenged wild-type C57BL/6J and Bpifa1-/- mice, or mock-infected and challenged 
wild-type C57BL/6J and Bpifa1-/- mice (Figure 5-3). 
 
Figure 5-3. Post-challenge body weight of mice during the IAV vaccination/ challenge 
experiment.  
All mice (n=36) were challenged on day 28 with 103 PFU of IAV PR8 and weighed daily until the 
end of the experiment (5 days post-challenge). A. Mice infected with IAV X-31. B. Mice infected 
with IAV PR8. The results are presented as SEM for each group. No significant differences were 
seen in body weights between infected and challenged wild-type C57BL/6J and Bpifa1-/- mice, 
or mock-infected and challenged wild-type C57BL/6J and Bpifa1-/- mice as determined by two-
way analysis of variance (ANOVA) with Bonferroni post-test. The green and blue lines represent 




Plaque assay was performed to determine infectious virus titres in lung tissue. 
There was no significant difference in the virus titre between wild-type C57BL/6J and 
Bpifa1-/- mice either mock infected or infected with IAV (Figure 5-4). However, Bpifa1-/- 
mice infected with IAV X-31 had lower viral titres in comparison to wild-type C57BL/6J 
mice. This finding potentially suggests an effective anti-IAV CTL response in Bpifa1-/- 
mice which is reduced in the wilt-type C57BL/6J mice. Further studies are required to 
investigate this. Both wild-type C57BL/6J and Bpifa1-/- mice which were challenged with 
a homologous were protected from infection and as such exhibited no virus titre in the 
lungs and no weight loss. Conversely, mice which were challenged with a heterologous 
strain were not protected and showed a higher virus titre and slightly increased weight 
loss, however, this was reduced compared to control animals which received no pre-
challenge infection.       
 
Figure 5-4. Infectious virus titre in lung tissue samples of mice during the IAV vaccination/ 
challenge experiment. 
All mice (n=36) were euthanised on day 33 pi, and lung tissue samples were collected for 
determination of virus titres using the plaque assay and MDCK cells. The results are presented 
as SEM for each group. No significant difference was seen in virus titres between infected and 
challenged wild-type C57BL/6J and Bpifa1-/- mice, or mock-infected and challenged wild-type 






Serum samples collected at 24 dpi and the BAL samples collected upon euthanasia 
at 33 dpi (day 5 post-challenge) were tested by IAV PR8 virus specific indirect ELISA to 
measure the IAV-specific IgG and IgA levels (Figures 5-5 and 5-6). All 
infected/vaccinated mice generated IgG and IgA responses to IAV. There was, however, 
no significant difference in IgG and IgA levels between wild-type C57BL/6J and Bpifa1-/- 
mice. Thus, in spite of previous data suggesting a difference in anti-IAV responses 
between wild-type C57BL/6J and Bpifa1-/- mice, the data presented here show that 
there were no differences in either serum IgG or BAL IgA anti-IAV. Furthermore, both 
wild-type C57BL/6J and Bpifa1-/- mice were protected from challenge. The fact that X-
31-infected mice were protected from PR8 suggests that Bpifa1-/- mice can mount an 
efficient anti-IAV CTL response as well as anti-IAV antibodies. This finding of no 
difference in the post-challenge IgA levels in BAL samples between wild-type C57BL/6J 
and Bpifa1-/- mice needs further investigation to outline the possible underlying 
mechanisms. Future experiments could be done using strain specific antigens such as 
HA or NA instead of the whole virus to determine whether the antibody response is 








Figure 5-5. Pre-challenge IgG levels in serum of mice during the IAV vaccination/ challenge 
experiment. 
Mice were infected intranasally with either IAV strain X-31 or PR8; serum samples were 
collected at 24 dpi and analysed by IAV PR8 virus specific ELISA. A. Mice infected with IAV X-31. 
B. Mice infected with IAV PR8. The results are presented as SEM for each group. No significant 
difference was seen in IgG levels between wild-type C57BL/6J and Bpifa1-/- mice as determined 
by two-way analysis of variance (ANOVA) with Bonferroni post-test. Negative samples 





Figure 5-6. Post-challenge IgA levels in BAL of mice during the IAV vaccination/ challenge 
experiment. 
All mice (n=36) were challenged on 28 dpi with 103 PFU of IAV PR8; BAL samples in a total 
number= 32 mice as shown in the figure were collected at 33 dpi and analysed by IAV PR8 virus 
specific ELISA. IgA levels in A. Control mice. B. Mice infected with IAV X-31 and C. Mice infected 
with IAV PR8. The results are presented as SEM for each group. All observed differences 
between wild-type C57BL/6J and Bpifa1-/- mice were not statistically significant, as determined 
by two-way analysis of variance (ANOVA) with Bonferroni post-test. Negative samples 





From the findings described in the previous section it is obvious that infection with 
IAV X-31 protected mice against lethal dose of IAV PR8, which raises the possibility of 
the role of anti-IAV CLT response along with anti-IAV humoral immune response. 
Though in this study potential anti-IAV CTL responses were sufficient to protect against 
lethal challenge with a heterologous IAV strain, in nature this alone may not be 
sufficient to protect against influenza re-infection. Indeed, seasonal annual vaccination 
is still recommended for many reasons. Firstly, in human and due to circulating 
influenza viruses are exceptional in their ability to undergo antigenic changes, thus 
vaccination is the most efficient way to hamper IAV infection (Cox and Subbarao,1999). 
In addition, available vaccines are formulated to elicit humoral rather than cellular 
immune response. In general, there are two types of vaccines; inactivated (TIV or QIV) 
or live-attenuated vaccines (LAIV). TIV induces higher levels of serum IgG and IgA than 
LAIV (Treanor et al., 1999), while LAIV induces high level of IgA in nasal washes than TIV 
which induces IgG response in the URT mucosa (Beyer et al., 2002). Stimulation of 
robust cellular immune response in the lung is dependent on active viral replication in 
the lung. Because TIV is inactivated, so it does not stimulate any cellular immune 
response, and LAIV only replicates in the URT. Therefore, both vaccines do not stimulate 
efficient cellular immune response (Spitaels et al., 2016).   
Secondly, despite the fact that cellular immunity plays a key role in clearance of 
influenza virus infection and may help in hampering influenza-associated complications, 
it does not significantly prevent infection. After primary infection clearance from the 
lungs, 90-95% of antigen-specific T cells undergo apoptosis. Only small portion of the 
remaining cells are designed to be long-living memory T cells (Welsh and McNally, 
1999).  Primary cytotoxic response can be detected in blood after 6-14 days and fades 




enormous variations in CTL reactivity pattern between individuals (McMichael et al., 
1986). During secondary response, CTL memory cells exhibit the same pattern of cross-
reactivity to primary response CTLs, which peak at day 14 and return to normal after six 
months (Ennis et al., 1981).   
In conclusion, the results above suggested that anti-IAV antibody production was 
not affected by Bpifa1. It was surmised that one factor affecting antibody production 
could be the virus dose. The experiments above used relatively high doses of IAV, which 
are probably unrepresentative of clinical infection and might mask any effect of Bpifa1. 
To test and determine different responses, the experimental design of vaccination/ 
challenge experiment could be altered, for example infection with IAV PR8 and 
challenge with IAV X-31 may give same or different results. To determine the 
contribution of CTL responses, the challenge could be delayed until these responses 
have diminished.  
 
 Effect of Bpifa1 on the production of anti-IAV antibodies  
In order to investigate the effect of Bpifa1 on anti-IAV antibody production further, 
wild-type C57BL/6J and Bpifa1-/- mice were infected using different IAV doses. Doses 
from 10 to 103 PFU IAV X-31 were used and mice euthanised at 7, 14 and 35 dpi. IgM 
was measured at 7 dpi as this immunoglobulin appears early in the course of an 
infection and its level peaks in serum ~ 7-10 days (Greenfield, 2014). While, for IgA and 
IgG were measured at day 14 because these immunoglobulins can be detected within 
10-14 days after primary infection with influenza virus (Cox et al., 2004). 
Blood, BAL and nasal wash samples were collected for analysis of anti-IAV 
antibodies. In addition, heads, salivary gland, mandibular ln, thoracic organs [lung, 




with surrounding mesenteric adipose tissue were sampled and processed for 
histological and immunohistological examinations. 
 
5.4.1 Effect of Bpifa1 on antibody response at day 7 post-infection  
 
Three doses of IAV X-31 were used at day 7; 10, 102 and 103 PFU. In the first 
experiment, wild-type C57BL/6J and Bpifa1-/- mice were infected intranasally with 10 
PFU IAV X-31. Serum, BAL and nasal wash samples were tested for anti-IAV IgM levels. 
Anti-IAV IgM was produced in both strains of mice but there were no significant 





Figure 5-7. IgM levels in serum, BAL and nasal wash samples of mice infected with 10 PFU 
IAV X-31 at 7 dpi. 
Mice were infected intranasally with 10 PFU of IAV X-31; serum, BAL and nasal wash samples 
were collected at 7 dpi and analysed by virus specific ELISA. IgM levels in A. Serum, B. BAL. C. 
Nasal Wash. The results are presented as SEM for each group. All observed differences between 
wild-type C57BL/6J and Bpifa1-/- mice were not statistically significant, as determined by two-





In another antibody experiment, wild-type C57BL/6J and Bpifa1-/- mice were 
infected intranasally with 102 PFU IAV X-31. Serum samples were tested for anti-IAV 
IgM levels. Anti-IAV IgM was produced in both strains of mice but there was no 




Figure 5-8. IgM level in serum samples of mice infected with 102 PFU IAV X-31 at 7 dpi. 
Mice were infected intranasally using 102 PFU of IAV X-31; serum samples were collected at 7 
dpi and analysed by virus specific ELISA. The results are presented as SEM for each group. All 
observed differences between wild-type C57BL/6J and Bpifa1-/- mice were not statistically 
significant, as determined by two-way analysis of variance (ANOVA) with Bonferroni post-test. 
 
Additionally, wild-type C57BL/6J and Bpifa1-/- mice were infected with 103 PFU IAV 
X-31. Serum and BAL were tested for anti-IAV IgM levels. Anti-IAV IgM was produced in 
both strains of mice but there was no significant difference in IgM levels between the 









Figure 5-9. IgM level in serum and BAL samples of mice infected with 103 PFU IAV X-31 at 7 
dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; serum and BAL samples were 
collected at 7 dpi and analysed by virus specific ELISA. A. IgM level in serum. B. IgM level in BAL. 
The results are presented as SEM for each group. All observed differences between wild-type 
C57BL/6J and Bpifa1-/- mice were not statistically significant, as determined by two-way analysis 
of variance (ANOVA) with Bonferroni post-test. 
 
5.4.2 Effect of Bpifa1 on antibody response at day 14 post-infection  
 
At day 14, three doses of IAV X-31 were used; 10, 102 and 103 PFU. Firstly, wild-
type C57BL/6J and Bpifa1-/- mice were infected intranasally with 10 PFU IAV X-31. Serum 
and BAL were tested for anti-IAV IgG and IgA. All mice produced anti-IAV IgG and IgA. 
IgG levels in serum and BAL were not significantly different between wild-type C57BL/6J 
and Bpifa1-/- mice. However, wild-type C57BL/6J mice had significantly higher anti-IAV 
IgA levels in BAL samples than Bpifa1-/- (Figure 5-10). Interestingly, the lower IgA levels 
exhibited by Bpifa1-/- mice in comparison to wild-type C57BL/6J could be due to the 







     
 
Figure 5-10. IgG and IgA levels in serum and BAL samples of mice infected with 10 PFU IAV 
X-31 at 14 dpi. 
Mice were infected intranasally using 10 PFU of IAV X-31; serum and BAL samples were 
collected at 14 dpi and analysed by virus specific ELISA. A. IgG level in serum. B. IgA level in BAL. 
C. IgG level in BAL. The results are presented as SEM for each group. All observed differences 
between wild-type C57BL/6J and Bpifa1-/- mice were not statistically significant, as determined 
by two-way analysis of variance (ANOVA) with Bonferroni post-test. Only wild-type C57BL/6J 
mice showed significantly higher IgA levels in BAL samples than Bpifa1-/- (*P < 0.05, **P < 0.01). 
 
 
In addition, IgG sub-classes (IgG1, IgG3, IgG2a and IgG2b) were determined in BAL 
samples as described in section 2.5.1.2. There were no significant differences in IgG sub-






Figure 5-11. IgG sub-class levels in BAL samples of mice infected with 10 PFU IAV X-31 at 14 
dpi. 
Mice were infected intranasally using 10 PFU of IAV X-31; BAL samples were collected at 14 dpi 
and analysed by virus specific ELISA. A. IgG1, B. IgG3, C. IgG2a. D. IgG2b. The results are 
presented as SEM for each group. All observed differences between wild-type C57BL/6J and 
Bpifa1-/- mice were not statistically significant, as determined by two-way analysis of variance 
(ANOVA) with Bonferroni post-test.  
 
In the second experiment, wild-type C57BL/6J and Bpifa1-/- mice were infected 
intranasally with 102 PFU IAV X-31. Serum and BAL samples were collected and tested 
for anti-IAV IgG and IgA. All mice produced anti-IAV IgG and IgA. There were no 
significant differences in anti-IAV IgG levels in the serum between wild-type C57BL/6J 
and Bpifa1-/- mice. However, anti-IAV IgG levels were significantly higher in BAL samples 
of wild-type C57BL/6J mice compared to Bpifa1-/- mice at all tested dilutions, whereas 
there were no significant differences in IgA levels (Figure 5-12). It has been shown that 






 The explanation for the lower IgG level In Bpifa1-/- mice in comparison to wild-type 
C57BL/6J mice could be due to that this immunoglobulin is less produced locally in these 
mice at this time-point alongside using this particular virus dose which led to a low level 




Figure 5-12. IgG and IgA levels in serum and BAL samples of mice infected with 102 PFU IAV 
X-31 at 14 dpi. 
Mice were infected intranasally using 102 PFU of IAV X-31; serum and BAL samples were 
collected at 14 dpi and analysed by virus specific ELISA. A. IgG level in serum. B. IgA level in BAL. 
C. IgG level in BAL. The results are presented as SEM for each group. Statistically, non-significant 
differences were observed in IgG levels in serum and IgA levels in BAL between wild-type 
C57BL/6J and Bpifa1-/- mice. The IgG level in BAL samples was significantly higher in wild-type 
C57BL/6J mice than in Bpifa1-/- mice at all tested dilutions, as determined by two-way analysis 






Furthermore, wild-type C57BL/6J and Bpifa1-/- mice were infected intranasally with 
103 PFU IAV X-31. Serum and BAL samples were tested for anti-IAV IgG and IgA and for 
IgG sub-classes. All mice produced anti-IAV IgG and IgA. There were no significant 
differences in IgG and IgA levels between the two groups of mice (Figure 5.13). 
However, due to variation between individuals, significant differences may be noted 
with increased sample sizes.   
 
Figure 5-13.  IgG and IgA levels in serum and BAL samples of mice infected with 103 PFU IAV 
X-31 at 14 dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; serum and BAL samples were 
collected at 14 dpi and analysed by virus specific ELISA. A. IgG level in serum. B. IgA level in BAL. 
C. IgG level in BAL. The results are presented as SEM for each group. All observed differences 
between wild-type C57BL/6J and Bpifa1-/- mice were not statistically significant, as determined 






Also, there were no significant differences in IgG sub-classes apart from the IgG3 
level in serum samples particularly at dilutions of 1:1280 and 1:2560 that was 
significantly higher in Bpifa1-/- mice (Figures 5-14 and 5-15). 
 
 
Figure 5-14. IgG sub-class levels in BAL samples of mice infected with 103 PFU IAV X-31 at 14 
dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; BAL samples were collected at 14 dpi 
and analysed by virus specific ELISA. A. IgG1, B. IgG3, C. IgG2a and D. IgG2b. The results are 
presented as SEM for each group. All observed differences between wild-type C57BL/6J and 
Bpifa1-/- mice were not statistically significant, as determined by two-way analysis of variance 






Figure 5-15. IgG sub-class levels in serum samples of mice infected with 103 PFU IAV X-31 at 
14 dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; serum samples were collected at 14 
dpi and analysed by virus specific ELISA. A. IgG1, B. IgG3, C. IgG2a and D. IgG2b. The results are 
presented as SEM for each group. A significant higher difference was only seen in IgG3 level in 
serum samples particularly at dilutions of 1:1280 and 1:2560 in Bpifa1-/- mice as determined by 
two-way analysis of variance (ANOVA) with Bonferroni post-test (**P <0.01, ***P < 0.001).  
 
 
5.4.3 Effect of Bpifa1 on antibody response at day 35 post-infection 
 
In a final antibody experiment to test longer-term responses, wild-type C57BL/6J 
and Bpifa1-/- mice were infected intranasally with 103 PFU IAV X-31 for 35 days. Blood, 
BAL and nasal wash samples were collected at 35 dpi and examined for anti-IAV IgG and 
IgA by ELISA. All mice produced anti-IAV IgG and IgA. There were no significant 
differences in anti-IAV IgG levels in the serum or in anti-IAV IgA and IgG levels in nasal 




However, it was observed that there were higher anti- 
IAV IgA levels in Bpifa1-/- mice in the BAL samples at dilutions of 1:5, 1:10 and 1:20, and 
anti-IAV IgG level in BAL in only one dilution particularly at dilution of 1:5 (Figure 5-16). 
The results of this experiment at this time point show that Bpifa1-/- mice have 
significantly higher IgA and IgG levels in BAL samples in comparison with wild-type 
C57BL/6J mice in the previously mentioned results using 10 and 102 PFU of IAV X-31 at 
14 dpi (Figures 5-10 and 5-12). The possible reason for this difference might be 
involvement of other mechanisms such as antigen processing and trafficking which 






Figure 5-16. IgG and IgA levels in serum, BAL and nasal wash samples of mice infected with 
103 PFU IAV X-31 at 35 dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; serum, BAL and nasal wash samples 
were collected at 35 dpi and analysed by virus specific ELISA. A. IgG level in serum. B. IgA level 
in BAL. C. IgG level in BAL. D. IgA level in nasal wash. E. IgG level in nasal wash. The results are 
presented as SEM for each group. Statistically, non-significant differences were observed in IgG 
levels in serum, IgA and IgG levels in nasal washes between wild-type C57BL/6J and Bpifa1-/- 
mice. However, there were significantly higher IgA and IgG levels in BAL samples of Bpifa1-/- 
mice than in wild-type C57BL/6J mice as determined by two-way analysis of variance (ANOVA) 




In addition, a virus microneutralisation assay was performed on the serum to 
detect specific, virus neutralising antibodies. The microneutralisation assay is a specific 
and highly sensitive assay used for detecting specific neutralising antibodies against 
influenza viruses in human and animal sera samples. A virus neutralisation assay 
provides the most accurate answer to the question of whether or not a serum sample 
has antibodies that have the ability to neutralise the infectivity of a given virus strain 
(WHO, 2013). The microneutralisation assay has further benefits. First, it primarily 
detects antibodies to the influenza viral HA protein and therefore can identify 
functional specific antibodies to the given strain. Second, when infectious virus is used, 
the assay can be performed rapidly once a new virus has emerged. Ordinary 
neutralisation tests for influenza viruses (based on the inhibition of a cytopathogenic 
effect in MDCK cell culture) are difficult and slow, while a microneutralisation assay 
using microtiter plates together with an ELISA to detect virus-infected cells can give 
results within two days (WHO, 2013). The assay is divided into three parts and is shown 
in Figure 2-8. The results of microneutralisation assay showed no significant differences 











Figure 5-17. Anti-IAV neutralising antibodies titre in serum of mice infected with 103 PFU IAV 
X-31 at 35 dpi. 
Mice were infected intranasally using 103 PFU of IAV X-31; serum samples were collected at 35 
dpi and virus microneutralisation assay was performed. The results are presented as minimum 
to maximum for each group in Whiskers box blot. All observed differences between wild-type 
C57BL/6J and Bpifa1-/- mice were not statistically significant, as determined by T-test and Mann-
Whitney U test. 
 
In conclusion, Bpifa1 did not have an influence on anti-IAV antibody responses at 
high dose infection or on serum responses at any dose.  However, at lower doses there 
were differences in the BAL. Thus, anti-IAV IgG at 102 PFU and in particular, anti-IAV IgA 
levels at 10 PFU were higher in wild-type C57BL/6 mice suggesting a role for Bpifa1 in 





 Effect of Bpifa1 on tissue samples using 10 PFU IAV X-31 at day 7 post-infection 
5.5.1 Histological findings  
 
A detailed description of the histological and immunohistological findings of this 
experiment is provided in Table 2 in the Appendix.  
 Nasal cavity  
The histological findings were similar in both groups of mice. Wild-type C57BL/6J 
mice exhibited mild to moderate mononuclear mucosal infiltration in the entire nasal 
cavity; in Bpifa1-/- mice this was of the same intensity, but restricted to the frontal nasal 
cavity. A few individual sloughed epithelial cells were observed in the frontal and mid 
nasal mucosa, associated with some debris in the lumen. Wild-type C57BL/6J mice also 
exhibited focal areas with flattened epithelium. Both groups of mice showed NALT 
formation, wild-type C57BL/6J mice of moderate and Bpifa1-/- mice of mild to moderate 
intensity (Figure 5-18).  
 
Figure 5-18. Histopathological findings in the nasal cavity of mice infected with 10 PFU IAV 
X-31 at 7 dpi. 
Moderate NALT formation in A. Wild-type C57BL/6J mouse (B18-1203) and B. Bpifa1-/- mouse 
(B18-1206), respectively (arrows). Scale bars= 100 µm, HE stain. 
 
The IH examination showed IAV antigen expression in some intact and sloughed 
epithelial cells especially in the frontal part of the nasal cavity in wild-type C57BL/6J 
mice (Figure 5-19A, C and E). In comparison, the number of positive epithelial cells was 




association with the inflammatory infiltrates in the frontal part of the nasal cavity 
(Figure 5-19B, D, and F); they also exhibited several positive neuroepithelial cells in the 
vomeronasal organ (VNO) (Figure 5-19G and H). Interestingly, the findings of IAV 
expression in the sloughed epithelial cells in wild-type C57BL/6J and Bpifa1-/- mice 
(Figure 5-19E, F) showed that Bpifa1-/- mice were more affected by the intranasal IAV 
infection than wild-type C57BL/6J. In comparison of this result to the results of the 
transmission experiment 3 in the previous chapter, which showed presence of viral 
antigen expression in the nasal cavity of Bpifa1-/- contact mice and absence of this 
expression in wild-type C57BL/6J contact mice (Figure 4-6G, H). These findings together 
confirm that there is a difference in susceptibility between both mice strains to IAV 






Figure 5-19. IAV antigen expression in the nasal cavity and VNO of mice infected with 10 
PFU IAV X-31 at 7 dpi. 
A. Wild-type C57BL/6J mouse (B18-1202), cross section of mid nasal cavity, with several focal 
areas of positive epithelial cells (arrow), scale bar= 250 µm. B. Bpifa1-/- mouse (B18-1204), cross 
section of the frontal part of the nasal cavity, with abundant positive epithelial cells (arrows), 
scale bar= 250 µm. C. Higher magnification of A. showing the positive epithelial cells (arrow), 
scale bar= 100 µm. D. Higher magnification of B. showing the positive epithelial cells (arrow), 
scale bar= 100 µm. E., F. IAV antigen expression in sloughed epithelial cells (arrows), E. Wild-
type C57BL/6J mouse (B18-1200), scale bar= 100 µm; F. Bpifa1-/- mouse (B18-1206), scale bar= 
100 µm. G., H. IAV antigen expression in neuroepithelial cells in the VNO (arrows). G. Wild-type 
C57BL/6J mouse (B18-1203), scale bar= 100 µm; H. Bpifa1-/- mouse (B18-1204), scale bar= 100 




 Lower respiratory tract and lungs 
Wild-type C57BL/6J mice (total examined numbers=4) exhibited a focal to 
multifocal (extensive) necrotising bronchiolitis. The associated lung parenchyma 
showed consolidated areas with partial or complete atelectasis (“collapsed tissue”) with 
occasional necrotic pneumocytes, type II pneumocyte activation and desquamation, 
and some neutrophil infiltration (Figure 5-20A). In some mice (B18-1202 and B18-1203) 
one entire lobe appeared to be affected. In addition, multifocal lymphocyte dominated 
peribronchiolar infiltration as well as a multifocal lymphocyte dominated 
vasculitis/perivascular mononuclear infiltration was seen; the latter was associated 
with evidence of leukocyte recruitment, i.e. leukocyte rolling and endothelial 
attachment (Figure 5-20C, E).  
Bpifa1-/- mice (total examined numbers=5) exhibited similar changes which 
included moderate multifocal to focal extensive (one lobe almost entirely affected) 
necrotising bronchiolitis (Figure 5-20B) with peribronchiolar lymphocyte dominated 
vasculitis/perivascular mononuclear infiltration (Figure 5-20D, F) and necrosis of 
alveolar epithelial cells. In addition, there was evidence of lymphocyte recruitment. 
Focal collapsed, consolidated parenchyma with occasional necrotic pneumocytes, type 
II pneumocyte activation and desquamation and some neutrophils infiltration was 
observed. Only one mouse (B18-1206) showed less intense changes, i.e. mild focal 
lymphocyte dominated perivascular mononuclear infiltration and leukocyte rolling; 






Figure 5-20. Histopathological findings in the lung of mice infected with 10 PFU IAV X-31 at 7 
dpi. 
A. Wild-type C57BL/6J mouse (B18-1202) showing a focal necrotising bronchiolitis with 
peribronchiolar lymphocyte dominated infiltration (arrow). The adjacent parenchyma exhibits 
leukocytes (including neutrophils) and desquamed type II pneumocytes in alveolar lumina 
(arrowhead), scale bar= 50 µm. B. Bpifa1-/- mouse (B18-1208) showing a focal necrotising 
bronchiolitis with peribronchiolar lymphocyte dominated infiltration (arrow). The adjacent 
parenchyma exhibits leukocytes (including neutrophils) and desquamed type II pneumocytes in 
alveolar lumina (arrowhead), scale bar= 50 µm. C. Wild-type C57BL/6J mouse (B18-1202) with 
extensive lymphocyte dominated perivascular mononuclear infiltration (arrows). The adjacent 
parenchyma is consolidated (circled), scale bar= 250 µm.  D. Bpifa1-/- mouse (B18-1204) with 
extensive lymphocyte dominated mononuclear infiltration of an arterial wall and the 
surrounding tissue (vasculitis/ perivascular infiltrate) (arrow), with consolidation of the adjacent 
parenchyma (circled), scale bar= 250 µm. E. Wild-type C57BL/6J mouse (B18-1202); closer view 
at affected artery, with individual leukocytes in the vascular wall (arrows) and leukocyte rolling 
along endothelial cells (arrowheads) indicating leukocytes recruitment into the parenchyma, 
scale bar= 50 µm.  F. Bpifa1-/- mouse (B18-1204); closer view at affected artery, with numerous 
leukocytes infiltrating the vessel wall (vasculitis; arrow) and rolling along the endothelial cells 





In both wild-type C57BL/6J and Bpifa1-/- mice, IAV antigen expression was only 
seen in individual degenerating respiratory epithelial cells within areas of bronchiolitis 
(Figure 5-21A, B), and in scattered intact alveolar cells (mainly type II pneumocytes) and 
degenerate cells in consolidated areas (Figure 5-21C, D). However, in this experiment 
IAV X-31 virus was not quantified by plaque assay at low virus dose (10 PFU) or image 
analysis which would be helpful and another technique of IAV quantification.    
 
 
Figure 5-21. IAV antigen expression in the lung of mice infected with 10 PFU IAV X-31 at 7 
dpi. 
A., B. IAV antigen expression in degenerating respiratory epithelial cells (arrows) and in the 
cellular debris in the lumen (arrowheads) of bronchioli. A. Wild-type C57BL/6J mouse (B18-
1202), scale bar= 100 µm; B. Bpifa1-/- mouse (B18-1204), scale bar= 100 µm. C., D. IAV antigen 
expression in alveolar epithelial cells (arrows) and degenerating cells in the alveolar lumina 
(arrowheads) in peribronchiolar areas. C. Wild-type C57BL/6J mouse (B18-1202), scale bar= 50 












 Lymphatic and other tissues 
 
From all animals, spleen and lymph nodes (mandibular, bronchial; mesenteric 
lymph nodes in wild-type C57BL/6J mice), and thymus were examined. In addition, the 
mediastinal and mesenteric adipose tissues was assessed for the presence of 
lymphocyte aggregates. In both groups of mice, the spleen exhibited relatively small to 
moderately sized secondary follicles and T cell zones, with occasional apoptotic cells in 
the centre of follicles. The red pulp exhibited moderate cellularity and mild (Bpifa1-/- 
mice) or moderate (wild-type C57BL/6J mice) extramedullary haematopoiesis (EMH). 
The mandibular lymph nodes showed indistinct, small or moderately sized follicles 
and T cell zones, were overall cell rich and exhibited mild to moderate sinus 
histiocytosis. In bronchial lymph nodes, follicles and T cell zones exhibited similar 
features, though follicles often contained apoptotic cells. They were otherwise cell rich. 
Mesenteric lymph nodes of wild-type C57BL/6J mice exhibited similar features. The 
thymus did generally not exhibit any histological changes. In one mouse of each group, 
it exhibited a few scattered apoptotic cells in the cortex.  
The mediastinal adipose tissue of wild-type C57BL/6J exhibited numerous variably 
sized, poorly delineated aggregates of lymphocytes, with some plasma cells and 
macrophages. Similar aggregates were also observed in the mediastinal adipose tissue 
of Bpifa1-/- mice, but the numbers varied more substantially, ranging from a few, several 
to many. The mesenteric adipose tissue of wild-type C57BL/6J mice contained 
numerous variably sized, poorly delineated aggregates of lymphocytes with some 
plasma cells, a few Mott cells and macrophages. Bpifa1-/- mice exhibited only a few 
poorly delineated similar aggregates. Viral antigen expression was not detected in any 




 Effect of Bpifa1 on tissue samples using 103 PFU IAV X-31 at day 7 post-infection  
5.6.1 Histological findings 
 
Histology and immunohistology served to assess whether infection with a higher 
viral dose would elicit different changes. In addition, antibodies directed against specific 
leukocytes (T cells, B cells, macrophages; see section 2.7.3) served to assess the 
inflammatory response in more detail. Table 3 in the Appendix provides all the 
histological and immunohistological findings of this experiment.  
 
 Nasal cavity 
 
In wild-type C57BL/6J mice (n=2), histological changes characterised by infiltration 
of leukocytes, and these changes were restricted to the presence of occasional 
individual degenerate respiratory epithelial cells. There was evidence of NALT 
formation, though this was only apparent as small aggregates of lymphocytes. In 
contrast, Bpifa1-/- mice showed focal areas of respiratory epithelial cells degeneration 
and loss and evidence of distinct NALT formation (Figure 5-22). 
 
Figure 5-22. Histopathological findings in the head of mice infected with 103 PFU IAV X-31 at 
7 dpi. 
Moderate and distinct NALT formation in A. C57BL/6J mouse (B17-1272) and B. Bpifa1-/- mouse 
(B17-1276), respectively (arrows). Scale bars= 100 µm, HE stain. 
 
In wild-type C57BL/6J mice, viral antigen expression was seen in many intact and 
degenerating individual respiratory epithelial cells in nasal cavity (Figure 5-23A), and 




neuroepithelial cells of the VNO (in one mouse) (Figure 5-19E). In Bpifa1-/- mice, IAV 
antigen expression in the respiratory epithelium appeared more intense and was seen 
in several individual and small groups of intact and degenerating respiratory epithelial 
cells in the nasal cavity. It was most intense at the dorsal roof (Figure 5-23B). In addition, 
a few individual neurons in the trigeminal ganglia (in three mice) (Figure 5-23D) and a 
few individual neuroepithelial cells in the VNO (in one mouse) were found to be positive 
(Figure 5-23F). 
 
Figure 5-23. IAV antigen expression in the nasal cavity and head of mice infected with 103 
IAV X-31 at 7 dpi. 
A. Wild-type C57BL/6J mouse (B17-1271), cross section of mid nasal cavity, with several focal 
areas of positive epithelial cells (arrows), scale bar= 50 µm. B. Bpifa1-/- mouse (B17-1276), cross 
section of the frontal part of the nasal cavity, with abundant positive epithelial cells (arrows), 
scale bar= 50 µm. Numerous positive neurons in the trigeminal ganglion in C. Wild-type 
C57BL/6J mouse (B17-1272) and D. Bpifa1-/- mouse (B17-1274) (arrows), scale bars= 100 µm.  E. 
Numerous positive neuroepithelial cells of the VNO in a wild-type C57BL/6J mouse (B17-1271) 
(arrows), scale bar= 50 µm. F. Individual positive neuroepithelial cells of the VNO in a Bpifa1-/- 




Immunohistology served to identify and highlight infiltrating leukocytes. Wild-type 
C57BL/6J mice exhibited a few individual T cells (CD3+) between and beneath epithelial 
cells in the nasal mucosa (Figure 5-24A) and the VNO. Bpifa1-/- mice showed T cells in a 
similar distribution, but in slightly higher numbers (Figure 5-24B). A few T cells were 
also found in the NALT.  
Individual B cells were found scattered between and beneath epithelial cells of the 
nasal mucosa (Figure 5-24C, D) and the VNO in both groups of mice. They were more 
numerous close to and dominant in the NALT. In Bpifa1-/- mice, they also formed small 
focal (sub) epithelial aggregates.  
 
 
Figure 5-24. Immunohistological staining for T (CD3) and B (CD45R) cells in the head of mice 
infected with 103 PFU IAV X-31 at 7 dpi. 
A. Few individual T cells in the epithelial cells of the nasal cavity in wild-type C57BL/6J mice 
(B17-1272) (arrows). B. High number of T cells between and beneath respiratory epithelial cells 
of the nasal cavity in Bpifa1-/- mouse (B17-1273) (arrows). Scattered B cells between the 
epithelial cells of the nasal cavity in C. Wild-type C57BL/6J mouse (B17-1271) and D. Bpifa1-/- 
mouse (B17-1276) (arrows), scale bars= 100 µm.  
 
Iba-1 positive cells (monocytes/macrophages) were relatively numerous as 




nasal mucosa (Figure 5-25A, B) and the VNO (Figure 5-25C, D) in both wild-type 
C57BL/6J and Bpifa1-/- mice. A large proportion of cells in the NALT of Bpifa1-/- mice was 
also found to be Iba-1 positive (Figure 5-25E). 
 
Figure 5-25. Immunohistological staining for macrophages (Iba-1 positive) in the head of 
mice infected with 103 PFU IAV X-31 at 7 dpi. 
A., B. Numerous macrophages in the nasal epithelium of a wild-type C57BL/6J mouse (B17-
1272) and a Bpifa1-/- mouse (B17-1275) (arrows), respectively, scale bars= 100 µm. C., D. 
Numerous macrophages in the epithelial cell of the VNO in wild-type C57BL/6J mouse (B17-
1271) and Bpifa1-/- mouse (B17-1276) (arrows), respectively, scale bars= 100 µm. E. Numerous 
macrophages in the NALT of Bpifa1-/- mouse (B17-1276) (arrows), scale bar= 50 µm. 
 
 Lower respiratory tract and lungs  
 
Wild-type C57BL/6J mice (total examined mice n=2) exhibited moderate 




dominated perivascular/peribronchiolar mononuclear infiltration (Figure 5-26A) and 
evidence of lymphocytes recruitment, mildly increased interstitial cellularity (with 
macrophages, neutrophils and lymphocytes) with focal collapsed, consolidated areas 
and scattered necrotic pneumocytes (Figure 5-26C). The changes in Bpifa1-/- mice (total 
examined mice n=4) were similar, however, the severity of these changes was higher 
than in wild-type C57BL/6J mice and included moderate multifocal lymphocyte-
dominated perivascular/peribronchiolar mononuclear infiltration (Figure 5-26B) with 
some evidence of leukocyte recruitment. In addition, extensive multifocal (affected 
almost an entire lobe) consolidated areas with macrophages, lymphocytes and some 
neutrophils and alveoli containing leukocytes, several necrotic pneumocytes and 
activation of overlying mesothelium and multifocal necrosis of respiratory epithelium 
was seen (Figure 5-26D). 
 
Figure 5-26. Histopathological findings in the lung of mice infected with 103 PFU IAV X-31 at 
7 dpi. 
A. Mild perivascular lymphocyte-dominated mononuclear infiltration in the consolidated 
parenchyma in wild-type C57BL/6J mouse (B17-1271) (arrow), scale bar= 250 µm. B. Moderate 
perivascular lymphocyte-dominated mononuclear infiltration (arrow) and extensive 
consolidated areas in Bpifa1-/- mouse (B17-1273) (circled), scale bar= 250 µm. C. and D. Higher 
magnification of A. and B., respectively show necrotic respiratory epithelial cells (arrows), scale 




Viral antigen expression was seen in scattered individual or focal aggregates of 
respiratory epithelial cells in affected bronchioli (Figure 5-27A, B) and in both intact and 
degenerating alveolar cells (mainly type II pneumocytes, occasional type I cells) and 
some macrophages in the consolidated parenchyma (Figure 5-27C, D). Additionally, 
both groups of mice showed individual positive type II cells in the alveoli (Figure 5-27E 
and F).  
 
Figure 5-27. IAV antigen expression in the lung of mice infected with 103 PFU IAV X-31 at 7 
dpi. 
IAV antigen expression in scattered respiratory epithelial cells of bronchioles in A. Wild-type 
C57BL/6J mouse (B17-1271) and B. Bpifa1-/- mouse (B17-1273), respectively (arrows). IAV 
antigen expression in the intact and degenerating alveolar cells in the consolidated parenchyma 
in C. Wild-type C57BL/6J mouse (B17-1271) and D. Bpifa1-/- mouse (B17-1275), respectively 
(arrows). Individual positive type II cells in the alveoli in E. Wild-type C57BL/6J mouse (B17-




T cells were found in abundance in the interstitium of consolidated areas and in 
the focal perivascular/peribronchiolar infiltrates (Figure 5-28A, C). They were also found 
to be recruited into the tissue (Figure 5-28B). B cells were restricted to the focal 
perivascular/peribronchiolar infiltrates, in which they dominated in both wild-type 
C57BL/6J and Bpifa1-/- mice (Figure 5-28D, E). 
 
 
Figure 5-28.  Immunohistological staining for T (CD3) and B (CD45R) cells in the lung of mice 
infected with 103 PFU IAV X-31 at 7 dpi. 
A. Perivascular infiltrates with T cells in wild-type C57BL/6J mouse (B17-1272) (arrows), scale 
bar= 250 µm. B. Peribronchiolar infiltrates with T cells in Bpifa1-/- mouse (B17-1275) (arrows), 
scale bar= 250 µm C. Higher magnification of A. shows rolling of T cells along the vascular 
epithelial cells (arrows), scale bar= 50 µm. Perivascular infiltration of B cells in D. Wild-type 
C57BL/6J mouse (B17-1271) and E. Bpifa1-/- mouse (B17-1273), respectively (arrows), scale 




Macrophages (Iba-1 positive) were found in abundance in particular in the 
consolidated areas (Figure 5-29A, B, C, D). They were also present in the focal 
perivascular/peribronchiolar infiltrates. Alveolar macrophages were positive for Iba-1 
in both groups (Figure 5-29E, F). 
 
Figure 5-29. Immunohistological staining for macrophages (Iba-1 positive) in the lung of 
mice infected with 103 PFU IAV X-31 at 7 dpi. 
A. Abundant macrophages in the consolidated areas in wild-type C57BL/6J mouse (B17-1271) 
(arrows), scale bar= 100 µm. B. Abundant macrophages in Bpifa1-/- mouse (B17-1273) (arrows), 
scale bar= 100 µm. C. Higher magnification of A, scale bar= 50 µm. D. Higher magnification of 
B, scale bar= 50 µm. Positive alveolar macrophages in E. Wild-type C57BL/6J mouse (B17-1271) 
and F. Bpifa1-/- mouse (B17-1273), respectively (arrows), scale bars= 50 µm.   
The trachea did generally not show any pathological changes. However, in one 
Bpifa1-/- mouse a few individual degenerate and necrotic epithelial cells were seen. Viral 




 Lymphatic and other tissues  
 
The spleens of wild-type C57BL/6J mice generally showed a white pulp comprised 
of moderately sized primary follicles and T cell zones (Figure 5-30A, C). The red pulp 
exhibited moderate cellularity, and there was mild to moderate haemosiderosis. In 
Bpifa1-/- mice, follicles and T cell zones appeared generally larger. Both primary and 
secondary follicles were seen, and they contained several apoptotic cells (Figure 5-30B, 
D). The red pulp exhibited high cellularity, and mild haemosiderosis was observed. The 
distribution of T cells, B cells and macrophages was as expected. 
 
Figure 5-30. Histopathological findings in the spleen of mice infected with 103 PFU IAV X-31 
at 7 dpi. 
A. Spleen of a wild-type C57BL/6J mouse (B17-1272) showing moderately sized primary follicles 
(F) and T cell zones (T), scale bar= 250 µm. B. Spleen of a Bpifa1-/- mouse (B17-1276), showing 
moderately sized primary follicles (F), scale bar= 250 µm. C. Higher magnification of A, scale 
bar= 50 µm.  D. Higher magnification of B. showing several apoptotic cells (arrows), scale bar= 
50 µm. HE stain. 
   
Both mandibular and bronchial lymph nodes of wild-type C57BL/6J mice were very 
cell rich, though follicles were difficult to discern and exhibited moderate sinus 




addition, secondary follicles with several to abundant apoptotic lymphocytes, and 
numerous plasma cells were often seen in the mandibular lymph nodes, and bronchial 
lymph nodes exhibited numerous apoptotic lymphocytes (Figure 5-31B). Again, the 
distribution of T and B cells and macrophages was as expected.  
 
Figure 5-31. Histopathological findings in the bronchial lymph node of mice infected with 
103 PFU IAV X-31 at 7 dpi. 
A. Cortex in a wild-type C57BL/6J mouse (B17-1271) B. Cortex in a Bpifa1-/- mouse (B17-1275), 
with several apoptotic lymphocytes (arrows). Scale bars= 50 µm. HE stain. 
 
The thymus of wild-type C57BL/6J mice appeared histologically unaltered (Figure 
5-32A, C), whereas the thymus of Bpifa1-/- mice exhibited mild thinning of the cortex 








Figure 5-32.  Histopathological findings in the thymus of mice infected with 103 PFU X-31 at 7 
dpi. 
A. Unaltered structure of thymus in a wild-type C57BL/6J mouse (B17-1272), scale bar= 250 µm. 
B. Thinning of the cortex in a Bpifa1-/- mouse (B17-1274), scale bar= 250 µm. C. Higher 
magnification of A. showing normal structure of the thymus, scale bar= 50 µm. D. Higher 
magnification of B. showing mild increase in apoptotic cells (arrows), scale bar= 50 µm. HE stain.   
 
 
Both groups of mice exhibited several, partly large, poorly delineated lymphocyte-
dominated leukocyte aggregates in the mediastinal adipose tissue (Figure 5-33A, B). 
These were dominated by B cells (CD45R positive) (Figure 5-34A, B) and contained 








Figure 5-33. Histopathological findings in the mediastinal adipose tissue of mice infected 
with 103 PFU IAV X-31 at 7 dpi. 
Lymphocyte-dominated leukocyte aggregates in A. Wild-type C57BL/6J mouse (B17-1272) and 
B. Bpifa1-/- mouse (B17-1275), respectively (arrows). Scale bars= 50 µm, HE stain. 
 
 
Figure 5-34. Immunohistological staining for B (CD45R) cells in the mediastinal adipose 
tissue of mice infected with 103 PFU IAV X-31 at 7 dpi. 
B cells dominated the leukocyte aggregates in A. Wild-type C57BL/6J mouse (B17-1272) and B. 
BPIFA-/- mouse (B17-1275), respectively (arrows). Scale bars= 50 µm.  
 
 
 Effect of Bpifa1 on tissue samples using 103 PFU IAV X-31 at day 14 post-
infection  
 
5.7.1 Histological findings  
Table 4 in the Appendix provides a detailed description of the histological and 
immunohistological findings of this experiment.  
 Nasal cavity 
 
At this time point, showed presence of no histological recognised alterations in the 
head sections, apart from mild focal with mild NALT formation. Additionally, wild-type 
C57BL/6J mice showed no histological changes, apart from moderate NALT formation 




intense (Figure 5-35B). In addition, small focal lymphocytes aggregates were observed 
beneath the nasal mucosal epithelium. Viral antigen expression was not observed. 
 
Figure 5-35. Histopathological findings in the head of mice infected with 103 PFU IAV X-31 at 
14 dpi. 
A. Moderate NALT formation in a wild-type C57BL/6J mouse (B18-0324). B. Mild NALT 
formation in a Bpifa1-/- mouse (B18-0321) (arrows). Scale bars= 100 µm, HE stain. 
 
 Lower respiratory tract and lungs 
 
Both groups of mice exhibited similar histological changes. There was moderate 
multifocal perivascular/peribronchiolar lymphocyte-dominated mononuclear 
infiltration (formation of bronchus-associated lymphatic tissue; BALT) (Figure 5-36A, B) 
and mild hyperplasia of the bronchiolar epithelium (Figure 5-37A, B), surrounded by 
consolidated parenchyma with several small bronchioles and aggregates of respiratory 
epithelial cells in alveoli (bronchiolar metaplasia) and type II pneumocyte hyperplasia 








Figure 5-36. Histopathological findings in the lung of mice infected with 103 PFU IAV X-31 at 
14 dpi. 
Moderate BALT formation in A. Wild-type C57BL/6J mouse (B18-0326) and B. Bpifa1-/- mouse 
(B18-0320), respectively (arrows). Scale bars= 100 µm, HE stain. 
 
 
Figure 5-37. Histopathological findings in the lung of mice infected with 103 PFU IAV X-31 at 
14 dpi. 
A. Normal bronchiolar epithelium from a control Bpifa1-/- mouse (B18-0322). Mild hyperplasia 
of bronchiolar epithelium in B. Wild-type C57BL/6J mouse (B18-0326) and C. Bpifa1-/- mouse 







Figure 5-38. Histopathological findings in the lung of mice infected with 103 PFU IAV X-31 at 
14 dpi. 
Type II pneumocyte hyperplasia in A. Wild-type C57BL/6J mouse (B18-0324) and B. Bpifa1-/-
BPIFA1-/- mouse (B18-0321), respectively (arrows). Scale bars= 50 µm, HE stain.  
 
 
The trachea generally appeared unaltered, apart from occasional evidence of mild 
multifocal epithelial hyperplasia. Viral antigen expression was not detected in airways 
and lung. 
 Lymphatic and other tissues 
 
The spleens of both groups of mice exhibited similar histological features. The 
white pulp was comprised of moderately sized secondary follicles with several 
apoptotic cells (these were more numerous in Bpifa1-/- mice), and relatively small T cell 
zones. The red pulp exhibited a relatively low cellularity. The bronchial lymph node was 
available for examination only in Bpifa1-/- mice; it showed secondary follicles with 
numerous apoptotic cells, and indistinct T cell zones. The thymus appeared unaltered 






Figure 5-39. Histopathological findings in the thymus of mice infected with 103 PFU IAV X-31 
at 14 dpi. 
A. Normal structure of the thymus from a control Bpifa1-/- mouse (B18-0322), scale bar= 500 
µm. B. Unaltered thymus in a wild-type C57BL/6J mouse (B18-0325), scale bar= 250 µm. C. 
Mildly thinned cortex in a Bpifa1-/- mouse (B18-0319) (transversal lines), scale bar= 250 µm, HE 
stain. 
Viral antigen expression was not detected in any examined lymphatic tissue. Also, 
in none of the mice was there any lymphatic tissue detected in the mediastinal adipose 
tissue. 
In summary, both wild-type C57BL/6J and Bpifa1-/- mice infected with 10 PFU IAV 
X-31 at 7 dpi, 103 PFU IAV X-31 at 7 and 14 dpi, respectively, exhibited the presence of 
apoptotic cells in spleen, lymph nodes and thymus. However, the number of apoptotic 
cells were more numerous in the thymus and spleen of Bpifa1-/- mice. Is it well known 
that thymus is a primary lymphoid organ in control of the development of mature T cells 
and has an essential role in protection against pathogens. Pathogens, including viruses 
are one of the environmental factors that can affect lymphocyte development and 




 Apoptosis, also called programmed cell death is a series of cellular events that 
leads to the efficient removal of damaged cells such as during development or cells 
resulting from DNA damage. Apoptosis is generally characterised by specific 
morphological characteristics and energy-dependent biochemical mechanisms. 
Apoptosis is considered a crucial component of different processes including normal 
cell turnover, hormone-dependent atrophy, proper development and functioning of 
the immune system, embryonic development and chemical-induced cell death (Elmore, 
2007; Pistritto et al., 2016). Apoptosis has been implicated in the pathogenesis of 
influenza virus. Infection of avian lymphocyte cell line has been shown that lymphocyte 
death is associated with apoptosis in in vitro (Hinshaw et al., 1994). Apoptosis provoked 
in lymphoid tissues may lead to immunosuppression and decrease in the lymphocyte 
count than normal level during the early stage of influenza virus infection (Murphy and 
Webster, 1990). Additionally, intranasal infection of mice with IAV led to apoptosis 
which was detected in thymus at day 3 pi using in situ (Mori et al., 1995). In mice, it has 
been shown that IAV PR8 infection at 7 dpi caused severe atrophy of thymus due to 
increased apoptosis of T-cells and suppressed proliferation, through involvement of 
IFN- ƴ production by NK cells (Duan et al., 2015).    On the other hand, the spleen has a 
significant role in the primary CD8+T cell response against IAV X-31 infection. The 
number of effector CD8+T cell populations increases in both the spleen and draining 
mediastinal lymph nodes, but the contribution of spleen to the pool of migrating cells 
to the lung is much larger (Wu et al., 2011). Additionally, it has been shown that the 
spleen contributes to the immune response to respiratory IAV infection by the fact that 
the spleen is a vital location of antigen presentation, T cell priming and memory 
generation (Turner et al., 2013). There are several hypotheses about the effect of 




lack of inflammatory response during apoptosis, the induction of apoptosis might give 
more time to the virus to replicate before mounting of any effective immune response 
by the host. The second hypothesis is that apoptosis is important for replication of 
influenza virus. On the other hand, influenza virus-induced apoptosis could be a 
response elicited by the host to limit viral spread and decrease tissue damage by the 
effect of inflammation (Schultz-Cherry et al., 1998). Due to the importance of the 
thymus and spleen in the immune response during influenza virus infection, apoptosis 
of these tissues could lead to immunosuppression and increase the number of damaged 
lymphocytes. Also, it is possible that influenza viruses may infect high numbers of 
immune cells leading to damage of immune tissues and changes in the ability of the 












































 In vitro and in vivo expression experiments of mouse Bpifa1 and human BPIFA1 
in mice 
 
Previous studies have shown presence of difference in susceptibility between wild-
type C57BL/6J and Bpifa1-/- mice to IAV (Akram et al., 2018), therefore the goal in 
undertaking these experiemnts was to confirm these observations by complementation 
of Bpifa1 in trans, which would also give the ability to analyse Bpifa1 mutants and 
human BPIFA1 in mice. Although cloning and expression of Bpifa1 in in vitro in HEK 293T 
cells were successful, several attempts to express mouse Bpifa1 and human BPIFA1 in 
vivo in lungs of wild-type C57BL/6J and Bpifa1-/-mice were not successful, no in vivo 
expression could be elicited. The first experiment was to clone Bpifa1 and express it in 
in vitro using HEK 239T cells. The generated data from this experiment showed the 
successful cloning (Figure 3-2) and expression of Bpifa1 in vitro in HEK 293T cells (Figure 
3-4).The finding of the in vitro expression of Bpifa1 is consistent with other studies, 
which showed expression of Bpifa1 with a characteristic 25 kDa (Gally et al., 2011; Britto 
et al., 2013).  
In addition, three pilot experiments using the in vivo-jetPEI® delivery reagent were 
set up to express mouse Bpifa1 and human BPIFA1 in vivo in lungs of wild-type C57BL/6J 
and Bpifa1-/-mice, however, these attempts were not successful. The first pilot 
experiment was set up to assess the ability of both wild-type C57BL/6J and Bpifa1-/- 
mice to express recombinant mouse Bpifa1 and human BPIFA1, this experiment 
included 6 wild-type C57BL/6J and 8 Bpifa1-/- mice (three wild-type C57BL/6J mice were 
intranasally inoculated either with mouse Bpifa1 or human BPIFA1 each, and four 
Bpifa1-/- mice with either mouse Bpifa1 or human BPIFA1 each). Results of this polit 
study showed no expression of Bpifa1 in Bpifa1-/- mice (Figure 3-5B) and BPIFA1 in both 
wild-type C57BL/6J and Bpifa1-/- mice (Figure 3-5C and D). The only expected in vivo 




one wild-type C57BL/6J mouse did express the Bpifa1 which could be due to sample 
processing. 
 Whereas the second pilot experiment included only Bpifa1-/- mice (n=8) and was 
set up to determine the ability of these mice to express recombinant mouse Bpifa1 and 
human BPIFA1. The in vivo expression of both recombinants was not identified in these 
mice (Figure 3-6A, B). This observation suggests that the protein is difficult to express 
in these mice, or the production of this protein is at low levels below the limit of 
detection by western immunoblotting. As a result of no mouse Bpifa1 or human BPIFA1 
expression had been seen after in vivo administration of these two plasmids in the first 
and second pilot experiments, a third pilot experiment was set up to assess the 
feasibility of the in vivo transfection technique by using only Bpifa1-/- mice (n=8) to 
determine the ability of these mice to express the GFP reporter plasmid pMSCV-IRES-
GFP. Results of this pilot experiment showed no in vivo expression of pMSCV-IRES-GFP 
(Figure 3-7). 
This is puzzling as the power of this delivery system has been successfully 
demonstrated in other IAV studies which focused on in vivo expression in the murine 
lung via intranasal inoculation (Cao et al., 2018; Kim et al., 2018). These differences 
between the results of this study and others could be attributed to the difference in the 
concentration of the plasmid/in vivo-jetPEI mix or the strain of mice used in these 
studies. Additionally, using intravenous administration of plasmid/in vivo-jetPEI mix 
(through tail vein or retro-orbital) or using intraperitoneal route would be another 
technique for a successful in vivo expression, which were achieved by other studies that 
have shown successful expression of plasmid constructs delivered by in vivo-jetPEI® (Ge 
et al., 2004; Ranjan et al., 2010; Lin et al., 2012). These delivery routes may improve 




Furthermore, the reporter gene (MSCV-IRES-GFP) has been used in several cloning 
and retroviral transduction studies for in vitro expression trials (Martinez et al., 2016; 
Shebzukhov et al., 2017; Kongkavitoon et al., 2018). In contrast, the in vivo expression 
of this gene was not successful in Bpifa1-/- (third pilot experiment) (Figure 3-7). This 
result suggests either the low expression or inability of this reporter gene to express; 
therefore, utilisation of other reporter vectors such as retro virus, lenti virus or 
recombinant adeno virus might be successful in future studies. Our observations raise 
the question whether it might be useful to change the route of administration or the 
concentration of the plasmids in order to express the genes of interest in transgenic 
mice.  In these pilot experiments western immunoblotting technique was used to detect 
the in vivo expression of mouse Bpifa1 and human BPIFA1. However, this strategy did 
not work and showed inability to distinguish between endogenous and transfected 
Bpifa1 as noted from the results. For the future work, it would be useful to use negative 
control samples from non-transfected wild-type C57BL/6J mice for comparison. 
Additionally, using plasmid constructs which express Bpifa1 tagged with V5/6XHIS-TAG 
to discriminate between endogenous and transfected Bpifa1 to improve the 
experimental design.      
In summary, although cloning and in vitro expression of Bpifa1 were successful, 
several in vivo expression pilot experiments failed to successfully express the gene. 
Alternatively, using other expression vectors such as retro virus, lenti virus or 






 Role of Bpifa1 in the transmission of IAV in mice 
 
One of the fundamental facts regarding Bpifa1 is its continuous expression and 
secretion by the respiratory system epithelium (Musa et al., 2012). However, its precise 
biological functions still unclear. The defensive role of Bpifa1 during the initial phase of 
IAV infection has recently been investigated in our laboratory (Akram et al., 2018). IAV 
remains one of the major global health concerns of the current century. Understanding 
the molecular biology of influenza virus is considered a great help to find means to 
prevent future epidemics caused by this elusive virus. Murine models have recently 
been used in several studies of IAV transmission (Diavatopoulos et al., 2010; Rigoni et 
al., 2010; Wu et al., 2010; Edenborough et al., 2012; Price et al., 2014; Klinkhammer et 
al., 2018). The aim of this chapter was to investigate the role of Bpifa1 in transmission 
of IAV between infected and non-infected wild-type C57BL/6J and Bpifa1-/- mice. From 
the results, a novel role for Bpifa1 in the transmission of IAV was uncovered and 
described for the first time. Utilising a murine IAV transmission model, it was found that 
IAV transmitted more frequently and efficiently to Bpifa1-/- contact mice than to wild-
type C57BL/6J contact mice, indicating an important role for Bpifa1 in the protection 
against IAV infection. In addition, it was investigated the effect and impact of co-
housing index and contact mice from two different strains, in different combinations. 
To assess this role, two transmission experiments were set up in which only female mice 
were infected intranasally with IAV X-31 (index mice) (Figure 2-5). Index and contact 
mice were co-housed together for 4 days, then lung and nasal tissue samples of these 
mice were collected, and the infectious virus titres were determined using plaque assay 
and MDCK cells (see section 2.4.5.3). Based on the results of these two transmission 
experiments, a third experiment was set up (Figure 2-6), in which all index wild-type 




euthanised at day 4 post-infection/exposure. Tissues were collected from all euthanised 
animals for histological and IH examinations (see 2.4.5.2). At day 16 post-
infection/exposure, the remaining contact mice (three wild-type C57BL/6J and three 
Bpifa1-/- mice) were euthanised, and blood, BAL and nasal wash samples were collected 
for determination of antibodies levels.  
During these three transmission experiments, mice were weighed daily and the 
body weight was recorded after infection (4 days). Notably, higher body weight loss was 
observed in Bpifa1-/- contact mice than in wild-type C57BL/6J contact mice in 
transmission experiment 1 (at days 2, 3 and 4 pi) when these mice were co-housed with 
index mice from the same strain (Figure 4-1B). Similar observations were made in 
transmission experiment 3 (at days 1, 2, 3 and 4 pi) when Bpifa1-/- contact mice were 
mixed with wild-type C57BL/6J index mice (Figure 4-2). This finding was consistent with 
that of Edenborough et al., 2012, who reported a significant body weight loss in contact 
mice after co-housing with index mice infected with IAV X-31. However, no significant 
difference was seen between wild-type C57BL/6J and Bpifa1-/- contact mice from 
transmission experiment 2 (Figure 4-1D), when these contact mice were co-housed with 
index mice from different strain. Surprisingly, Bpifa1-/- contact mice showed more body 
weight loss than wild-type C57BL/6J contact mice when they were mixed with Bpifa1-/- 
and wild-type C57BL/6J index in the transmission experiments 1 and 3, respectively.  
While these Bpifa1-/- contact mice did not show any significant difference in the body 
weight in comparison to wild-type C57BL/6J contact mice when they were mixed with 
wild-type C57BL/6J index mice in the transmission experiment 2. This puzzling finding 
needs further investigation for the future work to determine the possible rationales 




It was found that infectious virus titres were significantly higher in the nasal tissue 
homogenates of Bpifa1-/- index mice compared with wild-type C57BL/6J index mice 
(Figure 4-3B). In addition, a significant difference in the virus titre was observed in the 
nasal tissue of Bpifa1-/- contact mice which showed higher virus titre than wild-type 
C57BL/6J contact mice when they were mixed with wild-type C57BL/6J index mice but 
not when either contact mice groups were mixed with Bpifa1-/- index mice (Figure 4-
3C). These observations indicated that Bpifa1-/- contact mice were infected more 
efficiently than wild-type C57BL/6J contact mice. This important finding revealed an 
unappreciated role of this protein in protection mechanism against IAV infection in 
mice. Interestingly, infectious viral titres in lung tissue homogenates did not 
significantly differ between wild-type C57BL/6J and Bpifa1-/- index mice (Figure 4-3A). 
However, Akram et al., 2018 showed higher virus titres (> 1 log10) in lung samples of 
Bpifa1-/- mice in comparison to wild-type C57BL/6J mice even at 24 hpi. The observed 
difference in this result could be due to the difference in the virus dose used in these 
two studies. In addition, statistically non-significant differences were observed in the 
pulmonary viral titre between wild-type C57BL/6J and Bpifa1-/- contact mice when they 
were co-housed with either wild-type C57BL/6J index mice or Bpifa1-/- index mice 
(Figure 4-3C, D). 
Prior to this study, Edenborough et al., 2012 found out that high infectious viral 
titres in the saliva of index mice correlate with contact-dependent transmission of the 
virus, using a mouse model and transmissible and non-transmissible influenza virus 
strains. In future studies, saliva could be titred as well as nasal tissue, especially since 
Bpifa1-/- index mice support higher IAV titres but do not transmit IAV better than wild-
type C57BL/6J mice. The authors also found out that numerous viral strains within the 




preliminary studies to investigate the efficacy of therapeutic interventions that focus 
on minimising contact-dependent transmission of IAV, especially the H3N2 strain. 
Interestingly, it was found that transmission of IAV from index to contact mice only 
occurred when Bpifa1-/- contact mice were mixed with wild-type C57BL/6J index mice. 
The lack of Bpifa1 means that Bpifa1-/- contact mice are more susceptible to IAV 
transmission, but since there is no difference between wild-type C57BL/6J and Bpifa1-/- 
index mice it apparently does not play a role in preventing transmission from an 
infected host to another animal. This is interesting and expected since Bpifa1-/- index 
mice have higher IAV titres in their nasal tissue. 
  More importantly, it was shown that cell cultures derived from mice lacking Bpifa1 
support more nuclear import of virus RNP complexes and binding of the virus to these 
cells (Akram et al., 2018). This perhaps explains why Bpifa1-/- contact mice showed signs 
of infection whereas the wild-type C57BL/6J contact mice did not. Furthermore, a study 
by Yan et al., 2018 on volunteers with confirmed influenza virus infection and URT 
symptoms proposed that coughing was not a basic and necessary factor for generation 
and shedding of the infectious aerosol. This finding explains why mice, animals that lack 
the cough reflex, can still produce and discard (shed) contagious virions (Ortigoza et al., 
2018). 
It is obvious that co-housing of contact mice with wild-type C57BL/6J index mice 
leads to the transmission of more virus to Bpifa1-/- contact mice than co-housing with 
Bpifa1-/- index mice. The possible rationales for this surprising finding are still unknown 
and of interest for future work to uncover the underlying mechanisms that might 
modulate this transmission.    It has been reported the protective role of other proteins 
in limiting the spread of IAV in the respiratory tract. One of these proteins is surfactant 




lectins, which also includes surfactant protein A (SP-A), conglutinin and mannose- 
binding protein (Sastry and Ezekowitz, 1993). SP-D is produced in the lung by alveolar 
type II cells, non-ciliated bronchiolar cells and tracheobronchial glands (Voorhout et al., 
1992).  
A study performed by LeVine et al., 2001 in SP-D+/+ and SP-D-/- mice infected 
intranasally with IAV H3N2 and H3N1 and euthenised at several time-points (3, 5, 7 and 
10 days after infection),  showed that SP-D-/- mice lost more body weight than SP-D+/+ 
mice at 4 dpi and they had higher infectious virus titre in lung homogenates compared 
with SP-D+/+ mice at 3, 5, 7 and 10 dpi. Intratracheal administration of recombinant SP-
D enhanced clearance of H3N2 from the lung of SP-D-/- mice in comparison with 
untreated SP-D-/- mice. The authors also tested the level of proinflammatory cytokines 
including: TNF-α, IL-β and IL-6 in lung homogenates, and they found that these 
cytokines were significantly higher in SP-D-/- mice than those observed in SP-D+/+ mice 
at 3 and 5 dpi. Furthermore, they found that IFN-γ concentration in the lung was higher 
in SP-D-/- mice at 5 dpi. These findings indicated that absence of SP-D led to impairment 
of IAV clearance and increased the severity of lung inflammation, which propose that 
SP-D plays a role in triggering cytokine production and inflammatory response during 
IAV infection.     
Due to the differences in the infectious virus titres in the nasal and lung tissues 
from the transmission experiments 1 and 2 using plaque assay, it was sought to further 
investigate any other differences using histology and IH approaches, which were 
undertaken in the transmission experiment 3. As described in section 2.4.5.2, several 
organs were collected from wild-type C57BL/6J index and both wild-type C57BL/6J and 
Bpifa1-/- contact mice in transmission experiment 3. One of the interesting findings of 




sectioned at different levels: in Bpifa1-/- contact mice viral antigen was detected 
particularly in the frontal part of the nasal cavity, with decreasing expression towards 
the caudal part (Figure 4-6H), whereas in wild-type C57BL/6J contact mice viral antigen 
was not detected (Figure 4-6G). This finding strongly reflects the significantly higher 
viral titres in the nasal tissue homogenates of these mice in comparison to the wild-
type C57BL/6J contact mice. However, lung tissue sections from both wild-type 
C57BL/6J and Bpifa1-/- contact mice were negative for the viral expression (Figure 4-8E, 
F). This confirms that there was no virus replication in the lungs, and this is perhaps due 
to the low dose of inhaled virus particles by the contact mice, which did not induce 
infection and viral replication in the LRT. It is well known that the mucosal response in 
the URT is induced in the NALT (Asanuma et al., 1997; Zuercher et al., 2002). When 
macrophages present in the NALT phagocytose antigens, these antigens interact with 
local B and T cells, leading to the development of a large number of IgA antibody-
forming cell (IgA-AFC) precursors (Harty and Badovinac, 2008; Wu et al., 2014). These B 
and T cells migrate from the NALT towards the lungs via the circulation. In the lung, 
these cells differentiate into specific IgA-AFC to secrete antibodies against antigens. 
Therefore, it is obvious that NALT is a primary inductive site for the secretion of SIgA 
against influenza virus infections. In this study, histological cross sections of the head of 
wild-type C57BL/6J index mice at 4 dpi showed mild to moderate NALT formation 
(Figure 4-5G), this was moderate in wild-type C57BL/6J and mild in Bpifa1-/- contact 
mice (Figure 4-6E, F). However, only Bpifa1-/- contact mice exhibited viral antigen in the 
NALT (Figure 4-6H). This finding supports the fact that Bpifa1 is primarily expressed in 
the nasal cavity and upper airways, and plays a significant role in the host innate 
immune response particularly in regions such as the nose as previously shown (Bingle 




decreases during the first week of infection, which is mediated by PAMPs and cytokines 
as IFN-ƴ (Britto et al., 2013). The lack of Bpifa1 expression in Bpifa1-/- mice is therefore 
likely the reason for the detection of viral antigen in Bpifa1-/- contact mice.  
The initial infection and replication of IAV occurs in the conductive airways. This 
replication triggers immune responses in associated lymphoid organs, such as the 
mediastinal lymph nodes, which assist the first rounds of B cell priming after a 
respiratory infection (Coro et al., 2006). In addition, the lung, which is a non-lymphoid 
organ, plays a role in these primary responses. After the onset of primary influenza virus 
infection, the infected lungs support the development of lymphoid structures called 
induced bronchus-associated lymphoid tissue (iBALT), which contains germinal centres 
and plasma cells (Moyron-Quiroz et al., 2004). In the present study, the respiratory 
epithelium of wild-type C57BL/6J and Bpifa1-/- contact mice was unaltered and did not 
exhibit viral antigen expression, which suggests absent or low viral replication in these 
sites (Figure 4-8E, F). However, Bpifa1-/- contact mice exhibited mild histological 
changes, such as an increased interstitial cellularity, the presence of some lymphocytes 
around blood vessels and leukocyte rolling along endothelial cells of these vessels, 
consistent with recruitment of leukocytes into the lung. (Figure 4.8B, D). This 
observation suggests that Bpifa1 plays a key role in the severity of the histological 
changes, influencing the susceptibility of knock out mice to IAV infection. The 
significance of these findings particularly in the nasal tissue of Bpifa1-/- contact mice 
alongside the low IgA level indicates that transmission of the virus had efficiently 
occurred in these mice and they were more susceptible than wild-type C57BL/6J 
contact mice to the infection. These findings could further support the concept that the 




epithelium, which is the portal of entry of the virus (Cox et al., 2004) and emphasise the 
importance of Bpifa1 in protection from IAV infection. 
 Both SIgA and IgM are the main neutralizing antibodies present on the mucosa to 
inhibit viral entry. Secretions of the nasal mucosa contain IgA, which has the ability to 
neutralize HA and NA of IAV (Mazanec et al., 1995). After primary infection with IAV, 
the three main influenza-specific humoral immune response immunoglobulin classes 
(IgA, IgG, and IgM) are induced and released with mucosal secretions to minimise viral 
infection. However, IgA and IgM concentrations are higher than the IgG concentration 
(Murphy and Clements, 1989). It is believed that the IgM response is dominant during 
primary IAV infection while the IgG response is dominant during secondary infections 
(Rimmelzwaan et al., 1997; Kreijtz et al., 2011).  
As the nasal openings and the URT represent the largest epithelial surface in a 
living body, and the mucosal immune system serves as one of the first defences against 
IAV infection, it was sought to determine whether Bpifa1 could modulate the immune 
response, particularly in contact mice post co-housing. To study the effect of Bpifa1 on 
the immune response particularly in contact mice in transmission experiment 3; blood, 
BAL and nasal wash samples were collected at 16 dpi for determination of antibody 
levels by indirect ELISA as mentioned in section 4.3. Serology showed a weak immune 
response but statistically non-significant differences in IgA levels in BAL samples of wild-
type C57BL/6J mice compared with Bpifa1-/- mice. However, IgA and IgG levels in the 
collected samples did not differ significantly between wild-type C57BL/6J and Bpifa1-/- 
contact mice (Figure 4-4). This result shows the involvement of Bpifa1 in the adaptive 
immune response against IAV. Additionally, the weak or absent immune response could 
be due to the low doses of virus particles that were inhaled during the direct contact 




type C57BL/6J pups of 4-7 days old were infected intranasally with 250 PFU IAV X-31 
and co-housed with non-infected pups for 27 h, 4-5 days or 20 days, showed 100% 
transmission efficiency at the time of infection as shown by plaque assay on retrograde 
URT lavages. Additionally, significant body weight loss was obvious in these contact 
pups at 4, 5, 7, 8 and 9 dpi over the course of 20 days. IAV-specific IgG levels were tested 
in the pups by providing mothers with immunity against IAV through prior infection. 
Pups from immunised mothers exhibited less viral shedding during the first 5 days of 
infection in comparison to non-immunised pups, which is due to the passive transfer of 
maternal IgG. In contrast, our study showed presence of statistically non-significant 
differences in the post-transmission immunity, particularly in IgG levels, which could be 
due to the age of the used mice. In addition, this factor could be the reason for the non-
efficient transmission in adult mice shown by Lowen et al., 2006. Furthermore, the 
same study found that transmission of IAV is dependent on direct contact. On the other 
hand, in influenza virus infection of human, the consequences of infection are 
commonly more severe in the elderly (usually in individuals over 65 years) and the 
reason for this is the gradual changes in the immune system associated with natural age 
progression and the immune system is less effective than that in younger people, which 
in turns increases the susceptibility to viral infections and makes the response to 
vaccination less active (WHO, 2011; Lemaitre et al., 2012; Hernandez-Vargas et al., 
2014). In elderly people, both the innate and adaptive immune responses are altered 
during viral infections as influenza (Ginaldi et al., 2001; Leng and Goldstein, 2010; 
Solana et al., 2012). In general, the marked susceptibility of elderly people is due to 
several age-related defects such as T cell compartment (Nikolich-Žugich et al., 2012), an 
increase in the normal levels of inflammatory cytokines for example TNF-α, IFN- ƴ, IL-6 




responses are affected in old people, which is characterised by changes in the 
proportions of naïve and memory B cell subsets, decreased production of antibodies 
and affinity-antibody maturation (Frasca et al., 2005; Ademokun et al., 2010). It may be 
therefore interesting to investigate the role of Bpifa1 in the immune response against 
the IAV using aged mice.  
Collectively, the concept of influenza virus transmission by direct and indirect 
contact and by droplets and droplet nuclei (i.e., airborne) has been approved and 
indicated by previous research data (Bridges et al., 2003; Tellier, 2009). However, 
experimental investigations involving humans are limited (Alford et al., 1966; Bean et 
al., 1982), and the related contribution of each method of transmission remains 
obscure. Additionally, to study the factors that influence and contribute to the IAV 
transmission remain an interesting area for future research. The present study and 
through these transmission experiments, shows that high viral titres in index mice and 
the viral antigen expression in the nasal tissue of Bpifa1-/- contact mice correlate with a 
contact-dependent transmission of IAV, and that the contact mice lacking Bpifa1 were 
more susceptible to IAV infection. These results showed a potential and novel role for 
Bpifa1 in the contact-dependent transmission of IAV and the protective role that this 
protein offered to contact mice during the co-housing period.  
Using this transmission model alongside Bpifa1 might be valuable and helpful for 
preclinical evaluation and assessment of anti-viral and vaccine efficacy in combating 
contact-dependent transmission and prevention of influenza virus infection. In 
addition, mouse models might be useful to study the pathogenesis and transmission of 





  The immune modulator role of Bpifa1 during IAV infection 
 
In humans, seasonal influenza virus infections cause annual epidemics that result 
in millions of human infections in the world and represent significant health and 
economic burdens (Molinari et al., 2007). In addition, seasonal influenza is an essential 
cause of respiratory system infection leading to substantial morbidity, mortality and 
therefore global economic burden (WHO, 2014). The immune response against 
influenza virus has been a key point of research and studied for several decades, of 
which the adaptive response is multifaceted and complex, which involves both the 
humoral and cellular arms in mucosal and systemic levels (Krammer, 2019). The present 
study has for the first time revealed novel aspects of Bpifa1 functions, not only in the 
protection against IAV during its transmission between mice as discussed in the 
previous section, but the adaptive immune response.  
The successful generation and utilisation of Bpifa1-/- mice provide us with a unique 
research approach and critical observation to better understanding the in vivo function 
of Bpifa1. The novel results in this study could help and provide valuable knowledge in 
future research to fight influenza virus. BPIFA1 is primarily expressed in the upper 
respiratory airways, which is in continuous contact with the external environment, and 
is therefore regularly exposed to potentially pathogenic microorganisms such as 
bacteria and viruses (Zhou et al., 2008). The antiviral function of Bpifa1 remains obscure 
however, several recent studies have investigated the role of Bpifa1 during 
experimental infection with MHV-68 and IAV viruses in mice, respectively (Leeming, 
2010; Leeming et al., 2015; Akram et al., 2018).  
A recent study performed by Akram et al., 2018 uncovered a potential role of 
Bpifa1 as an antiviral and its contribution in the intrinsic and innate host defence against 




helped us to further investigate through the current study other potential functions of 
this protein against experimental IAV in mice. This protein has previously been shown 
its role in the defence mechanism against several bacterial respiratory pathogens 
including K. pneumoniae and M. pneumoniae through its involvement in bacterial 
growth inhibition, anti-inflammatory function and anti-biofilm activity (Chu et al., 2007; 
Gally et al., 2011; Liu et al., 2013). 
One of the aims in this study was to assess the vaccination response to IAV in both 
wild-type C57BL/6J and Bpifa1-/- mice, an animal experiment was set up to analyse the 
response to re-challenge after vaccination (Figure 2-7). Two influenza virus strains were 
used in this experiment, IAV X-31 and PR8. Influenza virus strain X-31 (H3N2) is a 
reassortant virus, which was constructed by the artificial co-infection of A/PR/8/34 and 
A/Aichi/2/68 (H3N2). Thus, it contains six of eight genome segments from influenza 
virus PR8 and the HA and NA of H3N2 Hong Kong epidemic strain. A/PR/8/34 strain is a 
prototypical virus of the human H1N1 influenza virus serotype, which is adapted and 
lethal to mice and grows well under laboratory circumstances (Kilbourne, 1969; Baez et 
al., 1980; Coleclough et al., 2005). Because these two virus strains are serotypically 
unrelated, antibodies that are formed against the glycoproteins of one virus cannot 
recognise the glycoproteins of another virus. However, the two virus strains evoke 
broadly cross-reactive T cells populations, since antibodies formed against nucleocapsid 
segments are effectively cross-reactive, and, as specific T cells against the virus have 
the ability of peptides recognition from all virus proteins associated with host MHC 
molecules (Marshall et al., 1999; Coleclough et al., 2005). Results of this experiment 
showed that all infected/vaccinated mice generated IgG and IgA responses to IAV 
(Figures 5-5 and 5-6). However, these differences between wild-type C57BL/6J and 




X-31 were protected from infection with PR8 and suggests that Bpifa1-/- mice are able 
to initiate an efficient anti-IAV CTL response as well as anti-IAV antibodies. 
It was found from this experiment that challenge with lethal dose of IAV PR8 
conferred complete protection only in mice that were previously infected with PR8, but 
only provided partial protection against sublethal X-31 infected mice through assessing 
the body weight loss and virus titre respectively (Figures 5-3 and 5-4). In addition, there 
was non-significant differences between wild-type C57BL/6J and Bpifa1-/- mice in the 
immune response represented by IgG level in serum and IgA level in BAL samples at 24 
and 33 dpi, respectively (Figures 5-5 and 5-6). This is consistent with Kreijtz et al., 2007, 
who reported that infection of mice with X-31 (H3N2) followed by a challenge with PR8 
(H1N1) showed clearance of infection with less clinical sings and pathological changes 
in lung tissue. They suggested that the previous exposure to the virus provides partial 
protection correlated with virus-specific CD8+ CTL in the absence of specific neutralizing 
antibodies for HA and NA. Whereas, this is inconsistent with a previous study which 
found that humoral immunity represented by the protection of IgA to HA in nasal 
secretions played a key defence role not only against homologous influenza viral 
infection, but also against heterologous infection (Tamura et al., 1991).  
SIgA represents the main antibody isotype presents in nasal fluid and mucosal 
secretions. This type of antibodies is secreted by plasma cells found adjacent to the 
epithelial cells of the mucosal surfaces where infection occurs, and is the principle 
humoral mediator of mucosal immunity (Gianchecchi et al., 2019). One of the aims of 
this study was to determine whether Bpifa1 has any role in the adaptive immune 
response against IAV infection in mice particularly the local immunity in the respiratory 
tract. Therefore, several antibody experiments were set up using different doses of IAV 




use of Bpifa1-/- mice clearly demonstrated a significant increase in IgA levels at 14 dpi in 
BAL samples of wild-type C57BL/6J mice in comparison to Bpifa1-/- mice, after a dose of 
10 PFU of IAV X-31 (Figure 5-10B), as well as IgG level in BAL samples at the same point, 
after a 102 PFU viral dose (Figure 5-12C). In addition, IgA levels were higher in BAL 
samples of Bpifa1-/- mice at 35 dpi using 103 PFU (Figure 5-16B). Interestingly, IgA levels 
were higher in wild-type C57BL/6J mice at early point, whereas the levels of this 
immunoglobulin were higher in Bpifa1-/- mice at later time-point. The rationale for this 
difference could be contribution of other mechanisms such as antigen processing and 
trafficking which need further investigations for the future research. 
It was found that IgA prevented the viral-induced pathology in a study conducted 
by Renegar et al., 2004, who found that mice which were infected with IAV PR8 for 24 
and 48 hpi and given intravenous injection of anti-IAV IgA were protected from infection 
in the URT. Results of 220 µg of IgA at 24 hpi using scanning electron microscopic 
examination showed distinct ciliary tufts and smooth, rounded and nonadherent ciliary 
tips. While at 48 hpi and 440 µg of IgA, there was no viral pathology (healthy cilia). In 
the trachea, the findings were similar i.e. at 24 hpi and intravenous injection of 220 µg 
of IgA maintained healthy ciliary tips and normal mucociliary blanket. In contrast, 
intravenous injection of 168 µg of IgG to influenza-infected mice at 48 hpi, which was 
unable to protect the nose and trachea, showed more protection to the bronchioles, 
whereas injection of 440 µg of IgA, which protected the nose and trachea, showed no 
effect on viral infection in the bronchioles. These results suggested that IgA is more 
important than IgG in the protection of the URT but not in the lung, whereas IgG did 
not have any role in the prevention of viral infection in the nose, but only in the lung. 
Suggesting that IgG is the dominant isotype in lung protection and IgA acts as a backup 




mouse study suggested that IgA was not necessary and required for the prevention of 
IAV infection in IgA-/- mice in comparison with their wild-type IgA+/+ littermate’s mice. 
The viral replication in lung and nasal tissues was the same in both strains of mice after 
4 and 15 days, and mortality rate after 14 dpi (Mbawuike et al., 1999). 
Several studies have investigated the protective role of induced SIgA during 
influenza virus infection in humans (Wright et al., 1983; Clements et al., 1986) and mice 
(Liew et al., 1984; Tamura et al., 1990; Tamura et al., 1991; Tomoda et al., 1995; Asahi 
et al., 2002). In contrast, the contribution between IgM and IgG in protection cannot be 
ignored (Liew et al., 1984). 
Alongside IgA, IgM is also secreted across the mucosal surfaces and may 
participate in protection through prevention of viral entry into host cells, as well as, 
intracellular inhibition of viral replication in the cells (Cox et al., 2004). It has been 
shown that IgM antibodies are protective during influenza infection, and the ability of 
this isotype to neutralise the virus in the presence of complement as well as IgG 
antibodies (Skountzou et al., 2014). Additionally, IgM is the first immunoglobulin 
stimulated following infection or immunization. Furthermore, the half-life of IgM is 
relatively short in the serum of normal mice that do not have any antigen, which is 
approximately 28 h (Vieira and Rajewsky, 1988; Shao et al., 2016). IgM antibodies 
appear in the early stage of host immune response against pathogens and are indicators 
of acute inflammation (Zinkernagel et al., 2001; Zinkernagel, 2003). The level of these 
antibodies wanes quickly after the appearance of IgG. Results of the current study 
showed statistically no significant differences in the IgM level between wild-type 
C57BL/6J and Bpifa1-/- mice in serum, BAL and nasal wash samples of 10 PFU IAV X-31, 
serum samples of 102 PFU IAV X-31 as well as serum and BAL samples of 103 PFU IAV X-




is that the immune response might be a dose-dependent and the downregulation in 
Bpifa1 levels during the first week of infection would have an effect on the antibody 
response. 
In experiments testing the antibody response, BAL samples from each mouse 
strain (three wild-type C57BL/6J and three Bpifa1-/- mice), previously infected with 103 
PFU IAV X-31 at 7 dpi were tested using western immunoblotting (see section 5.2) to 
confirm no mixing of the two strains of mice had occurred during the breeding and 
preparation for the experiments. Results showed that Bpifa1 was undetectable in BAL 
samples of Bpifa1-/- mice but present in wild-type C57BL/6J mice (Figure 5-1), indicating 
that the mice were correctly assigned throughout the experiments. This confirmation 
was consistent with (Gally et al., 2011), who tested the expression of Bpifa1 in BAL 
samples using western immunoblotting. It was shown that IgG2a is the predominant 
subclass of IgG isotype in CBA/CaH mice infected with influenza virus either type A/ 
Queensland/6/72 strain (H3N2) wild-type or a cold-adapted derivative of the same virus 
after several time points weeks using both intravenous, intraperitoneal and 
intramuscular injection routes of the virus in serum, lung lavage and saliva samples 
(Hocart et al., 1989). In contrast, during this study, there was statistically non-significant 
difference in IgG subclasses at 14 dpi using 10 and 103 PFU IAV X-31 in BAL samples, 
respectively (Figures 5-11 and 5-14); the only difference was seen in IgG3 in sera 
samples at 14 dpi using 103 PFU IAV X-31 (Figure 5-15B). However, several studies 
reported that IgG2a is the predominant and effective IgG subclasses against influenza 
infection H3N2 strain (Balkovic et al., 1987; Tao et al., 1987). 
Ahmeida et al., 1992 reported after intranasal administration of 50% mouse 
infectious dose (MID50) IAV A/Sichuan/2/87 (H3N2) live virus into Balb/c mice that there 




between infected and non-infected mice. In addition, the authors found that the 
highest IgG subclasses level was IgG2a at 7 weeks after immunisation among the four 
isotypes of IgG. Furthermore, nasal IgA level was measured and showed high titre at 
three days following homologous challenge infection. However, it was found in this 
study that there were statistically non-significant differences in IgG level at 14 dpi in 
serum and BAL samples using 10 PFU IAV X-31 (Figure 5-10A, C), and IgG level in serum 
samples using 102 PFU IAV X-31 at 14 dpi (Figure 5-12A), IgG level in serum samples; IgA 
and IgG levels in BAL samples at 14 dpi with 103 PFU IAV X-31(Figure 5-13) and IgG level 
at 35 dpi in serum samples, and IgA and IgG levels in nasal wash samples (Figure 5-16A, 
D and E). In contrast, wild-type C57BL/6J mice showed higher IgA level at 10 PFU IAV X-
31 and IgG level at 102 PFU IAV X-31 in BAL samples both at 14 dpi (Figures 5-10B and 
5-12C).  
Results of the present study showed that there was no effect of Bpifa1 on anti-IAV 
antibody responses at high dose infection or on serum samples at any used dose. 
However, at lower doses there were differences in the BAL samples. Therefore, anti-
IAV IgG levels at 102 PFU IAV X-31 and in particular, anti-IAV IgA levels at 10 PFU IAV X-
31 were higher in wild-type C57BL/6J mice. This key result suggests that Bpifa1 has a 
role in the local production of anti-IAV antibodies in the respiratory tract. 
The benefit of precise histological analysis of influenza-infected lung tissues is not 
only determination the differences in the extent of immunopathology between infected 
and control groups of mice, but also it provides essential understanding and knowledge 
of the underlying mechanisms of protection during primary and secondary infection 
(Sell et al., 2019). Airway and alveolar epithelial cells are the primary targets of IAV, 
which contain SA glycans as receptors, therefore causing alveolar epithelial damage and 




lung tissue sections in this study were similar in all groups, though more severe in 
Bpifa1-/- mice and at high dose, this was consistent with Akram et al., 2018. In contrast, 
Britto et al., 2019 found a significant decrease of lung inflammation particularly in 
peribronchial and alveolar compartments (8 and 24 hpi) in Bpifa1-/- mice in comparison 
with wild-type mice after intranasal infection with LPS from P. aeruginosa. However, 
this reduction was attributed to the lower expression of IFN-ƴ and IFN-λ, which limit the 
IFN-mediated cytokine stimulation. The explanation for the difference between these 
two observations could be due to the nature of the used pathogen, which might play a 
key role in the inflammatory response. More recently, it has been shown that Bpifa1 
acts as an essential regulator of neutrophilic inflammation during acute lung injury (ALI) 
in Bpifa1-/- and wild-type control mice induced by intranasal infection of IAV (PR8 strain) 
using 10 PFU. This effect was due to modulation of Cxcl10 expression in infiltrating 
neutrophils and macrophages (Khanal et al., 2019). In the current study, neutrophil 
infiltration was detected in both wild-type C57BL/6J and Bpifa1-/- mice infected with 10 
and 103 PFU IAV X-31 at 7 dpi. The explanation of this finding could be that the 
decreased expression of Bpifa1 during the initial phase of an infection elicits an 
inflammatory response.   
The positive staining of IAV-infected cells in the nasal epithelium of head sections 
was more abundant in Bpifa1-/- mice in comparison with wild-type C57BL/6J mice at 7 
dpi using 10 PFU IAV X-31 (Figure 5.19E and F). Interestingly, this finding is clearly 
correlated with that observed in NALT of Bpifa1-/- contact mice during transmission 
experiment (Figure 4-6H). The fact of Bpifa1 expression is depressed during infection 
has been demonstrated by several studies, and suggests the necessity of this expression 
in host immune response in sites as the nose and upper airways, which is the target 




expression of Bpifa1 protein is tightly regulated and controlled by the exposure to 
pathogens and inflammatory mediators. The amount of Bpifa1 is high during normal 
conditions and early stages of infection. The rapid reduction and loss of Bpifa1 suggests 
that fluctuation in Bpifa1 plays an essential role in host defence (Britto et al., 2013).  
It was previously reported that Bpifa1 secretion increases in the first 3-4 h after 
infection by a number of microorganisms, followed by a decrease around 3-7 days after 
infection (Chu et al., 2007; Britto et al., 2013; Leeming et al., 2015). At 14 dpi, the 
response was very different. Lungs exhibited signs of regeneration, i.e. mild bronchiolar 
epithelial hyperplasia, alveolar bronchiolar metaplasia and type II pneumocyte 
hyperplasia. These results could be due to the involvement of Bpifa1 in the resolution 
of inflammation and the increase in its expression (Leeming, 2010). The histological 
changes in the experiments testing the antibody response were more severe in Bpifa1-
/- mice particularly at high dose. This could be related to the reduced immune response 
represented by lower levels of IgA and IgG in BAL samples in these mice compared with 
wild-type C57BL/6J mice, which indicates the immune modulator role of Bpifa1 during 
IAV infection. 
In summary, the current study has demonstrated direct evidence and novel role of 
Bpifa1 in the immune response against IAV in a mice model. The ability of this protein 
to protect from and modulate IAV infection as well as enhancement of the immune 
response in human remains an interesting goal of future research. Additionally, 
understanding the precise role of Bpifa1 in the defence mechanisms to IAV infection, 
particularly using of Bpifa1 in enhancement of antibody response. Including other 
pathways as antigen processing and anti-viral responses such as interferons as well as 
involvement of Bpifa1 in the pathogenesis of other respiratory viruses, still a key goal 










The following abbreviations have been applied in all tables: LC - lymphocyte; NL - neutrophilic leukocyte; PC - plasma cell; DC - dendritic cell; ln - lymph 
node; sec. - secondary; EMH - extramedullary haematopoiesis; NALT - nasal associated lymphoid tissue; BALT - bronchus associated lymphoid tissue; 
VNO - vomeronasal organ; pos. - positive; NHAIR - no histological abnormality is recognised; p.v. - perivascular; p.b. - peribronchial; Ag – antigen.      
Comment: Heart, salivary glands and pancreas were always included. These did not exhibit any histopathological changes and are therefore not 
mentioned. 
 
Table 1. Detailed description of the histological and immunohistological findings in the examined tissues of mice of transmission experiment 3. At day 
0, wild-type C57BL/6J mice (index mice; n=8) were infected intranasally with 5x104 PFU IAV X-31 (H3N2). All wild-type C57BL/6J index mice (n=8) and 
three wild-type C57BL/6J and three Bpifa1-/- contact mice were euthanised at day 4 of co-housing. 
 
Lab No Animal Histological and immunohistological findings 
B18-1186 WT   
Index 1 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and occ. alveoli with necrosis of epithelial cells; evidence of LC recruitment; 
large focal collapsed, consolidated areas with necrotic pneumocytes, type II pneumocyte activation and desquamation, and 
extensive NL accumulations 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli and in consolidated areas  
Mandibular ln: Small follicles and T cell zones, mild sinus histiocytosis; bronchial ln: very small fragment; mesenteric ln: not 
on section; Viral Ag: Not detected 
Spleen: Moderately sized primary/sec. follicles and T cell zones, high cellularity of red pulp; moderate EMH 
Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: focal dense aggregate of LC with a few Mott cells; focal aggregate of LC with mast cells; adipose 
tissue next to salivary glands: several focal dense aggregates of LC 




Head: Sloughing of some epithelial cells in nasal mucosa; cell debris in lumen of nasal cavity; mild, predominantly 
mononuclear mucosal infiltration; mod NALT formation   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity and occ. neuroepithelial cells of the 
VNO; some neurons in trigeminal ganglion; also pos. epithelial cells in salivary gland 
B18-1187 WT  
Index 2 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation, and LC 
infiltration 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli and in consolidated area 
Mandibular ln: Relatively small follicles and T cell zones, cell-rich, mild sinus histiocytosis; bronchial ln, mesenteric ln: Not 
on section; Viral Ag: Not detected 
Spleen: Relatively small primary follicles and T cell zones, moderate cellularity of red pulp; moderate EMH 
Viral Ag: Not detected 
Thymus: Small fragment; NHAIR; Viral Ag: Not detected 
Mediastinal (and mesenteric?) adipose tissue: Several, variably sized, poorly delineated LC aggregates, some of them with 
numerous plasma cells (PC) and occ. Mott cells 
Viral Ag: Not detected 
Head: Sloughing and necrosis of numerous epithelial cells in nasal mucosa; cell debris in lumen of nasal cavity, mild. 
predominantly mononuclear mucosal infiltration   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity (numerous); several neurons in 
trigeminal ganglion; a few pos. epithelial cells in salivary gland (acinar and duct epithelial cells; tracheal epithelial cells in 
trachea 
B18-1188 WT  
Index 3 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation, and LC 
infiltration 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 




Mandibular ln: Relatively small fragment; moderate sinus histiocytosis; bronchial ln, mesenteric ln: Not on section 
Viral Ag: Not detected 
Spleen: Relatively small primary follicles and T cell zones, moderate cellularity of red pulp; moderate EMH 
Viral Ag: Not detected 
Thymus: Appears enlarged, but with thinned cortex and with cell rich medulla and slight increase in apoptotic LC 
Viral Ag: Not detected 
Mediastinal adipose tissue: Several, partly large, poorly delineated LC (and macrophage) aggregates; Viral Ag: Not detected 
Mesenteric adipose tissue: A few small, poorly delineated LC aggregates; Viral Ag: Not detected 
Head: Sloughing of some epithelial cells in nasal mucosa; mild. predominantly mononuclear mucosal infiltration 
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity and occ. neuroepithelial cells of the 
VNO; some neurons in trigeminal ganglion; also pos. epithelial cells in salivary gland 
B18-1189 WT  
Index 4 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; small 
focal collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation, and LC 
infiltration 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli (pos. epithelial cells also in bronchus, but not in trachea) 
Mandibular ln: Relatively small follicles and T cell zones, cell rich, mild sinus histiocytosis; bronchial (or mesenteric?) ln: 
relatively cell rich, follicles and T cell zones difficult to discern 
Viral Ag: Not detected 
Spleen: Moderately sized (sec.) follicles and T cell zones, relatively low cellularity of red pulp; mild EMH; Viral Ag: Not 
detected 
Thymus: relatively small fragment, medulla and cortex difficult to discern; Viral Ag: Not detected 
Mediastinal adipose tissue: NHAIR; Viral Ag: Not detected 
Head: Sloughing and necrosis of numerous epithelial cells in nasal mucosa; cell debris in lumen of nasal cavity, mild. 
predominantly mononuclear mucosal infiltration; mild NALT formation   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity (numerous); occ. neuroepithelial cells 




B18-1190 WT  
Index 5 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation, and LC 
infiltration Trachea: NHAIR 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli; trachea: several pos. intact epithelial cells 
Mandibular ln: Relatively small follicles and T cell zones, mild sinus histiocytosis and haemorrhage; bronchial ln: not on 
section 
Viral Ag: Not detected 
Spleen: Moderately sized (sec.) follicles and T cell zones, relatively low cellularity of red pulp; mild EMH; Viral Ag: Not 
detected 
Thymus: Appears enlarged, but with thinned cortex and with cell rich medulla and slight increase in apoptotic LC 
Viral Ag: Not detected 
Mediastinal adipose tissue: NHAIR; Viral Ag: Not detected 
Head: Sloughing and necrosis of epithelial cells in nasal mucosa; mild. predominantly mononuclear mucosal infiltration; mod 
NALT formation   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity (numerous); some neurons in 
trigeminal ganglia 
B18-1191 WT  
Index 6 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation, and LC 
infiltration; some peribronchial LC accumulations (BALT formation); trachea: several individual apoptotic/necrotic epithelial 
cells 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli; trachea: numerous pos. intact and degenerate/necrotic epithelial cells 
Mandibular ln: Relatively large follicles (when visible), moderate sinus histiocytosis; bronchial ln, mesenteric ln: not on 
section 
Viral Ag: Not detected 




Mesenteric adipose tissue: Several poorly delineated aggregates of LC and PC; Viral Ag: Not detected 
Head: Sloughing and necrosis of epithelial cells in nasal mucosa; some cell debris in lumen; mild. predominantly 
mononuclear mucosal infiltration; mod NALT formation   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity (numerous); some neurons in 
trigeminal ganglia 
B18-1192 WT  
Index 7 
Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation, and LC 
infiltration; trachea: abundant individual apoptotic/necrotic epithelial cells 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli; trachea: numerous pos. intact and degenerate/necrotic epithelial cells 
Mandibular ln: Relatively small fragment, follicles and T cell zones not discernible, moderate sinus histiocytosis; bronchial ln: 
small fragment, follicles and T cell zones not discernible, moderate sinus histiocytosis; mesenteric ln: not on section 
Viral Ag: Not detected 
Spleen: Relatively small (sec.) follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: Medulla and cortex difficult to discern (thinned cortex?); Viral Ag: Not detected 
Mediastinal adipose tissue: several poorly delineated aggregates of LC, macrophages and PC; Viral Ag: Not detected 
Head: Sloughing and necrosis of epithelial cells in nasal mucosa; some cell debris in lumen; mild. predominantly 
mononuclear mucosal infiltration; mod NALT formation   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity (numerous); occ. neuroepithelial cells 





Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
area of acute alveolar haemorrhage (euthanasia associated) trachea: NHAIR 
Viral Ag: Intact and degenerating individual respiratory epithelial cells (affected bronchioli); alveolar cells (mainly type II) in 
altered and unaltered alveoli; trachea: rare pos. intact epithelial cells 
Mandibular ln, bronchial ln: Relatively small follicles and T cell zones, cell rich, moderate sinus histiocytosis; mesenteric ln: 
not on section 




Spleen: Relatively small (sec.) follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: Cortex appears thinned, with several tingible body macrophages; Viral Ag: Not detected 
Mesenteric adipose tissue, mediastinal adipose tissue: Several variably sized poorly delineated aggregates of LC, 
macrophages and PC; Viral Ag: Not detected 
Head: Sloughing and necrosis of epithelial cells in nasal mucosa; some cell debris in lumen; mild. predominantly 
mononuclear mucosal infiltration; mod NALT formation   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity (numerous); some neuroepithelial cells 
of the VNO 





Lungs: NHAIR, apart from focal area of acute alveolar haemorrhage (euthanasia associated); trachea: NHAIR 
Viral Ag: Not detected 
Mandibular ln: Relatively small follicles and T cell zones, mild sinus histiocytosis, bronchial ln, mesenteric ln: not on section 
Viral Ag: Not detected 
Spleen: Moderately sized follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: rare small aggregates of LC (and macrophages); Viral Ag: Not detected 
Head: Nasal and tracheal epithelial cells appear intact; mod NALT formation   
Viral Ag: Numerous intact individual respiratory epithelial cells in nasal cavity and trachea (patchy areas) 
B18-1195 WT 
Contact 2 
Lungs: NHAIR; trachea: NHAIR; Viral Ag: Not detected 
Mandibular ln: Small follicles and T cell zones, moderate sinus histiocytosis, bronchial ln, mesenteric ln: not on section 
Viral Ag: Not detected 
Spleen: Moderately sized follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue, mesenteric adipose tissue: A few small aggregates of LC (and macrophages); Viral Ag: Not 
detected 
Head: Nasal and tracheal epithelial cells appear intact; mod NALT formation   
Viral Ag: Low number of intact individual respiratory epithelial cells in nasal cavity with weak reaction 






Mandibular ln: indistinct follicles and T cell zones, mild sinus histiocytosis, bronchial ln: relatively small fragment, mild sinus 
histiocytosis; mesenteric ln: not on section; Viral Ag: Not detected 
Spleen: Relatively large sec. follicles with several apoptotic cells; moderate sized T cell zones, moderate cellularity of red 
pulp; mild EMH; Viral Ag: Not detected 
Mediastinal adipose tissue: A few small aggregates of LC (and macrophages); mesenteric adipose tissue: several aggregates 
of LC (and macrophages); Viral Ag: Not detected 
Head: Nasal and tracheal epithelial cells appear intact; mod NALT formation; bilateral focal NL infiltrate in VNO   
Viral Ag: Not detected 
   
B18-1197 KO 
Contact 1 
Lungs: Increased cellularity, with some LC around vessels and rolling along endothelial cells of vessels; focal peribronchiolar 
LC aggregate (mild BALT); multifocal acute alveolar haemorrhage (euthanasia-associated) 
Viral Ag: Not detected  
Mandibular ln: Small fragment; bronchial ln, mesenteric ln: not on section; Viral Ag: Not detected 
Spleen: Moderately sized (sec.) follicles with occ. apoptotic cells; moderate sized T cell zones, moderate cellularity of red 
pulp; mild EMH; Viral Ag: Not detected 
Mediastinal adipose tissue: Several larger aggregates of LC (and macrophages); Viral Ag: Not detected 
Head: Nasal and tracheal epithelial cells with increased protein droplets; small amount of debris, some cells appear 
rounded; mild NALT formation; small aggregate of NL in VNO   




Lungs: increased cellularity, with some LC around vessels; multifocal acute alveolar haemorrhage (euthanasia-associated) 
Viral Ag: Not detected  
Mandibular ln, bronchial ln, mesenteric ln: Not on section 
Spleen: Moderately sized (sec.) follicles with occ. apoptotic cells; moderate sized T cell zones, moderate cellularity of red 
pulp; mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue, mesenteric adipose tissue: A few small aggregates of LC (and macrophages); Viral Ag: Not 
detected 




Viral Ag: One or two pos. epithelial cells (sloughed off) in nasal cavity 
B18-1199 KO 
Contact 3 
Lungs: NHAIR, apart from extensive acute alveolar haemorrhage (euthanasia-associated); Viral Ag: Not detected  
Mandibular ln: Relatively small follicles and T cell zones, mild sinus histiocytosis; bronchial ln, mesenteric ln: not on section 
Viral Ag: Not detected 
Spleen: Moderately sized follicles and T cell zones, relatively high cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue, mesenteric adipose tissue: Several aggregates of LC (and macrophages); Viral Ag: Not detected 
Head: NHAIR; mild NALT formation 
Viral Ag: Focal area with large patch of pos. epithelial cells (mainly cytoplasmic reaction) in nasal cavity 






Table 2. Detailed description of the histological and immunohistological findings in the examined tissues of mice infected with a low dose of IAV X-31 
(10 PFU; generally considered non-lethal in mice). Animals were euthanised at 7 dpi, wild-type C57BL/6J mice (n=4) and Bpifa1-/- mice (n=5). 
Lab No Animal Histological and immunohistological findings 
B18-1200 WT  1 Lungs: Focal areas with necrotising bronchiolitis with peribronchiolar LC dominated infiltration, multifocal LC dominated 
vasculitis/perivascular mononuclear infiltration; evidence of LC recruitment; with collapsed, consolidated areas with occ. necrotic 
pneumocytes, type II pneumocyte activation and desquamation and some NL infiltration, other areas unaltered 
Viral Ag: limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas  
Mandibular ln: Small follicles and T cell zones, mild sinus histiocytosis; bronchial ln: follicles mainly indistinct, when obvious, with 
several apoptotic cells, indistinct T cell zones; mesenteric ln: not on section 
Viral Ag: Not detected 
Spleen: Moderately sized sec. follicles and T cell zones, with occ. apoptotic cells, moderate cellularity of red pulp; moderate EMH 
Viral Ag: Not detected 
Thymus: NHAIR, apart from a few apoptotic cells in cortex; Viral Ag: Not detected 
Mesenteric adipose tissue: Numerous variably sized, poorly delineated aggregates of LC with PC and a few Mott cells 
Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in nasal cavity, a few individual sloughed epithelial cells in the frontal 
nasal mucosa; mod NALT formation 
Viral Ag: Focal areas with some pos. epithelial cells (occ. sloughed) in frontal nasal cavity 
B18-1201 WT 2 Lungs: Focal areas with necrotising bronchiolitis with peribronchiolar LC dominated infiltration, multifocal LC dominated 
vasculitis/perivascular mononuclear infiltration; evidence of LC recruitment; with collapsed, consolidated parenchyma with occ. 
necrotic pneumocytes, type II pneumocyte activation and desquamation and some NL infiltration, other areas unaltered; trachea: 
NHAIR 
Viral Ag: Limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas  
Mandibular ln: Moderately sized follicles and T cell zones, moderate sinus histiocytosis; bronchial ln, mesenteric ln: not on 
section 




Spleen: Relatively small follicles and T cell zones, moderate cellularity of red pulp; moderate EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: Numerous variably sized, poorly delineated aggregates of LC with macrophages and PC  
Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in nasal cavity; mod NALT formation;  
Viral Ag: Neg (but frontal nasal cavity not on section) 
B18-1202 WT 3 Lungs: Multifocal extensive areas with necrotising bronchiolitis with peribronchiolar LC dominated infiltration, multifocal LC 
dominated vasculitis/perivascular mononuclear infiltration; evidence of LC recruitment; with collapsed, consolidated parenchyma 
with occ. necrotic pneumocytes, type II pneumocyte activation and desquamation and some NL infiltration, one lobe entirely 
affected, with leukocytes in alveoli Trachea: NHAIR 
Viral Ag: Limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas  
Mandibular ln, bronchial ln, mesenteric ln: Not on section; Viral Ag: Not detected 
Spleen: Moderately sized sec. follicles and T cell zones, with occ. apoptotic cells, moderate cellularity of red pulp; moderate EMH 
Viral Ag: Not detected 
Mediastinal and mesenteric adipose tissue: Occ. small, poorly delineated aggregates of LC with macrophages and PC  
Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in nasal cavity, focal areas with flattened epithelial and a few sloughed 
epithelial cells in the frontal and mid nasal mucosa, some debris in lumen 
Viral Ag: Abundant pos. epithelial cells in association with histological changes and in lumen in nasal cavity; scattered pos. 
neurons in (trigeminal) ganglion 
B18-1203 WT 4 Lungs: Multifocal extensive areas with necrotising bronchiolitis with peribronchiolar LC dominated vasculitis/perivascular 
mononuclear infiltration; evidence of LC recruitment; with collapsed, consolidated parenchyma with occ. necrotic pneumocytes, 
type II pneumocyte activation and desquamation and some NL infiltration, one lobe almost entirely affected, with leukocytes in 
alveoli 
Viral Ag: Limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas 
Mandibular ln: Relatively small follicles and T cell zones, cell rich, mild sinus histiocytosis; bronchial (or mesenteric?) ln: Relatively 




Viral Ag: Not detected 
Spleen: Moderately sized sec. follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: Numerous variably sized, poorly delineated aggregates of LC with macrophages and PC 
Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in frontal nasal cavity, a few individual sloughed epithelial, some debris 
in lumen a; mod NALT formation 
Viral Ag: Focal areas with some pos. epithelial cells (occ. sloughed) in frontal nasal cavity, some reaction in lumen/debris and in a 
cell in VNO 
   
B18-1204 KO 1 Lungs: Focal extensive area (one lobe almost entirely affected) with necrotising bronchiolitis with peribronchiolar LC dominated 
vasculitis/perivascular mononuclear infiltration; evidence of LC recruitment; with collapsed, consolidated parenchyma with occ. 
necrotic pneumocytes, type II pneumocyte activation and desquamation and some NL infiltration 
Viral Ag: Limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas 
Mandibular ln: Indistinct follicles and T cell zones, cell rich, mild sinus histiocytosis; bronchial ln: moderately sized follicles with 
occ. apoptotic cells, T cell zones difficult to discern, cell rich 
Viral Ag: Not detected 
Spleen: Moderately sized sec. follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mesenteric adipose tissue: A few poorly delineated aggregates of LC and PC; Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in nasal cavity, focal areas with flattened epithelial and a few sloughed 
epithelial cells in the frontal and mid nasal mucosa, some debris in lumen; mild to mod NALT formation 
Viral Ag: Abundant pos. epithelial cells in association with histological changes and in lumen in nasal cavity; several pos. 
neuroepithelial cells in the VNO 
B18-1205 KO 2 Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 





Viral Ag: Limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas 
Mandibular ln: Moderately sized follicles and T cell zones, cell rich, moderate sinus histiocytosis; bronchial ln, mesenteric ln: not 
on section; Viral Ag: Not detected 
Spleen: Moderately sized sec. follicles with some apoptotic cells, moderate sized T cell zones, moderate cellularity of red pulp; 
mild EMH; Viral Ag: Not detected 
Thymus: NHAIR, a few scattered apoptotic cells in cortex; Viral Ag: Not detected 
Mediastinal adipose tissue: Several variably sized, poorly delineated aggregates of LC with macrophages and PC 
Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in nasal cavity, focal areas with flattened epithelial and a few sloughed 
epithelial cells in the nasal mucosa, some debris in lumen; moderate NALT formation 
Viral Ag: Abundant pos. epithelial cells in association with histological changes and in lumen in nasal cavity 
B18-1206 KO 3 Lungs: Mild focal LC dominated/perivascular mononuclear infiltration and LC rolling; bronchioles with a few degenerating 
epithelial cells? 
Viral Ag: Not detected 
Mandibular ln: indistinct follicles and T cell zones, mild to moderate sinus histiocytosis; bronchial ln, mesenteric ln: not on 
section 
Viral Ag: Not detected 
Spleen: Moderately sized sec. follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Neg 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: A few poorly delineated aggregates of LC, macrophages and PC; mesenteric adipose tissue: a few 
larger, poorly delineated aggregates of LC with macrophages and PC; Viral Ag: Not detected 
Head: Mild to moderate mononuclear mucosal infiltration in frontal nasal cavity, a few individual sloughed epithelial, some debris 
in lumen; mod NALT formation 
Viral Ag: Focal areas with some pos. epithelial cells (occ. sloughed) in frontal nasal cavity; a few neuroepithelial cells in VNO; two 
neurones in (trigeminal) ggl. 
B18-1207 KO 4 Lungs: Focal LC dominated vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of 
LC recruitment; focal collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation 




Viral Ag: Not detected? (if reaction, then extremely weak) 
Mandibular ln, bronchial ln, mesenteric ln: Not on section; Viral Ag: Neg 
Spleen: Moderately sized (sec.) follicles and T cell zones, moderate cellularity of red pulp; mild EMH; Viral Ag: Not detected 
Thymus: Small fragment, NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: Many variably sized poorly delineated aggregates of LC, macrophages and PC; Viral Ag: Not detected 
Head: NHAIR; moderate (to marked) NALT formation; Viral Ag: Not detected 
B18-1208 KO 5 Lungs: Moderate multifocal necrotising bronchiolitis with peribronchiolar LC dominated infiltration, LC dominated 
vasculitis/perivascular mononuclear infiltration and alveoli with necrosis of epithelial cells; evidence of LC recruitment; focal 
collapsed, consolidated area with necrotic pneumocytes, type II pneumocyte activation and desquamation and some NL 
infiltration Trachea: NHAIR 
Viral Ag: Limited expression, in degenerating individual respiratory epithelial cells (affected bronchioli); scattered alveolar cells 
(mainly type II) and degenerate cells in consolidated areas; trachea: neg 
Mandibular ln: Indistinct follicles and T cell zones, cell rich, moderate sinus histiocytosis; bronchial ln: small fragment; mesenteric 
ln: not on section 
Viral Ag: Not detected, apart from a few pos macrophages in mandibular ln. and in bronchial ln 
Spleen: Moderately sized sec. follicles with some apoptotic cells, moderate sized T cell zones, moderate cellularity of red pulp; 
mild EMH; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: Multiple, often large, poorly delineated aggregates of LC, macrophages and PC; Viral Ag: Not 
detected 
  Head: Moderate suppurative rhinitis with inhaled plant particles embedded in mucus and inflammatory debris in lumen of frontal 
nasal cavity; mod (to marked) NALT formation 





Table 3. Detailed description of the histological and immunohistological findings in the examined tissues of mice infected with IAV X-31 (103 PFU; 
generally considered non-lethal in mice). Animals were euthanised at 7 dpi, wild-type C57BL/6J mice (n=2) and Bpifa1-/- mice (n=4). 
Lab No Animal Histological and immunohistological findings 
B17-1271 WT 1 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration and evidence of LC recruitment, 
increased interstitial cellularity (with macrophages, NL, LC) with focal collapsed, consolidated areas, scattered necrotic 
pneumocytes and moderate degeneration of respiratory epithelium; trachea: NHAIR 
Viral Ag: Intact and degenerating individual alveolar cells (type II, occ. also type I) and scattered/focal respiratory epithelial cells 
(bronchioli) 
CD3: Dominant in interstitial infiltration and abundant in consolidated areas and around p.v./p.b. focal infiltrates 
CD45R: B cells almost exclusively in p.v./p.b. focal infiltrates where they dominate  
Iba-1: Abundant in p.v./p.b. focal infiltrates and in consolidated areas, otherwise more rare 
Mandibular ln, bronchial ln: very cell rich, moderate sinus histiocytosis 
Viral Ag: Not detected, apart from one pos. macrophage in mandibular ln 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Spleen: Moderately sized primary follicles and T cell zones, moderate cellularity of red pulp; moderate haemosiderosis 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Mediastinal adipose tissue: Several, partly large, poorly delineated LC (and macrophage) aggregates 
Viral Ag: Not detected 
CD3: Variable amount of T cells in LC aggregates, but not dominant population 
CD45R: B cells dominate the LC aggregates 
Iba-1: Mainly in periphery, fewer in centre of LC aggregates 
Head: NHAIR, apart from focal mixed cellular infiltration close to VNO; no NALT on sections   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity and numerous neuroepithelial cells of the 
VNO 
CD3: Few individual T cells between and beneath epithelial cells in nasal cavity and VNO 
CD45R: Scattered individual B cells between and beneath epithelial cells in nasal cavity and VNO 




B17-1272 WT 2 Lungs: Mild multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration and occ. evidence of LC recruitment, 
mildly increased interstitial cellularity (with macrophages, NL, LC); focal collapsed, consolidated areas with necrotic 
pneumocytes and moderate degeneration of respiratory epithelium; one bronchiolus with adjacent parenchyma with NL-
dominated infiltration and some epithelial cell degeneration; trachea: NHAIR 
Viral Ag: Scattered individual intact cells (pneumocytes, macrophages?) and scattered individual respiratory epithelial cells 
(bronchioli) 
CD3: Dominant in interstitial infiltration and abundant in consolidated area and p.v./p.b. focal infiltrates 
CD45R: B cells almost exclusively in p.v./p.b. focal infiltrates where they dominate  
Iba-1: Abundant in p.v./p.b. focal infiltrates and in consolidated area, otherwise more rare 
Mandibular ln, bronchial ln: Not on section 
Viral Ag: Not detected, apart from one pos. macrophage in mandibular ln 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Spleen: Moderately sized primary follicles and T cell zones, moderate cellularity of red pulp; mild haemosiderosis 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Thymus: NHAIR 
Viral Ag: Not detected 
CD3, CD45R, Iba-1 As expected (tissue specific leukocyte distribution) 
Mediastinal adipose tissue: Several, partly large, poorly delineated LC (and macrophage) aggregates, in the largest with several 
embedded Mott cells 
Viral Ag: Not detected 
CD3: Relatively few T cells in LC aggregates 
CD45R: B cells dominate the LC aggregates 
Iba-1: mainly in periphery, fewer in centre of LC aggregates 
Head: NHAIR, apart from occ. individual degenerate respiratory epithelial cells; NALT as small aggregate of LC   
Viral Ag: Intact and degenerating individual respiratory epithelial cells in nasal cavity; neurons in trigeminal (?) ganglion 
CD3: Few individual T cells between and beneath epithelial cells in nasal cavity and VNO 





Iba-1: Numerous individual pos. cells with DC morphology between and underneath epithelium in nasal cavity and VNO 
B17-1273 KO 1 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (> WT) with some evidence of 
leukocyte recruitment; multifocal collapsed, consolidated areas with macrophages, LC and some NL and alveoli containing 
leukocytes, scattered necrotic pneumocytes; variable, often extensive necrosis of respiratory epithelium; trachea: NHAIR 
Viral Ag: Intact and degenerating individual alveolar cells (type II, occ. also type I) and scattered/focal respiratory epithelial cells 
(bronchioli) 
CD3: Dominant in interstitial infiltration and abundant in consolidated areas and around p.v./p.b. focal infiltrates 
CD45R: B cells almost exclusively in p.v./p.b. focal infiltrates where they dominate [strong serum reaction] 
Iba-1: Abundant in p.v./p.b. focal infiltrates and in consolidated areas, otherwise more rare 
Mandibular ln, bronchial ln: Cell rich, moderate sinus histiocytosis, small aggregates of apoptotic LC 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Spleen: Large primary follicles and T cell zones, high cellularity of red pulp; mild haemosiderosis 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Mediastinal adipose tissue: Several, partly large, poorly delineated LC (and macrophage) aggregates 
Viral Ag: Not detected 
CD3: Variable amount of T cells in LC aggregates, but not dominant population 
CD45R: B cells dominate the LC aggregates 
Iba-1: Mainly in periphery, fewer in centre of LC aggregates 
Head: Focal areas of respiratory epithelial cell degeneration and loss; no NALT on sections   
Viral Ag: Abundant intact and degenerating individual respiratory epithelial cells in nasal cavity (>> WT), a few individual cells of 
the neuroepithelium in the VNO 
CD3: Several individual T cells between and beneath respiratory epithelial cells (> WT) 
CD45R: Scattered individual B cells between and beneath epithelial cells in nasal cavity and VNO 
Iba-1: Numerous individual pos. cells with DC morphology between and underneath epithelium in nasal cavity and VNO 
B17-1274 KO 2 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (> WT) with some evidence of 




leukocytes, several necrotic pneumocytes; multifocal necrosis of respiratory epithelium; trachea: individual degenerate and 
necrotic epithelial cells 
Viral Ag: Intact and degenerating individual alveolar cells (type II, occ. also type I) and scattered/focal respiratory epithelial cells 
(bronchioli), some macrophages; trachea: not detected  
CD3: Dominant in interstitial infiltration and abundant in consolidated areas and around p.v./p.b. focal infiltrates 
CD45R: B cells almost exclusively in p.v./p.b. focal infiltrates where they are abundant [strong serum reaction] 
Iba-1: Abundant in p.v./p.b. focal infiltrates and in consolidated areas, otherwise more rare 
Mandibular ln: Cell rich, moderate sinus histiocytosis, secondary follicles with several/abundant apoptotic LC, numerous 
plasma cells; bronchial ln: Relatively cell rich, numerous plasma cells 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Spleen: Relatively large, mainly secondary follicles with several apoptotic cells, moderate sized T cell zones, high cellularity of 
red pulp; mild haemosiderosis  
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Thymus: Mild increase in apoptotic cells and mildly reduced cortex (< WT?) 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Mediastinal adipose tissue: Several, partly large, poorly delineated LC aggregates 
Viral Ag: Not detected 
CD3: Minority in LC aggregates (appr. 10%) 
CD45R: B cells dominate the LC aggregates 
Iba-1: Mainly in periphery, fewer in centre of LC aggregates 
Head: Focal areas of respiratory epithelial cell degeneration and loss; no NALT on sections   
Viral Ag: Very few intact and degenerating individual respiratory epithelial cells in nasal cavity, a few individual neurons in 
(trigeminal?) ganglion 
CD3: Several individual T cells between and beneath respiratory epithelial cells (> WT) 
CD45R: Scattered individual B cells between and beneath epithelial cells in nasal cavity and VON, focal sub epithelial areas with 




Iba-1: Numerous individual pos. cells with DC morphology between and underneath epithelium in nasal cavity and VNO 
B17-1275 KO 3 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (> WT) with some evidence of 
leukocyte recruitment; a few consolidated areas with macrophages, LC and some NL and alveoli containing leukocytes, several 
necrotic pneumocytes; multifocal necrosis of respiratory epithelium; trachea: NHAIR 
Viral Ag: Intact and degenerating individual alveolar cells (type II, occ. also type I) and scattered/focal respiratory epithelial cells 
(bronchioli), some macrophages; trachea: neg 
CD3: Dominant in interstitial infiltration and abundant in consolidated areas and around p.v./p.b. focal infiltrates 
CD45R: B cells almost exclusively in p.v./p.b. focal infiltrates where they are abundant [strong serum reaction] 
Iba-1: Abundant in p.v./p.b. focal infiltrates and in consolidated areas, otherwise more rare 
Mandibular ln: Cell rich, moderate sinus histiocytosis, secondary follicles with several apoptotic LC  
Bronchial ln: Cell rich, numerous apoptotic LC, if identifiable, follicles are small 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Spleen: Moderately sized primary and secondary follicles with several apoptotic cells, moderate sized T cell zones, high 
cellularity of red pulp; mild haemosiderosis  
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Thymus: Mild increase in apoptotic cells and mildly reduced cortex (< WT?) 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Mediastinal adipose tissue: Several, mainly small, poorly delineated LC aggregates 
Viral Ag: Not detected 
CD3: Minority in LC aggregates (10-20%) 
CD45R: B cells dominate the LC aggregates 
Iba-1: Mainly in periphery, fewer in centre of LC aggregates; expression also in activated mesothelial cells covering the adipose 
tissue 
Head: Occasional degenerate respiratory epithelial cell; no NALT on sections   
Viral Ag: A few individual and small group of intact and degenerating respiratory epithelial cells in nasal cavity*, a few 




CD3: Several individual T cells between and beneath respiratory epithelial cells (> WT?), some also in trigeminal (?) ganglia 
CD45R: Scattered individual B cells between and beneath epithelial cells in nasal cavity 
Iba-1: Numerous individual pos. cells with DC morphology between and underneath epithelium in nasal cavity and VNO 
B17-1276 KO 4 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (> WT) with some evidence of 
leukocyte recruitment; extensive multifocal (almost entire lobe) consolidated areas with macrophages, LC and some NL and 
alveoli containing leukocytes, several necrotic pneumocytes, activation of overlying mesothelium; multifocal necrosis of 
respiratory epithelium; trachea: NHAIR 
Viral Ag: Very few pos. cells (intact and degenerating individual alveolar cells (type II, occ. also type I), some macrophages; 
trachea: neg 
CD3: Dominant in interstitial infiltration and abundant in consolidated areas and around p.v./p.b. focal infiltrates 
CD45R: B cells almost exclusively in p.v./p.b. focal infiltrates where they are abundant [strong serum reaction] 
Iba-1: Abundant in p.v./p.b. focal infiltrates and in consolidated areas, otherwise more rare 
Mandibular ln: Cell rich, moderate sinus histiocytosis, secondary follicles with several apoptotic LC  
Bronchial ln: Cell rich, numerous apoptotic LC, if identifiable, follicles are small 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Spleen: Relatively large secondary follicles with several apoptotic cells, moderate sized T cell zones, high cellularity of red pulp; 
mild haemosiderosis  
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Thymus: Mild increase in apoptotic cells and mildly reduced cortex (< WT?) 
Viral Ag: Not detected 
CD3, CD45R, Iba-1: As expected (tissue specific leukocyte distribution) 
Mediastinal adipose tissue: Hardly any on section, with some LC aggregate 
Viral Ag: Not detected 
CD3: Minority in LC aggregates (10-20%) 
CD45R: B cells dominate the LC aggregates 





Head: Occasional degenerate respiratory epithelial cell; distinct NALT   
Viral Ag: Several individual and groups of intact and degenerating respiratory epithelial cells in nasal cavity*, a few individual 
neurons in (trigeminal?) ganglion 
CD3: Several individual T cells between and beneath respiratory epithelial cells (> WT?), some also in trigeminal (?) ganglia, 
proportion also in NALT 
CD45R: Scattered individual B cells between and beneath epithelial cells in nasal cavity; dominant cells in NALT where they also 
aggregate in the overlying epithelium 
Iba-1: Several individual pos. cells with DC morphology between and underneath epithelium in nasal cavity and VON, 
proportion also in NALT 





Table 4. Detailed description of the histological and immunohistological findings in the examined tissues of mice infected with IAV X-31 (103 PFU; 
generally considered non-lethal in mice). Animals were euthanised at 14 dpi, wild-type C57BL/6J mice (n=3), Bpifa1-/- mice (n=3) and Bpifa1-/- control 
mice (n=2).  
Lab No Animal Histological and immunohistological findings 
B18-0319 KO 1 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (BALT) and mild epithelial 
hyperplasia of bronchioles, with surrounding consolidated areas with several small bronchioles and aggregates of respiratory 
epithelial cells in alveoli (bronchiolar metaplasia?) and type II pneumocyte hyperplasia; trachea: NHAIR (maybe some 
epithelial hyperplasia)  
Viral Ag: Not detected 
Bronchial ln: Sec. follicles with numerous apoptotic cells, indistinct T cell zones; Viral Ag: Not detected 
Spleen: Relatively small secondary follicles with several apoptotic cells, small T cell zones, relatively low cellularity of red pulp  
Viral Ag: Not detected 
Thymus: NHAIR, apart from relatively thin cortex; Viral Ag: Not detected 
Mediastinal adipose tissue: No LC aggregates seen; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR; Viral Ag: Not detected 
B18-0320 KO 2 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (BALT) and surrounding 
consolidated areas with several small bronchiole and aggregates of respiratory epithelial cells in alveoli (bronchiolar 
metaplasia?) and type II pneumocyte hyperplasia; trachea: NHAIR, apart from evidence of multifocal epithelial hyperplasia  
Viral Ag: Not detected 
Bronchial ln: Sec. follicles with numerous apoptotic cells, indistinct T cell zones; Viral Ag: Not detected 
Spleen: Moderate sized secondary follicles with several apoptotic cells, small T cell zones, relatively low cellularity of red pulp  
Viral Ag: Not detected 
Thymus: NHAIR, apart from relatively thin cortex; Viral Ag: Not detected 
Mediastinal adipose tissue: No LC aggregates seen; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 




B18-0321 KO 3 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (BALT) and surrounding 
consolidated areas with several small bronchiole and aggregates of respiratory epithelial cells in alveoli (bronchiolar 
metaplasia?) and type II pneumocyte hyperplasia; trachea: NHAIR, apart from evidence of mild multifocal epithelial 
hyperplasia  
Viral Ag: Not detected 
Bronchial ln: Not on section; Viral Ag: Not detected 
Spleen: Moderate sized secondary follicles with several apoptotic cells, small T cell zones, relatively low cellularity of red pulp  
Viral Ag: Not detected 
Thymus: NHAIR, apart from relatively thin cortex; Viral Ag: Not detected 
Mediastinal adipose tissue: No LC aggregates seen; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR, apart from mild focal LC aggregate formation beneath nasal mucosal epithelium (mild NALT formation) 
Viral Ag: Not detected 
B18-0322 KO C1 Lungs: NHAIR; trachea: NHAIR; Viral Ag: Not detected 
Bronchial ln: Not on section; Viral Ag: Not detected 
Spleen: Moderate sized follicles and T cell zones, moderate cellularity of red pulp; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mesenteric adipose tissue: A few small LC aggregates; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR, apart from mild NALT formation; Viral Ag: Not detected 
B18-0323 KO C2 Lungs: NHAIR; trachea: NHAIR; Viral Ag: Not detected 
Bronchial ln: Very small fragment; Viral Ag: Not detected 
Spleen: Moderate sized follicles and T cell zones, moderate cellularity of red pulp; Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: Several variably sized LC aggregates; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR 




B18-0324 WT 1 Lungs: Moderate to marked (> KO) multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (BALT) and 
surrounding consolidated areas with several small bronchiole and aggregates of respiratory epithelial cells in alveoli 
(bronchiolar metaplasia?) and type II pneumocyte hyperplasia; trachea: NHAIR, apart from evidence of mild multifocal 
epithelial hyperplasia  
Viral Ag: Not detected 
Bronchial ln: Not on section; Viral Ag: Not detected 
Spleen: Moderate sized (sec.) follicles with some apoptotic cells, small T cell zones, relatively low cellularity of red pulp  
Viral Ag: Not detected 
Thymus: NHAIR, apart from relatively thin cortex; Viral Ag: Not detected 
Mediastinal adipose tissue: No LC aggregates seen; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR, apart from mod NALT formation; Viral Ag: Not detected 
B18-0325 WT 2 Lungs: Mild (< WT 1 and KO) multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (BALT) and 
surrounding consolidated areas with several small bronchiole and aggregates of respiratory epithelial cells in alveoli 
(bronchiolar metaplasia?) and type II pneumocyte hyperplasia; trachea: NHAIR, apart from evidence of very mild multifocal 
epithelial hyperplasia  
Viral Ag: Not detected 
Bronchial ln: Not on section; Viral Ag: Not detected 
Spleen: Relatively small (sec.) follicles with some apoptotic cells, small T cell zones, relatively low cellularity of red pulp  
Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: No LC aggregates seen; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR, apart from focal suppurative rhinitis due to inhaled plant particle; Viral Ag: Not detected 
B18-0326 WT 3 Lungs: Moderate multifocal perivascular/-bronchiolar LC-dominated mononuclear infiltration (BALT) and surrounding 
consolidated areas with several small bronchiole and aggregates of respiratory epithelial cells in alveoli (bronchiolar 
metaplasia?) and type II pneumocyte hyperplasia; trachea: NHAIR, apart from evidence of mild multifocal epithelial 
hyperplasia  




Bronchial ln: Not on section; Viral Ag: Not detected 
Spleen: Moderate sized sec. follicles with some apoptotic cells, small T cell zones, relatively low cellularity of red pulp  
Viral Ag: Not detected 
Thymus: NHAIR; Viral Ag: Not detected 
Mediastinal adipose tissue: No LC aggregates seen; Viral Ag: Not detected 
Heart, pancreas, oesophagus: NHAIR; Viral Ag: Not detected 
Head: NHAIR, apart from mod NALT formation; Viral Ag: Not detected 
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